var title_f30_21_31056="Adult TB case 1 lateral view";
var content_f30_21_31056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Classic adult TB lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 497px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    18 year-old high school student, chest radiograph, lateral view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Bernardo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31056=[""].join("\n");
var outline_f30_21_31056=null;
var title_f30_21_31057="Cinnarizine: International drug information";
var content_f30_21_31057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cinnarizine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1978276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antigeron (BR);",
"     </li>",
"     <li>",
"      Antimet (ZA);",
"     </li>",
"     <li>",
"      Aplactan (JP);",
"     </li>",
"     <li>",
"      Aplexal (JP);",
"     </li>",
"     <li>",
"      Apomiterl (JP);",
"     </li>",
"     <li>",
"      Apotomin (JP);",
"     </li>",
"     <li>",
"      Apsatan (JP);",
"     </li>",
"     <li>",
"      Artate (JP);",
"     </li>",
"     <li>",
"      Carecin (JP);",
"     </li>",
"     <li>",
"      Cerebolan (JP);",
"     </li>",
"     <li>",
"      Cerepar (CH);",
"     </li>",
"     <li>",
"      Cinabioquim (AR);",
"     </li>",
"     <li>",
"      Cinageron (BR);",
"     </li>",
"     <li>",
"      Cinarizin (HR);",
"     </li>",
"     <li>",
"      Cinarizina (AR, ES);",
"     </li>",
"     <li>",
"      Cinarizina Ratiopharm (ES, PT);",
"     </li>",
"     <li>",
"      Cinaziere (GB);",
"     </li>",
"     <li>",
"      Cinazin (CH);",
"     </li>",
"     <li>",
"      Cinazyn (IT);",
"     </li>",
"     <li>",
"      Cinedil (HR);",
"     </li>",
"     <li>",
"      Cinna (DE);",
"     </li>",
"     <li>",
"      Cinnabene (AT, CZ);",
"     </li>",
"     <li>",
"      Cinnaforte (DE);",
"     </li>",
"     <li>",
"      Cinnageron (CH);",
"     </li>",
"     <li>",
"      Cinnamed (CH);",
"     </li>",
"     <li>",
"      Cinnarizin AL (DE);",
"     </li>",
"     <li>",
"      Cinnarizin R.A.N. (DE);",
"     </li>",
"     <li>",
"      Cinnarizin Siegfried (DE);",
"     </li>",
"     <li>",
"      cinnarizin von ct (DE);",
"     </li>",
"     <li>",
"      Cinnarizin-ratiopharm (DE);",
"     </li>",
"     <li>",
"      Cinnaron (CY);",
"     </li>",
"     <li>",
"      Cinnipirine (NL);",
"     </li>",
"     <li>",
"      Cinon Forte (PT);",
"     </li>",
"     <li>",
"      Cintigo (IN);",
"     </li>",
"     <li>",
"      Cisaken (MX);",
"     </li>",
"     <li>",
"      Corathiem (JP);",
"     </li>",
"     <li>",
"      Cronogeron (BR);",
"     </li>",
"     <li>",
"      Cysten (JP);",
"     </li>",
"     <li>",
"      Denapol (JP);",
"     </li>",
"     <li>",
"      Dismaren (AR);",
"     </li>",
"     <li>",
"      Eglen (JP);",
"     </li>",
"     <li>",
"      Folcodal (AR);",
"     </li>",
"     <li>",
"      Hilactan (JP);",
"     </li>",
"     <li>",
"      Hirdsyn (JP);",
"     </li>",
"     <li>",
"      Iroplex (AR);",
"     </li>",
"     <li>",
"      Katoseran (JP);",
"     </li>",
"     <li>",
"      Natropas (AR);",
"     </li>",
"     <li>",
"      Pericephal (AT);",
"     </li>",
"     <li>",
"      Pervasum (ES);",
"     </li>",
"     <li>",
"      Purazine (ZA);",
"     </li>",
"     <li>",
"      Razlin (JP);",
"     </li>",
"     <li>",
"      Roin (JP);",
"     </li>",
"     <li>",
"      Salarizine (JP);",
"     </li>",
"     <li>",
"      Sapratol (JP);",
"     </li>",
"     <li>",
"      Sepan (DK);",
"     </li>",
"     <li>",
"      Siptazin (JP);",
"     </li>",
"     <li>",
"      Spaderizine (JP);",
"     </li>",
"     <li>",
"      Stugeron (AR, BE, BR, CH, CY, CZ, ES, GB, HR, HU, IE, IN, IT, LU, MX, PT);",
"     </li>",
"     <li>",
"      Stugeron Forte (GB);",
"     </li>",
"     <li>",
"      Stunarone (IL);",
"     </li>",
"     <li>",
"      Stutgeron (AT, DE, HR, HU, IE);",
"     </li>",
"     <li>",
"      Toliman (IT);",
"     </li>",
"     <li>",
"      Torizin (JP);",
"     </li>",
"     <li>",
"      Vertigon (IN);",
"     </li>",
"     <li>",
"      Vessel (BR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Control of vestibular symptoms of both peripheral and central origin and of labyrinthine disorders including vertigo, dizziness, tinnitus, nystagmus, nausea, and vomiting; prophylaxis of motion sickness; adjunct therapy for symptoms of peripheral arterial disease",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Motion sickness: 30 mg may be taken 2 hours before the start of the journey; may be repeated every 8 hours when necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vertigo and vestibular disorders: 30 mg 3 times/day or 75 mg 1-2 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule: 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Suspension, oral: 75 mg/mL (20 mL) [contains alcohol and parahydroxybenzoate; banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 25 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10356 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31057=[""].join("\n");
var outline_f30_21_31057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978276\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978267\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978270\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978264\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821188\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978269\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10356\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10356|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_21_31058="Chalazion";
var content_f30_21_31058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chalazion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31058=[""].join("\n");
var outline_f30_21_31058=null;
var title_f30_21_31059="Cephalocele";
var content_f30_21_31059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetus with posterior cephalocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 270px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEOAY0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDLsINP1G3S7s3jExi4K9XGOhB7/wCRmuAvo5LPxNIHJggnbbIyqUXIHH51r+Bbl9P064RwxmjjybeVTlRx09+tV/EX9o3NxLJLamSzkIKZwHGRyGz060AO0rW7eX7TpsqmK8RiBdIu4Hjjnn0rqdN8QapgQkpcWUoKrKY+NwHU+nPr+lUNG0rS4rcTadKLXUcFXik/jwBxz171tWmo21z+5EKhwxXgZUtg55xx6/iKAMyHTLs2rTMYnGctbsQAqnB4J+n+c1qae9nFcytIHty+BJHkHecex6Z7VmyQLFcTSusjwqOF24IwOMc8d65xr1Y9TjhsX/czsh/etgq/XAzQB6ppOvi10x3jCw3Zk+Q/xEZ6/l39KzbzUbe5W2nvp0IU7d+MEMc4zx1zgGs60sPM/dyv58mQ29Dzk59Pw61LJ4Za3SJ9Sjm+dR5SYxswc/n9cUATDU72MRz2bKywsFcHGdvqR6Vos01wonijcRSLkSoAFLbiefzxXL3BsbQsbe5mMGdgfcRnJ5J/z9a6rSbuOSyWK6LxOUCxHfjLdM/iP6igDSsLaxXT3e6u445uCkLRgq+ByeOhxx/Wq2s6bp13NYvYWRS48oBhG5cH1GD9D0zWnbpoDaYi3FncXF9GAr+XJlDnkd+Tx19q5iw3SajAlpJcW8jxggM+Qck9aAK0fhm5Go3EUdnKPOIVtrbuAOOfoa3Wgga4gRrS7ZEJBA+9gHg46EA10MN9f+FL4rqDR3DKF8q4DZZAwyOnsfTHFRL4pNlclruGO8t3JMagFAoySw2459s96AKUnht9ftHk8Ps0l9CPM8kjATOdq+mODj/9VZVsbjRJv+Pua2vE/wBbCwzzzk9/QVPb6xcyavNdeHBc2TzN8xBO1lPTJ9Mnr9a6/wAL+F9VtIRqGqwW+os8YdpfN3Hvzn1wf5UAIutX1hBdTl7S8SZVSVI4vlYkevr0rk7jUYb23FtcqiyNIX3BSHyB3I7ew/wrT1LXZbvVGh0ixjt4Y2xJCx3K5wex6N9PantBot5JCyWmotc53sgwBv8AbuBigDk7Y3Etx9milkchgvKblUYPBA5xzz/Otzw/aanbYOhTSrdrgFTwzE+uPQDNdNB4H1A+H4Zo7MQXpn37Bw2wjgE9sZP5VdfwXq2nXMFxZXyROX25gBPlHHvkkcc80AclZxXmm20x8TWbXMszlgpjKncTktnt9Rjv9aj03Trie/W60XRHjt/LLMY24bHQkfX27CvWPEFnugs/7QctPCu6SeOPdnGDkg9Bw3p1qGHxXZW8Sx2UUOCSsa42Hb2/OgDL07w7LrdjPdXymO7jzD9ngIQZ7En1wf8APfWtfC1zB9nVbxYGdyZdnUrjoPf14rP/AOEiSa5+1wTS/aipLW0HIkx2PHBwDz78Uy51e51i5lVNJ8m8gXMgmmwynbxjB47f/roA3NG8IW1tA/2oLNIzNwwO0DPQYPTA/M0zUri10zzNNktp57OQGRpI0GF+bJUn27d65ebx9qWl28UMkEEsiKSzMWJx/iMHpWTf+Obu/t76O8uHhAUlVgORjPt2+vrQBevtce4vUk0uCK3sowMpctkkDqB1x6++aztS1AXl5JPq9qI4MYgii+UZzjcx9eBj6/WuYtbhtqh5zI8gLqokIYkYOTkd88cfhVnWNTkmsorVYdqoSuFJbJwOcn/9dAGuuvQx21lJHboI4rdk83uSOc9eOnb+XNZ1p4g1QNeG0mlMTDCrI33gOCf8+lcwbN5czxmfydp+ZjuTt8v1/Xj2pivJPdqkcm22xsyrEk7fQ9uMUAdOfFK2nlXF5aRG5BID53E9uPx9KpXvxA17Uxez/aHtkVxG37sKSg5+XuAc1k31pPvkmKodhOMc4Ucg/wCfWmaksxKR3N150fBdcFQxJPBx6Y6UAV77UJbvU4Sb+SaXyy4jY5IJbj+h/CrSzXi3Fl9pbanmbQwjHQ7uC3Y989utQXVjaNLFduu0cJvUDIH9OntjNbtl/Zb2DK63bvFgKMnaoPcNnngnntQBmNr13aXXlRIwVTvOxeGHOASenJ+nNUW125W5fzZDBcTYHljLMqknkt1GMdT6+1dRqN3oMOiyWkVnI106bWlLZZv97Poc/jj6VxI0S5tLxbu6dI4VxArKCWfsP6flQBLLq0yeXFZrE6Mu8sASxIHJ+uc1m3XiK/ulkjtzJBhhuiZCRnBOAM9elaw0a4/eTRYSLbkCQ7QOBnA71mTxQQzzbZTLJu3424B+XGcn/PFACSaxNap9pjd5kBJdfuquB3GfbpVTXPE1/qN5BFCbeRDlixGFVc89etS32lpeRtFLM4V8u8MOOTycHvxTH8M21hpks19dMilSMkBiQMDbmgDnvFmoEQrE175/zBDFGBt6nj+tebXDujd9x/Suw1eLSmlzZzNF5DDOVzu9vx4rnr+3invMW6O24YOBwXOemPegDM811wQad9olC7Q5H9abdwS287xTBlcHkH9KiYYPBzxQBKJnwAGwPagSybcZOKiBqzpk8dtfQzSwR3Ecbqxil+7IAc7Wxg4PQ4oAuXuk6nYaVYald2skNlf7/s0j8CYIQGKjrjJxnofwrO82Qsc+p49K9i+O/jrR/G/hjwbc6RFHZy20UsE9gmALcjaAFx/D6f8A1q8ac5JPckmgBwkfIAOKnhumjLYJYflVXPP0NOU46ZH41pSnKnNSg9RNXPe/FVnHewmWydI22A7uh9xkf5/Or0N559gsDSxlztMTSxgZIXuQK5W6ubeSKdUlRWSIeZHzkDGNwGPx/Gul0KSW4WCK+hUW+eLqM5A+XjjHBHSsxnOWL399qbNcWVo0UPJw218Edj68V0chtrG2eeOaQZPmCM/KzfL1HvxTr62uYriS0kUyxSIdhiIXdxjv36VJ4R0uUy3DXReZYyVUytwQQTwSaANK3llvlhe5QmApu8xhjj0P0yP1qppfhu3ju5ZbcJcxsxKsy8r6nnr/APXqRLW3sbiUy3bNaOfkRxhY/YbhispJ71Wuo7C4FxhlLx546Dke+KANt4p7VUtihMYlByBg7cDpyfX+dbVtPJLGwuoPtEKR5WR+pJyPX2rB0u4kmtrZ9UIjmQ4RehOAc59TwRitvSdSuISyRRxT2br0Zcsh5xj8T/SgB2kaFBc3e+4miidtv7udduee3b1pNW0P7bfy2/kgrgkLF8wXjPHXH/1vxpJJZLvzHSXZKcbiy5Zlzj/gPHOf51uaBr93YXPlJc20mQhAL5Ygcjd9cev60AZug+GxYaQ4uJXnnbCuJc/Iex6+hPH1rq9C8KSL5cENzELpxtdSmSnPVT0+v0rdvPFGoWdrDqWraJbmzkAG8HOB27fXj3rZ0/xXpNzpj36wGJ0XPlqMNjP4frQBxd74BvzqUKzRJLaFwpZZRnvzj8vz7Yo8SfDySylVdNWNrKdkVnkcbo3z1+nuOnpWVrM99fs1xZSyurTKWZHIfGeQT2/kPetPXLzTbe7WN7m+ggwDcRSZw55y2c+2PfFAF/w34ROmSyW+oslu9zHsVwQUfHOB9frXRf8ACDaebaKC0v7qGMMd6xy/K/U4x0HPP4Vyvh7xHp1vcxPBc3OoiGNUgilwBHkc47dvwpmo/EUf22gs9NVUgGJkeTG4Y9uOD/OgDZvPCOj6bqgQJK0t2h2TA/MknRRx2PP0qaXUX0qKN7bTdy2p5kKHJJBGcgfMM55qBPiSpIja1InK7gCCV2+uao2HxKuwjrcRQysW4cjaB/s8f5GR160APk8fatPAYIdNlWZ84m2/d6YwB/X1q7Yza1Jflr69gtEgyzCZwC52/eAx3z2+lc/q/im+1F8JILdXHlokYI4K84GOQeOv6Vx15ObhAGvXuXVCgeQkkcDAH9Me9AHpN947jtDJY3Fs+oeaXDORlemcLxyMVxV7cz6lqmI4SotwWKRLlccbSM9xnge1a3hrwKL3RrK7uNVmV7hRM0YiBUHkY69K25vA1oqyFbubduyXVACcDA7+hoA4ttTltUddNklhvEc7F24Zju6+/Hr6VUXXNSstbubhmSS6YBWaQ5yQOMj1/wDr1b1ay/4RvXGU3quI/mRsbWUHB5Xnuf8APahLL9qvrV44m+0Fvm8knEh9CO2efrQA7Umu49OeW5nEt9N1KnJGegx/hiskWMjh3KMrsu1FycHnqTn/ACRWpqiTxFoyVhLPnYAM4I6E9sVLDb3VxcmHTSzEIzSBzjAxkY7de/0oAw59Gu3uDMSylRlZj8ox0AA7V1f9i3ZgaaGwKmKIs5m6Y6ZHr0FdL4S8PTajaiPU0EKBmkRnk4Zgckbc8jnr7V3tla29/FdTC23xyptCuTknGCPb8PWgDyKDw5qmpWNtHAqxRAMxQHJcngnA6nitay8C3VxYM32ZI7lXBSNWGOOp9OfX1r0k2On6bpgZ4GSG3G/y/vfMewPfrirmn3duxWG2haMkbmGMAevPr/jQBwOl/DS3i1IT6ncEpMm0whsZPH19P/103V/BQtWVLYSz+a3yoicqeCSxHTgD/Jrv7mEz3xedGiWHHlSiTG7PX/PsKxr3T9RkBtLM7Iwu4zSSE7yScr9KAPLU8NpqNzcRpLsmik534CgA+3Xk9KqtpVzaxhvLztkKmMJjOT1wRwPc/SvQdE0xriJZF+eKOUCQeVy4zk++MCn6tYpda9uks8WpQvhjt6cZYf3SRQB5Hc6bqd5L5lrab237iUGcYJPGM8Yx+Y96ku7C6hu7eCdXiYMrNFjcwI9QPr1Hp9a7i5l1G1SS900S29puMfyfNhumRx92s+WBb7UFZVZ52Xc+QPnH0464/WgDk754biXZbLJIqbRlkC889+4wMVlatpbpEinHmowLdGONuPxH41193YW8hmzGytCPnkBwueflH+fWrGom2h0OO3eeNZEBGyBMk/L/ABN16/h/KgDz6306NZrloipLEncOGOAM4/KpNbtp53V/OE9pHhWgHfOMnA/2efx6V08NpJdwrLIEsosFV5HORkD6/wAqnudDhSKYLdbZnXfM2AVUYPHPUnjjnr+YB4/r2i5eTUY7ARxmRY8Lnnp83HHp6Vxt3Y/ZLpRa/vH6/Ln7wz0Fe6X0RjnW2HmMGYbWdcDjAz1xnPqayLzTUgeWSIhZlBI243HOeOOOeeO9AHi97oOpTXAF1AY53TfudgM8dD+n51zjqVcqeor1zUrC8uZnnlaNJeQiEZ4xgD68GvPte017G5UTMzTHLSDGMdPSgDGhby5FcqrBWB2sMg47H2rX8T68uvahHdLpWlaYETZ5WnweVG3JOSMnnnr7CsbHNHG/p3oANxIPHY03JLZIFA5oPWgAH1qaByN3ylvocVCBx0496lhXOevbpW2HlKNROG/9d0/yE9tT1nw5p1vqWo+deXO6aSPZuOCp5GP5GvTrTR5NGjVgEksXk6YyoyP0/wA/hzOiWi3Dz29vEvmRKEYEdx3B49f85roba+u4jIt8ksBZ+VIOOmMA5rEZBqj2oklaEKqA4VJWBUZ9D2xjGPeudv76+Fo9ppNzEtyGJkSIHp68/hz3rb1Z0vYJRbyMjMWwpI3Nx3/M/pWPHFqFvqlu9tF8+w73VM54OeP+A/pQBTkstTmtkfVrkBwnKFQo6jIGO+MD05qC3xa35Wxb7NBJ1kPzF+OwNdbbXawaq0d0qTuULKHwcj+nviqeqafYSwT7oV2y7SFViW6foP8APagB9jbvNCrzxi7WGXO9hkDg59P/AK1WbNY45rZYp0WTPIJIC59OfQGqunEabYwta3LyEuRIrnO0bT+Pc/SoJZFit9yrmSQ7UKdickc59DmgDpU1fyfNLW3mRdAwOCg/ryTVfVbpLOSG+FqsTlRhjyO3P9fxrltY16aO0t3t7UuAypLnhvbJ6ZzVe/lup/KTLiAqGYTNuw2ei844oA9ah8VSa7p8MMs5mcqC20FljUAc49/603Utba0hggEklzb7S0ZaEAdOSR3zXlR1m5h1CCKxZhNICrlCAFXFWoZ5Cyi5utxgXCBnC7ck9Rnn/wDX9KAPWdX8bSwWdrLa2EEClQrSwxjLk98cfifr9a5XWtTkvLiO6vZY5Ygp3bwPl9MD06f5zXMDVCkxc3gkt/M2HySP5U1o3vSs0l2fMXIEe3GRj1H9PftQB0Iu45nSOzTypy24dQGOODnPI49uoqnNIkbYmLRzNj98ZOJCM559KptcSXKR3ah5ZI0EaIFHI9ST+P5VWu9OuryWBXglZA4kKKM9Rxg56dfp60AdNb6r8wuL5lLxYQxEgKBg/wCfyq3ZamjLI3kQsrMcPuIAPQHv781gaXpWo3JliFnNDZqV2u8fVh6e3vXV6f4P12eUwz2vlGP5wFUfMvqvrx9KAObutaiSaSCztZ5mTbu8sZHII6+mRXe+FtEsPEOmrPDG0N5CwDwyg7DgcMp64I4796ykj/sG8j8q0S5kbAwyZJA6nPBHUVdsfFl4uvH7DbRx20WVkgfjAym4Z/E4oA9P8PadJZ6Xa2zkNJCqq53Zzz+orRntd0pO9ERcc56n6VnadfLMsMsMqvDNyGU8EH/69W9Tm2qkakbuvWgDm9T8Pafdapc3d5BAWGAtwzZ+UDkkdPXkntXCaj4vSTWPK0rT4o7JW3xzIAHBA+8eMDqT+Vd540t5U8OmRbmOCDdiYliG2+nAzz1PsMd64XTfCxu7eW8G2GPeEzjh84x+PQZ96AMC/lvPtHmXUvmRTfNIzDjOB+pI6+grbsNTs9N8zUC8c13IWKqQfpgn1x9OldFN4OjSxluf7SgeOBiBub5EPp746Zrg/FUqQQFUaKZbdi4KDgEewP16+lAHougeLxf3scbiwYFdsjeWQyqM87un5+tdo19Bo8k8tzcW62RGVCDBT0zzz+FfLVtrckjRS2sDxqQwaQuDu69P159xW7qfiX7THZQ3U7sUGFVumAOw7f54oA9fv/ijp41F7W0sbm42xsQdoAfn+Vc0/wAU72SG4EUQjc8rhMFBjn+WcmvNtT8TWcd3cmNjLI6YQlicHjp6DP8AnrWTfa3cWxmgkJSJ8sty2H2AjnOOnSgD1GLxhqJtWOo3hKmTeSTknnjA/p6fo1vHojvl8iVpIwd7Ln5QevY8854968U1/W/MSJIpAsSlWRyp+dgOM+nWpbTUpLm3RxH5krnf5qfKgB44H4j8qAPZU+I9/p8V4YGgijOTyhKqd2PlJPesTUPiRcxg3F/PI74DgOoG8E9PQDivLtQ8QXkusQafNFFsiUHYCfmJIOc/hVO48QwXVpMdRZnT5hhVyWAYdT1x2/GgD2O5+IN3NpZ/sZ7ezikjzIWAGTz1Ptz+lReHfHDwo0cweW5mAXMQIYj3Y8eteFTa2kl1ausfmW5I2wAEBlz1YdzxWvd67cXd6I7G4a2jdQrsQoCd8D9B/wDroA9yi1LS3m2OrLEGDPvG4sTnnFa15rfhrVGOLZvJXC528rxknk9eeBXgui+Iri4s5hdzwqkP7tnPRmJAGOepxWsmpw/bTHaz7Ix1UYYZ2k9xgd/pQB6ZKum22oI6vJHZSMCIz1II4OM/Wrt5qdpd3yWMEG22ABkVV2lm4zlvy/OvM21+H7Kb26abywfLQls4XpkH16dK0LDUp/tga2YQRlmJZm54xk8cZJoA73UYrG7ljSGCU3JcZIAAXBHGe3Tn61z+t6b9nmIhlMoRSWKLhc4PHt0/n0NRw6hdQXE00lwsjH7ofaCM4yD/AJ9arvdHUbkwtLKDIS0hUD58Zz+nQgUAcXqEWo3E8slkqwoRtV5l3biO4/HB6fzrzzxLDFZahmeVrm42nzZOgLEdMdsV77PZtLYq9pE85/1an7qKQvU+/GeuK4HxZoNuNPuBeYLYMqiJeXc9MnrigDxORSGyQAGGR3qLvkGuyvNF/s3S2e4tZJGuBjzG6R4549//AK9cnOmyQjBC54z3oAhxjnPbFN5J/WlIypx0pNuT1/GgBAaenfrTQMr+NT2yBt27jp3xW1ClKtUUI7sTdlc9z1mbU9Mae7tOFkjVX2gZ564x+FP07xB/aEe93kZ/NZWEinqF6rz9KiRriUiWaR2QxqGQDhSBk9P5Yq3pd2LrxDNDMwFuZQFGwBQcHv8A4ViM2oJNto0s0qSzhTk4wcHjH55GP8ONYZgtob1GtTG5yRuBKAjAyCO/A6/zrN1CzMd1+6UNBLkcEfLjgY9/06VnPbTqyiGRCyr/AKtn6jkkYx6fyoA39R02w1KUyTwmSUsHjIb5c8cH346ZqlqkA0u1kaJBE5wu24HIYYHB9McZ/wD11VfVbmwt5PtEsSOq5RQmeAP4W7/nWdqurN4g0wlR9nfcNwc8kdMc9B0oAxNd8SXEQlkiAiw3lOpAK7sHkfh/OqHhvU9W1SV5bZSXVBuyeMYPOOvpzTNQ0a+2wyDbLAWO4HkgleCRTdHsVtLkW91cSpNEo3BOBjJ4z9O4oA147y4F1NHOsN0vG7PDKemSAccVVEkM7y2z38v2dAv7tRk59MDrj+n1qATy5W0jt0kv2Y5kAIATtn34rMsBeWN7ClxGEdT882ckDbjn8+nvQBvRolklneRWoZNpTzTkZ9OPfIq7ez2d1cGSTS5Wl2COWRj8m0A4OPbmoI7ObULsRtDNJEgDRvEduTjqR+FdXaTEWLoQFLDbukXBUD/Pv9KAMvw9ZadIWctKi8MpwQAMHofXp1re0rTNORhLcS7EzujiZ8Hdk7iR7gZ56Vm3epJHJDbiSINESy5OAc5zgdeSentWTb6j/pRknjWC6UYSFvug84OR9PTtQB6RcalBDepbXUEEymMCNowMhuOTj1q5occc9tdyXQmE0u0RGKPhBjHP5V5xbXkUt0J8hFjBGFbgn1A/Dim2HieWPUDasJYIsB1+cAcg+p+tAHpl3quo/ZEt1vBhcNsZNoK7ffqf5VixazdjUQz3l20SHli5G3j7uAfcfSso67YveKNbuSIpcFJkTKg9hz368US3drFLvsrlp7USHKlTu2Y6989DQB6I+pWOuxTyJBDBJGu5jG5BOBkj3bHcf/XrHvLO3j043FufKmYgCIKTszzhifYfqOtUNO1ywmng8i3MkmAeFwfqTnpnn+tdTe66dWuobS1tIY4wokAU8kr2I4556fzoApeBtZj0fVX0jUpxtlYNArMFAboQPTOBxXYeJNaOn2j3LQ7pCNka5xuPfPsOv6VxOvaJPqt5NNaaVue3ADhepYrgkc9ua5XxG+rXGq20+qXYZIYRH5LHaBjGdwOPm6nPf9KAOzs/GNk+jTWN9Ym5luMgSytnLEjrkjHrwe9ZniTxHcyWVvHh7aFSRsVccAcYPbk4/OuG1nWrC2tt7k2iqG5/vn8s9DiuS1HWptWW1tUuZ4oJl+WeYgK3qAOmaAOq1PxReCAxAzSxt95gCVT69v8AP0rC1m5eS3u9+qQySeWxVMZ49F6YzwKzLm8lsbtLS+1TzISMMikncOMZPTpWDfCV76aWxMawsWUeYQSMZ/L+tACafezfZYpxIY9xeKJS/MZ4/lXTRxS6ikSvcyTi3Ylii8H5Rnn05/nXLpqC6vpUcNwFR4JCfPVQN3Qkc9utdho8Vr5Sw6deKzxE79rYJPUA/h9e9AFqZUsxax2dom8b1aVhkAH1zz2qtBoqtPcyPIjhmB3sfk6cjb0x3/OrqwRyQXNt9kYSE7FmU7iM89e3/wBeprtRFY+VHEEUIecj5j68Dk8jpmgDA1GxSz5gkDgf64E8Kn+znpXOSamttEPssTx26vtVsbTkfd6/19a27tFtVhkDxyNGcuZJN28nt9OnX0qnr2rWs1qI5LWEwxuCEiPB6cgj8aAKq3Yv4U8ywUpGNvnLJiR+ff64/Cs25N3NdNCYfNh+7+5j5Hz9CeO9Lbz2M90sjmS38xSHZVAjU9sfkKj/ALSkHmxw3EiwrLuTDffBOeTQBStLprC6T7J+9c5AjkH3DuOKt6bCbjU4ku4ZI7c5DbT3HHX15qld2Cx/vDMhkKb3G7kfN09zzWzbNcaHZxzz3EErOAFhDYIz2OPY0AYwn8hzDGJhEp6OOG5pX1MtJlWfeT91DgE4x0HFP1fV7m7eN8QhQmAFHAGMY/z61kiRIZXdkDMCCO4BIoA3LbWLmySQSQhy3KJKchPbH0Nbb6+ws4pnuf8ASdv3FHCjAyP6f/rNcVcXDP5kjRDax+vNT2f2eQlmyjKhIB5DHHOf1oA9Dj8Ry4gV5A0j7QkaSYAzjhj9c/l9K6qz1N0kt0Ygs6kkHADdccHoOeuf614lps073ayWwy/mDgDryMD88V2SPe2pa5mkae9kUqAvzFfvHnFAHq+l6ldXJAeSOOCP+BcqnTqT+WP61dkngMZNrCLmUD7+cKoI45/z0rjNGZJtPRdRiaC3XG2MHJY5Hbt078dK6Ma0HixbQpa2hbZnnecdRx37ZoA5jxPompatqiPHOq2seWaFF4Tn1x3J715/4/sLiK+EN3B9lliULFEUKs6knnGOmc/lXtN/qUCwMkZK5VndmAJ74PX1xx7V5V8Tjqer6hFf6nfXN4YkEcbTyF227ycc9Bk8fWgDzYjGKavXntmppiS3A/h9ahIGaAG44zVm2QvuwxGMd6rfSrFrn5sfyzXXgeX28ebbX8iZbH0q8sceoy2qpLsMePMWMdsfe7fhS3yWbLcQ3jJE+4lJVAUHjpxW9dxsiSXFtHE2EUkZGG/z6+lVmt7KQvcQxyqGkJZFwQGx1Hp1HFchRzsQ1G3skjuX863O4MygEn0IGfr0q5pVzBefvogfNGUcOnPXj8PbHSq91eLYLJaCaOaAAhUEPzJnvgVn6PrQtb+eJc+YvzHBB469/rigBnieG2urmJVuja3A+6nByT0bPf8A+vXPXdvNZTSzXdwguZcDhAykcfr/APWrqJpxrkpiuIRZXUQ3wlhnPcfQZ+lc94t0XVpEk/ewySxsjARMFIAGM+v50AY1jcy73WN8FXdJGkyyZIz/AF/WnR+Jprb5JbSMyOu2K4xjIzjPT8qyNQubrSJJYZkVfMOQmcqwGccimQ3crMkNwpWFkUhcg4Pf9TQB2AsLq5vLd9VuYI0zsIQbC4we/wDD0rf0TRbe5ib7IUjOzBEjAbzjHPrgjp/KuVuzPYXlncyRXD26EHO8YU+vXrWdpfihrW+kmswWaSUtszkbT0AB+lAHo9hp91YW6rICi5JZkXevf3+n+Qazm1RrWG5jRWeaMfNFPHhWGegp66ldtavILx4rZAp8grkIOvTJrCjuft0lte6hd2wijB2NypLHgZ9untQBa8TfYoItNuriBFfeFDr/AAEg/SsHVtVju7dEsnlmmRsMy9FXnofQdap+N9bF5cSRiKM20bbQAeAeOQB24rkrCd9siRTPETn5k4J4PH+fWgDr9ZihEfnR6hPI8KhxAVB7Djj8fyrJGotqDlo7eNPLGVXcck46c/WqVi1099DFbtJ50y+W+eRt7H34rRu9La0uZIYZEVFXezOMZJBPT2/qKANW38RCHVQ7r9qgCqVgfI2tt7euK6yx1i4v0kt5JIIIcBoo2fO3jIz+fTrXlOqXjySRfvf9Vja2MHpWhaPJbsZZbjzrZxuZhkHI/wD1igD2OzA+zgRmFL0KNxbo4wO+fUVe0/XJF1wu0dyLmJMiXG0ZwOfcdefeuJVL021vcibz7QQKzoh5Bxz+dJpGp30N/CLi2c2eWIYjJx2z3/8A1UAe3+HvGsiaoftFy0azMHklVQN/HGTjn/OaPHVxbag3mW6QJGpIJcgSM2CS2B/ujjPOK86munBdQNgOFG4AdO4zxx6de1Vmv59Nt2uL65a4iy4JXgHPfr0A4/xoA5XxtaTT3MtvDHO6up2kHjg56D9a51WuZba33M93HbhmkgZCFjHt3/8A1V0uua/Fc3C2ys8aOuRKgPUHp06Vx/iS4u4bgJHMRDLlFIHGDjigBmoskU0yBmYYV4w0hJz6jHPSsVJpHE3LbwxYAjOB3zU+oy3E169spA5AyO44qxHaxyots9w1vMoZneUcZ9AR+H60AVra9u4ra4hSNGicEn5BgHjn61t6DLNauYYVRIZiVeZzgqcDvXOrLNIsUars8tiA/b8TXQWFt9jnim1S5je15kManP4H86AO7hnltrOax0y9cSOjMjk53Gl1bTboLHuZ5peGxHNg5AHOc8j6egqjpuuaTc6nGka5Uxltyrt256gHpzz/APWp+r6zp9zJM9stzHPACqJsPzMQe/4/5xQBi6y1qYpllZ5WgLSyJ/fJAGevGKw9Hiln3NkquwgnG4c8g57Hrz7VLKEtLw3M0R85/uwsvDOScn6dPzqrcyyXcdyI5Y4iJBuTbsMjfy4oAg1SUQWKW0MqTRYBbAwwOeme/wBRVOZhO5WCARx5GSAcdaiu4PIjWOQ7JNvA65BPX8qZOstsoG4tk9VPB54/lQBJcIwkUgGRgf3jDpnPH4U9rdpgzSKxUDcCh4/zms8SOkZPIyeKQSySP97r29TQBbit5pbQumAhA6nO7r0qvcWs8MYeZHRHPG5evHWtDS5hZJ9pRg0kf3ULYGSPT2qvf6rd3t08lxMXOMcnjGMYFAFVvMMewjCRkk++aaGYbhuHIJ5HqBT7WaPzc3IZ4+cgNins0UjgQR7MA53GgCW3vvszHbGpbjDenNdL4f8AEFlp9qz+STdMSABzjOe59q557dPP5cTuCBtHAznp+tQCRrKf7ibwT9BzQB1J8aTCRxIjSbyDknH+e+Pwq3N4uvb2RYtNtv3zgqjgEtnHTn8a5O5kS6YS+VhmxubsBgdBWhpl5NaXEUm0RwDO0YwOnWgDv7SxuIdM83VrqUXLZJSI/MxPJPp0x+Vc7rdtd2oV55ZHVyFSNQflAPTPvmuk0e+sY7U3l/cKTk7Q/PfBwM/Wm6lrttqO2HTwo28lzz3PPp2/UUAcHfQRw2ywW0QmnKF5WPAUY/Q1zMilT35446V1GtXIj/0eAO6yZDyMPvkDnHt0rN1S0AJPCBeAAP50AYhOMnvmrFmcbsuE6de9RMjAnJ74qzp7D95+H9a9HKYc+LhH1/J9rET0ifR17dST2txBAVNwgUD97wwAHbvmr2i6ukE729w5t5FlP3cByCOcg9ucZqjLolpeTmYMPNDDEgO07foO3Tj37do9T0tIrsSxTIZo3OWcEjaeMHHH69q84s0PEFppkF010kxEsgOxlbkjg4Ix9TxXDyaLFqc32wSywXAyBC3ynjjtx0xzXd+TDf2jKblUlQnKs4yWHcHv2FY1xGqXXlqqyKerF+pBPGffj0FAHAwnVYNRnhW8lEKZUxuQcDHI/nV2a11KG5e+tLyRwqqmxlwCOnOffHStDxAlvplzPdfZkMbxkNsPJ4//AF/lXH31w5v5ILNZIopjvjO/hMgcHP1oAmsp5LvVoI9ShSVg7ZaQegPXr3q7rNuixSxTQITGcxyofmHHBxWFi3tFERvP9IL4k3fwt0yOelWbmyvdPvRKCZo2jyzZBDZ5zn/9VAFvxJd3CwxWNzcvKJNpjnTAHQYH8q5KKVFuY8htyjAKdiBwffoKs6pcx3F+kY3wLuy25t2MAVViiZ7144X8pXIAkk44x3NAHoHhS8la2fTtQni8qdgTKeShxkD2rF8ZaXLpcwjtjHJZtHuUryWwef8A9dc/MktvdLCHAnU53q2QRj/69dppJ0u68Px3N9I5uIlZG3vwwI/r0oA5aKCzfSUkaE/aGk27Q2dy4/Q5qlbWiQ34T7QEQxl1YjAJx0qfVoo2uX+xpshVsLgn5h2/rUFoLie3eKOTjBBU4xjk4yenNAHUeFJ4IbhI55I5EAJaU/Kw44we+OOK6rWotBv7CSZxvmAx5yKQR1wfy/lXnmg3llps00eowieNlC7ev+cVoXd/p0xuBYj7PGy5AZjg4zgAdh7UAUtX062tIo/MuFkWYgrt5Kcc59q3YNK0ufQwsIvFuNpU7jhXJ54+vHFcsdR+0NHGkcKbXXGB94gY/pXS/ZdU1CVLUtHJKxz5KcFVAODnpQBraRZ2thpJuLuSeCVDsPGQxxwcGon1yW2id7SdpIpXKb5QBg5HCjNVdZ0a5W5trbUJzHGRwW+UAkc8+1U30u5gkW4sPLmih3ff+6RkfN2496APRdMubq/tLcTwidURT3wenJI7/wCHeuZ1t4dQ1Z7CTzbeZSysituU5wevTqBWimtNF5UUVuHuZ1G45KjPTk9+ayddt4hbPeS2rR3xcsZlJ4GMj8On60ATXmjXt9ERLbxxEYH7jAzyOT+tXbbwnHq9o6XEoxEW8uLjH1z+FYehz6je6dKscqxw8Y3Nht3HftVTVNXvtLaaBglsH3DzIXJLDP16c0AUb/TdNtnnikE/lo7binLKcj39D+lc9dwSko1uZZYmY7UYckA9cVWmvriW4lBmJEr5Zj/F9asW+qT2hZWkEg5GSeQPagCj5jRIY33BV5AHYmrdrdFZ1wqtCOqSHg+v+RVLzm8o4I2E/d9alRoUI3w/eB796AOnh1G3jmiltYY0YAllU8D3/T+VaNzcXE98bi6YyxW5AwnByOcfyrn9HiFkGuLi4iVJUYBgN+09gR+H6ipoLlJZEhmJjtGfiQ8ZH96gBmp3n2zUWnlneMxucb+So65ArU0TUUVZDJPBudyGleLk/QDiuc1e2S1vXFvLHcQkbtwOceo/SpLWzMunyeYY4pEYsDIRz0/wNAGhr8sl3stXgiBjG7zlUZI4PbtyTWIrPazEAKwLcBudvv8ApUM1xKAEaXcU4BB6c0kly/ktG33mPJ9RmgCuH/eBs8g9DzT4ozPIQMA55J6Yqu2ATg5xVmMx7MMx5wTigCI5LjHCk9AadNEFmZQw2r3/AAq8bmMokcUSqmB9T9apXRaSdzgZ9FFABDEGEgyoA6Fjj8qlhtSUbB6DJbPtTIi23BXC/dBPRa2X0QW8Id7yJ3ZdwhAJI4746UAVZIJorZZiI4okbhc4L89azpDuBZ1+bnGfxqzqAl+0lZHG8HoDwKbPbGBMiUOCCWA9jQBErgj5icgZA96kmuTIiFwzEHnJqrFGXJODgDJpmGzjGccZoA1bjUDNaxxKgUDPz9+vSui8M6nHFaukUSAr0dzjBz1z0rjIw0jLGOrYHPAzmul8R+HL/wAJXsdnqT2sssiiVPs1yk6HDEclCQDkdDQBryCARSXZmSS58vIbGFx3wP0rmNQKPLIW5Yux8seue9Mtnkk3yNJyi7VI7cVqPbafZ27yib7TdSAhcHBBxnJoA5tiHXOBkcAD0qSyBG/JGeOtJLuSQllAYn7tPgSQAnH3gOvH9K9DK3bFQb8/yZE/hPe5vElvZSmCW3LI4AXBzsGAM/59K6G2MGosBBKkTK2Y2JABGOQP8iuC1rRJbWN4IfkWULlmLMwHGc80upXcml2qx2swaWF8FIyRu4ORn06V55ZP4tsTaNcPlgrLjBIBzjt/nvWBoltqUESTWWoI5dy2wpk+4rUiWz1izeDU1uY3x5pBlIxnP4VBazN/ZVzJakLHblthB/eFc+3Udf1oAgvPGfnXBTV7Mo8aFAU4HbOfeuQ1O7N7LJcyMVhUgBUIGOODWnJHFqcjyBj9owWf7QR8x+orDttNubnUZLSEcKfmG7A7dKAGLA00sQuGdYWYgzMM9jjmvTPDPh+GKwNxHqCtYyQYeN+cnGf1H8+K4y00m+uPOtrK5Xam8GEn5sAV2PhLR0uNLtZ7i4uESJSChXAJHBH0/wDr0AeaeILVrfUZA4IjZv3T4wCvYj14xSPutYoWaIl9oZXB6nGQfwrtvF9s1ndzyXEUV1G6L5BB3bW6dP1ribO6ltZ4mnAeIMBs4IHHoaAImunlI2ormRhgtyQSP8/lXZWmgM/h0G0JuJXALIQAQcfwn0yf0rEvTbSRs8UsUZkw21xg5KjP9fzNdX4R8RpaaLBax2Ml02wjCpksec4NAHJa0Z4ZEjuLWSFQoDburNjpj1rGN0VV4woUEfwjFe2N4bj1eCWSddjSYZUClfLAHv3xzXmut+G4bSd1a5kQgcM6gg9O4oA5uJkEpLj5Tx7nNdP4X0BdQWO7VlmjWTBhx82P8kVlnQJDGGS6t2k7ITjP0pNDfULSdjZ3AgcZUkvj3/xoA6rxVoNntilsRNbOACVZOOFrN8Pal9h1ENPNM3DKZY2IJPbr1FehWPirSHsFhuy0l86hmkZt2Tjn9efxrC1byPE999mtrNbWFGzKVIQkj2+lAFPXNVW/tmhL+c1w4WJzwQP/ANRrN1S0vYLD7HFPNFHGduGGFIGB1+vauvh8MtDLIFEEkqqroZ/nCL6AiuQ1v+07zUp1nKrDbjBjXK7umTz/AD9qAMa6W4s7jbcXJljYBgN/IGOx9K2p9Sia0VY7eQTNuwzuzL0Hbvxj/PFc1fssySSNIdq4CoDjHtWlYamILCLLEBSQuxhvGc+v+elAEN3rlxaEWY27I2IYgYyc/wAqyNQvJLob3kPUgKOw+vf8abfyrLPKS7nrt3c96W0s4pIt91diFSeFA3GgCkQmSct7U6GEz3KxM6oCdpZugrUgs7CSZD58otVz5jlQGPToK1LGbw2LORLqGWSRXISToSOcE4PPagDL0mKziM5mxNIinYCflJFZ0zb3Zg+WZvmAGAa1dcOjrZQjSklE/SRnPB/z1rHWQE4cBs9+mP8AOKANZbG7hRHaKOOGVcfM3BH+f51X1acfaAsWzYh/h6f5xitnT9Ys4LGaK4gL4U7EYZIPXr+X5VkwKJZZTDG4hmJwGUnGOcj19KAKLSYDgjkknIPTNRoWnbaWye2T0qa5V0zEEAwx5xyc1VIKsQCSM9aAHP8ALJgENxg470EqM7/mPamKDgY69eD2pGbLsSOc0ANBzx2oGdx/Kkxjml7kDNAE6SBYmGBux1pDN8gVAAT1Pc1D2wfShVZj8oyeuKAJhK+0K3QDC+1TMJI8SM5ww6A89B/j+lRCCXALoyg8gEdRUgI/uM0hH8XIH4UAWGlhldTCgjIIALck1XufnUYP7tAVU4x3NastrZW0EW6dTc7sttAKgZHH86NQ2TWKGO28lFX7xTBcg/8A1xQBixbyPl4A6+lNJy2F+UHNSl0EZXaw3Yyc9DURBPI5PNADCTk56+tKJGyBk/QU0mpYk3bc85bjHNAF6xjnktZBACSw5J9KJ28mIRRsG2ZDFec/U10HhvwzNe2zTzzNbWKKxeQ5HTPA/X/JrJ1YRWd20dtHvhJYLkZ78H34FAGZZOiXIlmTzAhztPfr/Wp3u3uZneTA4AAHAAqFyzhlcbXLfr6UQxfMwABPGQTjFduXSccRFpX3/J+pM9j6F8XWOpafBK8B820kZdq43Yz7/X9a53TLuLzYvt1vmfzSNrpyxxxk4Hoa9F1PU0s45FkXMDADazfIemCD27flXAeKdOkvdStbzSlUx7nR0Q+3X68VxFEGvyXUVxDPBaCOFUIkLKGPb8+nWsyGwg1S3kmttRKx/wAabcev6VZ0WR7USvckpIgZXLMWwPpnpx+lS6pff2XGL/TrVZNzEuEA2MvPJFAHM6jb2ulW7paX5ndlwEdAdxz6iqenX1vaauz6xp5zxkFiMY6cf54qz4q1awvollOmfZLsAFXVuG5HXH41oWmjR+IdIhvVuYxLDwyN147dOn50AbvhbVtFnu5LgWklt8j/ADiMEDjt6VHeeK7Oxa6tYgJ0C7knXq3HIP61iWVrrEVpNcwWqm3VSGicZwMHgevGa43V7jLlok8rJzgZ4PI6n6UAe2+H7nRNcthLNI0bqRtZ1yM44GB+PauF+IEU2l6lCkttam23KVeNNpOAOv8AP3rmtO1a6gsBDb7G2sDsAyewr0630CbxL4Ri8xTIY1DBvMG7OB/9fj2FAHlepawuopFDJaQoFYYdVw2MYx/n0rb0I3cckklvFN9nRPlRBn8se1YJ0K+N/JBHZzs0TAfdJ7Z/HqK7b4e+KhbyDTroRouQobZymOKANLw94zmfULiOe3lxgeUCM4OOjfXFYPjDXFv5BILd2YDBcDG3rwQOK6HxXrUGnXLSW1tHcrIoDyRnpweM9q891TUbC4gfyklinfJbB+XP0oAuaHHJqN4EaW3hjB3ANjMnYfnWZrdjLZ3jJMgTj+DkYHAP14p3hewub25Z7V4hKnTzTirWpaVqUeoB9VBjhJ+aRPnUeooAy4LUmWIw3JGep6Y4rrdCjgkkHkXjPcYOE3HLH+tZ2o3lqlmEsyhfhPNRdpI245H9ay4Gkt7l7i3bZMmctn5WI9BQB2k+s63EpIILIdojMeQQO4JrWur77ZZrFLDGmqTIQXnj2qP9kEdOcGuVTxNfX1nvtJbeCeIBSgGC3B5+tSaTrt3fX8I1S4+7uCEjk8DH0780Ac7q9jeWayJcwhEB5cKdrH1Bx+FZG4lFQAMD+lexalYWFwj2r6hLl8EjjCr/AJzx61xOt6To2mQg211K0wYg+YuVOB07e1AHGNjJIPTmnNIvlgBcMGJznr7fzqW4USXPybfnxgAY71pWugXN3eeRBG+9hkADP45oApQWl3NGTDBIeeWA68f/AFjVR1aNyhUq65yD616TpPhLXrK7X7aIkhT7247gvHI29z0pbjQIGvbuOaS3E+CY38vhjQB5rJIzIAcZ9hUP9TW/rulJYqFjuvPbqSEwAaq/2HfNEskUDSjdgrH8zDp1FAFaF0aJuSsh6fTvVlryVJo1MvniMYUgHGPSmraz2lwwu4vKbBJWUc4PtRDOLSQsiMXZTgsMYOaAK1xcSzy73OC2eDUBVuW9OOakuJpLiYyNyzHJxURB4yD75oAbzjijHJPv0qWI7SDwc+tSi2e5nIiHPU7jjHNAFUdQTyKQ4J7jtU9zZy25w5X6q2c84qAjGc55FACbhVy2vGtQfLRN3csM9sf1qmev1oB5zQBqx3qndLcqZWH3VzjH1qpPck3LSQjZ6DPSoixKnv70wqcmgDS0q/FpO9wyq83VCwzg5qS71me+dftZGAMnAxzzWfbzm3bdGAH7EjOKaA8p3EgYGSTQBKSZ34QkDAIA6ClWKIoCWIPP0pLe48rcq5MbcEDjdVjTrC51KfZawsVAJJxwMD1oAzieTg133gPw3BIVu9VjKJuDR7uhA7kVh2GiSJIFEH2ufcP3aZwB7mvU9F0a5le2OrTbBG6ksnAjXPOBxk44/KgCt4kE1zohitlit9OjjP3QAX2j7ufy/wA5ryS8vZJZy27DLkIoAAUZ6D8zX0h8f7bSrP4feFU8N3KR6U3nGSRAPMlYKud3+1knPpXzHIoaZvLzgEkZoAfjZjnMhP1xViJIhnLNnjnmqZYh+u41Ytkkk3ESFBx2612Zfz/WI+zim9dHts/NfmTO1tT6CfVra+kktJImjlQDMLnJ6jPB6g1k+IdFmt4pLnSJjBcpI25QfkfA7jqOtdv4w0G3vDKYxF9qjKnLfI7HqeR/KuA1az1H7Z++S8aJJG3bCMEY/WuMo5hdTtPtck+rOJVkXapTPXv6egqvq17a+Wo0662QEfOgXAPOcD/Pam3+mG4txJYlLpMOxVjhkbvkd/xrJs5IJbZ0vbbywSQGXHyk9MjqaAJlgjbzIxE91GFGHVSSh9/z/StTStWl0yR4muUSIH5oyuCQf0zg1TW31TSrfzoJv3DjDNHyQOOSPxFXvCt9H5Utpc2pujI4O9Pmz7HPT6+1AHo1p4iWPww8j2rS5Q5YDG8ba8Yu/N1G4u2iCuWO8xjqOe1dubnW7HTpoYbeQ224gRyDkLjpnv16VwBvJ7GcSWyvBMCWJxg/jQA+3imt3IMDx8gsJFIHbg8f5zXp/gHVLCDRI4xqAMitmVHbbzxnB/HFcdY6/Bqoij1uIu4YKkqnp07Ul14dl0+eKW3uYbi1YjeG42g9cj/PagD1PL6tNI+n3hhdGzhf3hYEZycdfwrkLix+y3L3Gu2kWxRnz0j2g5PAIGOfervguextbrFtfG3ZVy0Yk3A4AwR+laGu2I8S3Ki2lkZlQj73yuCT2yfQdKAOR1q/0W60+RLJZ45hjI34D444JrjdUktZxHJFF5Ld+c+n/wBevRvEfgdYNPXy7homUhtpAO47ef6ce9ecRWlyZ2hS38wgYIK4wBQB2fgbR/tsBktN0qggHBwc9xgdMVuayLz7KLWERN5OSXY7RgDkY4P4Vo/D66OlwJDcWSsAw+WRfl781e8dSWVlbvdiNDHtwEABZDnt+n5e9AHjE6GSSQxwbpCSvXG3A5P6/pVcNLayhmIdDgsuevTj1rc1qO0mgE1tebrlgCE2Yb7vIzWdZs9reqBbRvK6kjzWzk4oAsXGk3lxa77XTTFCcNvBzkYBOf0rLN9NZzfIXGDg7vU9cGu/Fn4n1G3VEgghtcAZbAHTB6H6fnXJ+IvDt5YbzPLbyHJOxHBPbNAGLLqUzyPJG5DtyT757elJNqEt5HsunzjkNjkn61RdSDtYHPSnYxjecUADSkEEMfxrodK8Tz2UkdxgmZBtDKcH8fXt+Vc0R82KFPAHvQB2lz4/1eeXcbhtmPuYGOg9qg1Dxxqt0Gw6JuGNwQBgPY1yx2kt0HoafaStCWkQKcDHzc0AdSniV49Bjie284MeZZkBG4YJwT7VPbeOpre4WcQqsgVkKpgAg49RXJ3GoTywLEz/ALoD7oHH/wCuqbEnJ75oA7N/EunXfnTahZtNcOTxkY9qfcXOmS4nu8S3MiHaqpsEI5wOOD3rj7OIT3SxtIsQPGW7VrXekx2kMjSX9rIRyqK2SeP0oAfotla3lxLHJKIR83z4zgemPzrZ03R9Mt3efUbxbmPP3APmY9640yNG52Ngex7U77ZNsx5rD8aAO1TVtMtoJWs7G1VVXaFfBY5I5HvwKxdS1ETO0kcCwmQLmMcktkVz7ykkjJ5re8Pz6Vbr9p1BJJbpH3IoJA6jFACJpdzeLumHlqq5UEc9Tx9f8ayru2aMurAjZjIJyRmuqv8Axhb3GAunoExj73T0xXLX18buR22IuTnIHNAFQBfpgUwjHQ5p2PlyOlSxwtIwCAgMQOehNAEJZiu3PHvTkBOBkc8DJq/d6fDCVWK7jmJHzbR92s9wFfCtkDuKAH8IwBxnjmnSvvfavAB/KmZJRj/Omk5575oAltwglQP93I3fTvW7/aF49rFDar9ms0BBCDG7Hr6msCNlV9w/KtaylutQnwIWmWMcjPCj1/rQB2NjeTNZwW9im51C72VOWGOpPfk16la6LooiEt14uuLnIwif2c6kY5x97/PSvJdA1kwXUsU6bYY0G1Ih9449ateIvF80UrrbpHCoY7R94kHH65zQA7x9Jf3SpZvcYtAxdLdX6E9yP89BXnFxCRcNGjA7SQD0zWibtpZGuL53eQgELnBxzUe8eWHEMcef4icsRjjAoAzU2rIAx49a0ILglAkUbMqgZ6dapTHbIOCf4skdTU1o9wWcwuEyBnj613ZapPEx5U29drN7PvoTPY+uNfuPOE0GoW7K+V/fL8oboR0rlo74Rs5uJcNHI4ViBhhj19TXY6zrd7FBIXtkaLcCEZfvYx+XX/Oazb3+xNWicSW4tbnLZj6jIBPH5k9q4Sjz24sYws09lprMjhgzA7fxH51wEyzecTGDIw3HYYz8p3dD69K9d1JL6GJ/JuopYcBk2JlgM55ry7Wp75LycvPGLduVlRSAvf04NAGXJc6nMUAh8kuoyOgcD2PFdjptxDaublIWZJMCQxx459SR/T0rI8M2w1BbmO5vt4X7uTkHI5HtxWsumiwvT5F2qt5mTE4+VgccY+lAGrb3eqMksSyw3ay7ig35PIJx+X8q888XNPLdMtxZCKYdHxjIye/417Ylmt1pkRhW184BkZkblBjt69Sfw964fXNDudQRobq6Z2VcxEAEd+PY9KAPOdPtLtZN/wBmlaBTklVPHtW/YeG9Vv7dS0qxq2CEJJOCoGeOn/166Pw9pUyXbI/nwMG2MgPD59AePWtx0NtEPNnDxx52seqrjnPTPORigCTwv4WgsiROAs7jJHl8cL2YfX+ddNZ6cIkOEi2MS3mRnJUc5/TNYmny6mDEY5YJYAAVJDKWyOB39sfWulstXENvI7ffKldqfKM474oAi1OyF5FGbeLG3BeR8Z4HY/Q4xXJ6v4Y8sTSRvIzrG2ySMgHoeOOvSuz0/XLt7fyopI035OJx2xx0PXgD8fep9QsL69tZ13Wkz4++j4I78+3+eaAPGNG0q5kR5bqW5iZJdvmI4yOPvYzXPa/qFy955P25rmJRtDZ6k9Tiux1fw3f6XJMz20khc58wycj/AD+ua891ISnassSK4O0MP8aAIpZBEwCyssijbnHBOP8AGs55WO3eT8g4x1rTNqqW4814Q+T1PzDis8hIhIC+9iOCKALml61PaXO53klTAGxpCADW/YaGNUmV9RvFtlLHG35+uP8A6351ytzHMkCGSEAEDBGOlLZXb27RyJMVdGyBjOKAOp1TQtNjt5o9Nu57y9XAA28D2/LNchNbzRsVlTDg4PqPrXXPqFumlO1nNKs5GXY7QWOOv61x80kksvmOxZmzkk+lAFdgVPI5xSohLYAyfSmk5PFW9PvJrKfzoNu/1YbhQBLbabd30pjtLSV24ICg8fjTb7TryxfZd20kT5I+YY6Cr7+KNWUuY7pk3DHyALj6VnXmp3d7LvuZ5JHJySTQBUEZJAUEt1xWlbWF3d3RS2s3lYj7qrntV3SNQ02106dJ7aVrl0KrIGHf+VaeleOJdL0f7Fa2kIds75SuWORz1+tAHLahaSWNw0M67JU+8M5xVYEljx2rpbHX4LV7p/sMMjz9Xl+cg+1bWgR+F1sN18n2vUbjO2Jei5HA9qAPP2xjIHOT0pvbp/8Aqr03RtDjg1aaa901Vtt5MShgQv1J6cVleLbGfULtl0vS1SKP5D5CfeP+ePwoA4fHI+lBJ5+vNbNxoOpQwq1zatCDkDzDtJ6etFp4a1S6jaRLciMdXchR29aAMYDjHp3oBwBWpqOmR2USh7lJLhjkog+6M96opazPCZxExizt344z6ZoAhyQMfnThIcjkgUjLtHUZNN6D0oAUknv2oCnqKTkinLuI2jPNACsSRzwBSH7n+0O9DHJ5z1pwCE8fdznmgBmOCT0NXba6ltox5cjIhyCAetMit/OjZ1ZVxg8/5+lS6Wii9QOoc5wA3Tp3oA6TQp7kwBjEHJBEbzfKoGOw7ngflUV7dW9tO8jASSk8Aj5VOevv0rO1K5Zpwq3QWFBhUjOQOKyZjvk3ZJXtmgAmk/ekk7sd6l+1khs8yHkFucVGiIwbcD0wAPWlWAAqWzg+goAjAd2Lvj15q1aI43bWJJxnaAcdfWmtGhA8ss3A+Xrz/nNKhnX/AFe+JccBR2/MV35ZKUcVFxTb1+F2ez2In8J9jXmowSxzwSjLSFW2NjYc4+Yd+/6VgalaGHTWurKIC3LEhHGT04GQM9c/5NJqWgXc0pSAyQ/OBgN83I/zn6VieIP+EmsLNXtRLcruY7ecFfw6jNcBZz9zHqEkUnkuYUxkRr/FntnPX/Gsg6ZrH9kyeSqFcZ2zE7xz9Paqkc+qXWrvPYpLbERZmikz82D1A/StPUptYa6Rmne2sJBhldMhMnv7/X6UAc9bahdaPbvNe6fHIrkZmTHynPt+FV9S1KS5QX8t1ulJyEJ2lQDwBXc366M9o9tcbJTsxiPJ3e/tXOWunwXusmzijaxgY/IspHYZyM+350AXPB14yTb7tppS5b5EG4beSD69fpXca3rLadYiSKBWgUBVDgZzzwRiqGm+HbjSXheRBcgKQJeBgcjp0FaWqabcX9p/o9uSY0wBvwPxxz2/UUAc54g1dbm3JuLdFiBDeZG20jGMYHUf5FcQb57mOKO1eWSTdhZGO4c9QfUdKt+L9Ont2AIkjnkIzg5QnHI9a4tGls2GWZe+0dR7igD1vSNbvbt2tJ7dRNGQjBHGCMccfjXXRTx/ZY1W38iZgd5I+bPc9/Q815B4R1J5NQwtxFGxLEq+fmGPX8K9d0cxSLEVVzMDhT1z04/z6e9AF3/hF57yJZhIxRCuBEMls+2c4/lt61r6XbS20AfcpkMbFllGwgY9f0ro/D1zeRSKy/Ybd1ACiXPzdOf5dfzqTxDetfM9ndG1mZ1YjycDHfGfT1oA871GKeeQYti0eRvJYkHjvzxnmuc1rQ/D95bSIFCOOd7YB68498V3U1rb2nmNLd4jZj8o4yRjj68/pXIa7DBfxPHZQOkgGFDKAQ2PX3xQB4/4p0WCynQ6d5kkRPLN34/z+dc6YTnGGY4J49hXqz3Wn3CvZXsk8NxA20uy5GSozzj/AD3qWHwZYTTL9kmEsRyxP3eD/PtQB5WNPv2tJJfJfyVA3EjFUWBjfBOcGvpq01HStGtjDe2kLAKow+MHj6deBXO69qGiyTzTTaNCsSHCJ5H3+Bz69O9AHhk1w02HJVSBj5Vx/nrUByeFyTXqN9F4T1W0cu8enDcSAkYVs9ulcle2ukQ3O3TpridQxG9125GP55oA56C3eeTADBQCxOCeK7zw14Bu9X09J91uFlQOmZPmxk11Hg7TZXiSOOCD+7LEc5c54r1nwj4eRrm2SbTCsRIXMSFQo9R6dvzoA8C174YalZW7S2yedt5GG6jbnAHc/wCNcFc6fdWsjR3EEkbjIYFelfoJc+CNNmtUjW5a3uAAfmwxX6ivJfiH8NhamQuqCLLH7TwHP4d8f1oA+VDaT+WjeUSO3fiozBMCyGJ9w5II9K9d1/SW06382zv47eIDkTptIB9OPbpXmGrXLS3DFXLkkrvzyaAKDK0b7XBGemaEkaORWjJVlOQVOMUjlt/JyeeaAThsHB/nQB1dh4k1CS2S3e4RIuELP6Y7nGa6e18YR2M32XTV8+UfLnA2senFef2OpLa28ka28DPJx5rjJXjtWekhWTcrEc5yKAPRNVMdzcSXevXEbEpmOJZc44zwPXp+VUrPV9Ojed5A9yxwI4ATtxxXFTEYUB3bjvVnT47MSK13O6qeqxrz+dAHSNpskyT3E81vaorkpbhwSw9qyHjJtY4EMzBiCUYFEPJ6+vUc0y31dLLUGlhi86EHCLPzx70X3iO9vFcSMoBOcYHy89qAKnkRJHKSN7AdAeF/H8qz3UckevFP3nnnOev51Hk4HWgAA4z70KcYI60Y5pV5YZPFAC4JVjilCM3PTBpQQT83K471etbaW7mKWyhndtqov+fSgDR03QZZ7Y3EnyDblY06nnp7VWi0mZYZ57gMAgPC8ke5/wA+lelaPoN3o2kqdTndIsEmCHksT6n6ZrHfRrmXTZ7OxgnjEjf6yXgDOeM9+KAPPVhYuDgAEYyT7VLMHmk2ALsTuvQ89a6P+xrfSyxuk+3Sfd2jKgcdc/Xj2q34qbRpb+3bQ9HudJsvLxJHJctcbm3ddxUY7cUAcvFZpFHmXezlsbQOMfUfjWjDaXJiKyxgE4wgPIHI5/MVY1d0khVbTbDaxqNpf7z56c/nWQb29uHCoXVioUAHGetAEl5G9jJFF5iLIQMhSDzkimSEiQmMytnqxxzyfWogstveCS5j8x+PlYZx9fzFTzXT3Mm9hGoxgc7R1P516GVSUcVBt231XoyJ/CfXGvy6l9nMtvPa3TsQCNwBwemefcH8KxbTxBPDCqyqLZSS3lsNyjvwfT0Fc8/9oWmptFJcJcQylNsikDDcEcdv16Ve1K0s5oDFqlvPFK7Njg8gKOeDk8+leeWZviBUvI1H7v7Rn+CTD9eoPTsP1q9Y3dtHata6vatNCyghyvGM/wCHNZ19pKXMcUcW97dWHls/PbPXseK24kWZCGtHyP7h4A55/l3oAqtpWhXKSJFcxR4AIZRtYE8gevp7c1RbRrC1klFwqz5cJuYfMQMYwSO3+NXNbgt1jZUtvLkABQFOSc9e2f8APviG01SB96ORbXceBKGBKsOAD+R7UAcxf6uNCuxLDdXIiblYXbcG5xwT2ya6/TNTFuBPaPJDLN8zL9/J9CD06+vasHVILHVVDS3PlGIneAgAH4/h2/8A1TwfY5ZWh051YIo4X7wwOp9On60AbupWb6vOBfafaSDcWUt8vTuPXJ/lXmPirw7Y6bK07WtwiSBv3cR3gA4x/Ij/ACK9NtYJXuwLeRJm6eTI20qAMkDPfp696wvGN59mSIPaSCdjhuNygdSR2HH8qAPDzcpaXiyWquhU52P7V6JoHjm3YRR3CPD33IcqPwrkvFNrbPcCWxdC5H7xQOpx+X/665u2d4ZiPu8cg+lAH0DB4+iS7htrl2ubSQ/KSeQfY59q7qK+s3mj+zJcebKDkMdwJ7ZI/wA/lXyzpuoO84gNuJifmUBsFeOo/LP4V02keMtRs7xPtLyNAgJ8ssOntQB7xJa29xeTNO6naVXZISTnuOPfOaz7pYtu5o3giC987vf0P0H6Vx9v45WbZJZGRJkGCsu0qeB6881rWXjVLycJqcJWU/L5jY6gHHQ89aAK0nhmW6vnurS5MURU74zEPm4659xVXUl1m30u4XTrSMxx5GdpB/4DXXP4vmgkktYlhktsZVXQkAehI61m6l410pLiNL0RGXd9yEk5xxjp3z+YoA81ey1I6Q81zYwzXBG5TIzeaDjJOK5bU9Z1NVFrfSy5UEYYdRXvK6xDNdGSztomLDClsk5Iz6dsk96wPE/hZ9VuRPd2sSydVIXBHA4/DrQB4ZHb3E4GxXZSfWtS2tWSJvOHkgMGyzcnHpV/xdoF7pkgeVy0ZHyuoIAHpisRIA0DSG5Lsp6c4A//AF0Aev6K93/Z8Ukd8A4OFOAM9Ocj0rptH8c6vHeR2l3y6NzcRvgD0+p/z6V88vqdysXkJKyJuyQpPzHjFaFtNe3WySeWbbEOCWwAPT+VAH0cdevYr5bi3u5i7jBZH9V9+n/1hS65rD3kcjP51yyoTtBwDknP868f8PzKkXmzapuZRxAx+nP+fWrNz4lvIdqyWLeQcguG3Fh9R70ATePNJu9U0wzxwlRDlupYAc9D/kV5FPC8fLKVB9fpXqU3iW71TTJIII5QzIQRg5J6c+g715zrVtfwTH7bbyRhmO0spAP0oAzNpbgU+NOSCCTyAKbyGznHpSNkE5GaAEcYbr+VLk42gmpFkUMdyA9Bk/Sm7/m6DNADGUhsH8qVHK56en0oYgjj1pnOcjvQA4nBz3FNzkUpBBOTRjI4FADT1p6IzZx7DmgRsMDbyenFbOh6TNPfRxyxsinBK45YdcY96AMu2jUzBGUuPRepNdFDpVv5EZ8qRXllAHQhRtz37nP6V1t/oUCmKOz0GQyMB+93bcDjpXTaV4XhuLiCI20G1CMRopkYtt6kfTOPp70AefReFGAQhRMzjITBODwcH0r0fwZ4aDxw+RbQpIkmJNqHk885z7V3J8H3enxCc2bSlxkFkJ4+nPvVy6uIhpbW9nGsMqnaQVAOOp7e36DoKAMHWE0/T9MZSjyOindg4A55/T9MVwcl7J/ZLSfahFbMvzbQc49Bx7V2y24m824vy7xLlfL4UdemOnbntXP+IdY0y3QRssQXIAUAHH4469D/ACoA4D+0LSymae1tZC2dwkuByRt5wDUGrC41eAZ8yJQCS0zBQefT6Y/Stu61HfcAabprXE5zuldfunA6fzxXKa9bzRXE0t3dRtKw5RSTt6flxQBRkit4MEytJnaPfGOeKksrW6P+kqpgtQ2NxGCeDx/n1qvbWkk0qyvJHGg53SHOR9K0L6eLERF3JO5AHlBflXt/KgBl4hntEWJNoZgxz36H8+cUwTNGBboQBEMccdz371VdrjH7v5QEGc88cf8A1qs3Vg9vBbs5CyOpLDv1zz+denk9X2WMhO17X/JkVFeJ9B6ZtmRoFg+0pGwCAn5146gdu2PrTNT1MxXoGo25FnGWOc5Kjkc+3A+lKtuxvGSDfbTBghYH5fxPqc5z3qDVLSd2+YS/aVJG4HAI6454zmvMLMa6eKbUxLot3MIwgY5+4GwCcg/55HpUM2pa2l1a+YBIGO0tG3yHnjPbrWtFYpayLJfQSAsgAlQ479vQcA0y4gt4oZMvO6Ec7j868/qPzoA0NVttQGnrc/2exk2rskDbww9P/wBfFUdHWxkuwNQna3nBzhhkEE9RWr4e1O5ihMNufPtXUbQ5BAX/AGsnpz/9frTtTtdIkmaaSEw3ZY8qcrj1HrjIoAknstHe3km0vUrUnDHy5kHB+n4VyDWUkWoTTyWccLYI3xMNrdwf0H45rO1yW6mlEVtaJt3ZMpwueuQfbnoc/hWlp+vPFC9pcW8bzouXZH++PUZ/D360AWb7VINJtTMZjcMrkL69B368Z/T6V0WkXkWo2Kyu0Lo4HyHkDgZHt0x3rkbG4tb65aa3MQbdkxAqTnqcD3rR8PLbCaWSF43hchJFZfv4H+NAEuv6DZ6xaymFYI5ThVlVdp7fTPI/nXk2r/D7WrGKSeQRSRrkZVxnj2Pfp+dfSmhy6UjSxX8fU71dj04GBx755Namq6NBf+XEYbHynAHD/Ng/Xv07UAfG93ouo6citcQSR7yArD6U4WUjx73kXcoIwTzwOtfZupfCDSbrTW865ljt3+YBSWPTofQf5+nlmu/DnR9JVo3TzokBJlQ/MODzz/T0oA8GmtljnUPOzJgbvLOSDjkUolk2E27EEZ+Ueg/ya7DUvCc8FzJc6es5VTuUlQwPfn865280fUWDXDxqgbOQDgjA9KAK9vr2oW6tDDeyLE4AbPOPWmPcSLcq8V4H2tlm25wPoazZ1XJ2Ek9930p8ZPkTZUBlGeaAO+tfFljaWy28/wBqeYYJaM89jUF58Q7tMm2adGySDIc5yMcj868+Zm3AsTkDj2pySyNGATuAPQ+1AHQ6h4v1HU0Md8ySwn7wI68dTWDLMI5JPJ+UMc4qq7FmJGMk9BT44S7f4nGaAJYkEj8bi2TitOa8kitBbEvE/OfTHXmtnSoIoYIbmxs3FyvyHcCQW4/xqSTw+YTNearIrOfmWMNjt3B7dqAOUKZAEUzNIex/xrQs7i6tpjBPM0SnnJ+bNIosnmaQlDEhJ2jIOOcD9K6HR/D8WsSH7FDIoJzmV85B6YHHHNAEemeLJrKALGYmmIIJaMYNZni65v75/tF9cxMNx2Ii4HbJH+fWu3vPh0Ft1mM7KEUkIijb29z7VRTwrpWq2zzLJKhViCTJgZ46DHegDzHJVt2PpShztYYHP+c12mueHbe3Ty9OtLiYruBbBYnH4f8A6q5V0S3ikIjb5sqpft60AUT94nHNA4b3FSGNmG7Hyk8n8KsJaxiRV8zc74xgdDQBV2ex96aFyOh9a69fDslvaG7ezuZ4+NoxgD6+o7/hXO3aSzXBIjYZwAqr+AoAZFal2IZkRs45PU1LHYOdpdWiz90FSS1aUumyabaQTXNr+8OHGecjtWvo0dxNqC/bIHaZhlfl4AOP8/8A66ABdGurdGnKrG8Y3ndjOeK6LwLol01xNcPIsk8rZX5SMjvg12lloyG3jSO2Ri5HyKPMPXv6/wCRXY6TodsbdWvLR4rcADYB82fY9MUARwaMkFrGyFC7jkLwBn9R1/z26rQPC93FbrLo84W7Y4Mi/wAPHBOfb3pPCI0i9upHS1M4hB8qEJ8q88bmPU5FWNU8YX9jqNxFbwmHcxyFwAnpn+XJx0oAk8VRjQ9OhTU9SuHvJECOEAYcnHU5IHP6V5lqklzbzhFlSS1LMZFGN2ScY/Ud6tapqFxdvJJqLQ4ILDD5JPGOuM9Olcf4mmWW7zJei3t0PzIuDv44Ax2NAGrcajDJbbJ7tMIpKwr1xn2/x715R401WCe72ROh2OfkAyBjPfr3qsl2i3t08bFoMHDY4I3deefSsO4MUh82PaCO56n8On/6qANh/Ed3PaRWUMixnpuAA4x3NQatNYpAsEUr3s5BLy5IAPpg/wA6xcCU8AITzuPer1ppwVZJJJkATdhAcsxGfyFAFURySSHygxxgYx0HXBqWIyRlAiF3A4x9TTrJSZnBk2oD8zk9ewFaEM9ytvssrZwG2jnqDzyKADR54bSMy3SGSYLlVbJ2++B1/wDrU3V3NzKsoUtkn5s9fw7VnyxtbO32ghpsAFQfujHr+QxToLl7iLYwjYISQGQEjPbOPau/K03ioKKu9fyZM/hPb9fvJtMVJLoz4V1KsfmUc9Pbp+NaNn4jW4s0j+1QzTiRvlJy23gdePSsrUDPeWc/2mVZMumYsBSMcYI78k9+1cvPeJoSedb27ZkZgGZCGx6H2rgKO5fVZnsm3bnWNCrICTg/QjHQmvP21i3S4eSCaWMscld3TJxkepz/ADrorLWY9R012aOMsse5wjc9j0H41ia/o91fabBeQWsEYT7zocNjd3HX160AbukXtvNCv2K9Ic7N25cZI7EdOc5r0jwraJc3C/2hHaTyF85chT06DPfg14G2pXukgxbY/JO0B9oBBx1BH0rs/CPiF5pXxKHk3AujKR04GP0oA9q8SfDOG7smuNNvre2wu4wSKNvXt+mPrXiviPwPeebM0oEQQbTJCOCMdv8AD3r0TS/Fmqy2ZtIne5QEo0EqqQB04P5cj9O0erfbbu1kyjDcmcI+SOOnPfjv6Y+oB5l4f0BLS7aOa4UyCTAbYMn681valbMsflr5ToNvO7Yx6fr06dM/lVntr+wnknjsRLbySAF0OSPRsfh/Om6xq09rGrPBHc2wH+qf5SPlH4HpQBpabIllKpS6Zk+ZPnO5egz+WPXtXoNjeeWDcJd2brhS8ZOc9Og/AV5VbS2Woaag0tY7eYDPlO5Izjrjvyf1rSt7aW2s45J2jKKmWEOeSOSABx6daAPUX8Q6ugeTSrv902RtVtwHYZ/H+fvVf+17q/kkfXbawC7GCSOmCwH44z2rC8O6xYrGzTTyxREjMbqAc9Mfn/nmtHVdUtHhhjHMUgMYJQYzjAx09uaAKVzcQSGR0QRA7gY1O4YxjOPz/OsTWdAfU4XeWNipHHyYbv144B4/OutWaC1iPn7k5G11QE456/lWrYXlvIixzj7TGFXa3ljIHPcfh19aAPmTxN4Jls7p5LQPNFuyYwvPT+VcfdWVzM00sVrIsUbYY7Tx9TX1r4o0rTUVJLOaFZBkFZJepAHU+tctNpVlLCY1WGJZCc7Y8A8Dv6c0AfMUm5jukOTwc05YScldzHPOB9K+mD8NvD1wuZHWUsuFEa4wegH9Tz2ol+GOn20JZIdydAxYLgbRkHn6cUAfNNlavcXAiXO4sF6ZrtdA8PTafN9o1KzSeBBkbzwP8/0r1G10LSdOikaOxiWZeQ/lE4J4H8j/AJ64qxTy3ztJICmdqQ7SUIK9cfn370AUrXU7EBn05VZyzFoidq59P8+tVNatdR1uydpY7O3hTkBySSMA8961bG3ms/Mmke0bA3EJHjkeo9ePrWHr/iy+2PawQRwR4+8YzhsD+EUAcPNCIb91BDxrglolIxxzwa7bwx4vv18q1htLaaVAdhaPJPXkgfhXJT6dcrIWYSEyjexGQMMOhr0z4NaBHresxW1vYusajdd3IY5VR1H1J4H1z2oA6uKLUNQsVF1DGqOu7CjaR34z/OsuHwteC5VLJN5JZzGpH0wT3r3rxP4ciutNE9pB5dxBD5UQQZyoHC474HSsnwP4cj1aE3U8rE8qA5C4bqRgHJ/z+IB5jqGk6hb6c8ZjtbTI+8AMtgdP856+9cjoHwufVx5uqoYIs7lYMS0n/Ace3P419U3Pge2uLlZndXCcKjrkYPX9c/nV+C1e3UR3NiN/CiW3jDAAdDjFAHzZqPwysJ7OSO3tjsBBXyo+CMH5hxn1/T8OK1LwYtncOFiaARyfu8Lj0IJFfR3juDUtIkaa2luI43+bDSg9ug/H0rz+z0e51+R7i8Uq23BYuRuHGP556UAeaXOo3LQ/Z2nJRBkrEgO75ehPY81XNhOUFxIsEUhO1QwGccHgDp1+uK9Wg8J29vOtvAQys4UgICS209M8+n+NdNpfwv1G4Ae4traEMQ37/wCZh0GAO3SgDyTT9Ok1CWJbqHMa8qSvGQR259eldra+CLq6WKSInB4ESLyxI6E+leueE/Cmm2QWc6YskiH5Xcg4OOvpW/canYRwE2VxaoqAlypAKj/9eaAOBh8M3Oj6bDEBFHMy73wQuPbJ56559vzuafe2Y8OudZuS0hIUQRDGMdz69M9f5VS8YeKRPcpPYJ5ttGM7Qhy+DjOc8j29K4LW/Gs91G0FvYpnsYgAduPu9j/9bigDorHVPImL2QZLTJzhTggE5HUew61zut+IIbrULhLe2i84EFpHzgKFHI7DgD/69c9c+IbgSCFo1CZO5t+0L82QM9c/41w3jbxTbTI9taM3nscMIj1GONzUAaXinVYPJaf7QjSphsLlupGTnPHNcRrXiO1vNqiKUxqwLZb73rzWLqj3IiRWXy4gOAO54zk/hWSvJJJwAeRQBp3bJNbosS4Kg55/z7UxLDEBcuCyjJA59/8A61QW/wA7Oznaqg4z1PtSSXcpiZAyhW6gD60AJJI/nq7sWK4IBNdXr3iLU/FlzbSajHZLJGhQG2to4MgZPKqADya5FbeVhuVWIPfHBq1Hb3Ea/NlOCeeDQBoRLG18xuuI1YYAxk/lWs+owEotuj/MNqomNx+9nJ7dRXOxJKbtY/lXBG6Rudp7nNWZbm1gl+SVpW427BgA80AR62qxRhpAiSOAfLXqO/zVQtzwVRnUjrgD+tMnlEz7pPvEDkntSxFYV3Et8/pz0/8A111YKcIV4ym2lrtvsTLVaHpt5NfajfyW63MTxkg+dGCAFyME/T/Gr1rdyaUiJePb39rI7rtY5xngGsZ5/JuYbcAwSeYAgiyBtPr3qG88PzzXP2me4BTLkojfMoz+RrlKOwgk8O6jtl01hb3TJ024+bnt3/Sk1ltQngW1DJMHOC6HbtGfQ9/auesdPtI7ELHKWZEBaSNwNwz+h56V2um+HI0theWN3LIh6xzEnPPXrx07elAHE674c1JLci3gEyMAxUkknP8A+s0nhvVG0S9aOW282IsQ4cZKHP6j/Cuv1Z5IrlGPmkoQTz8owfQdqpXlvax6nHciKGaSYbDvPAHB/Xj9aAOw8K6rDJM/2KaIM4J+bnIx69u/p0roBfwWwe4mhWSRhnLZxnPfqD06VxGgwxEBrmJbeQhgPLxkZyB+HP8AKuqh80QhY5Q0mwffIIPtz396ALGuQadf2ry20klvIzYMRGCPp6gevbvXHWWjwHbFKWbyz8jOpYDIHByOBXe6tZzNaos0ItmaRQHiGQcj0z6VyOvqNJ3zCdyqn+Hrx1x0NAFF9DZD5sdrEkgH8K/w4x1x9T/+urMEzieKK6h2Dkl1yF9ccHjOM/jWXd+IJCjCFpBISpKodzYxjJ654/l71paVr8aQuJ5LedAmcOMMCR1wepoA07mOC8jJjltrldxymRu6f/XH5VUgsHkkiia4mjiVc7cZGeOPpmue1V7K4uXudMjjE0eBuDEKT9P89a6G0uFe1jmdHZ1UMeT83X+Z9f5UAa1xqH2UYcQlFOC7Hrn29801NTa3gERncLIxwqJ8u7+8fQn1FZum3dvqEzwNEow20owwO2CD9DV2O4h0d2QNBKOSYn5OOpAB9elACOhZhhWaRiMoM9vr0Pf8a0ILqVENrMoC5ODjoSPUj2PFMttY0u9l89rlLV1zlShGTt6fz7HpXQ6Pdafc3Eg1GNrmzByHDAAZB545HX/PNAGUp8qIszNJA4xk/KAD/wDrH41DqNrdXao1rcQQkNuIXgDgccn2/l0r0BG8Dy25+zrJM0ZAEYLZDeh7ZH481He6Zol1B5tjp14rNwArEEDGM+1AHmEt1cWlsRcWtncyAfeD8kY5z6fjWXHNHq7yDMEDruDIVBbOPbr3/Ou2u/CepW8Qlg0CFoySW8yXDEDp39P68VjW2i3k8byLZwW4BIKQSg7hzk5/zzQB59bWGoQ6zMqXkn2cyM2wqMHsOfr3q/qdppqruvJFknI+UYwTx0zx/nt66V5pK3UbwzXEqyMMkKSSuenbpwOn6VlXgtLKUJMZZyNqopjyCR0JxwOOaAOU3pdO6TW86wKy7QpJOcDGBX1F8OPC1p4a0OKKOERXs+JbkjGd3OFJ77cn9a80+Gtibq5fXfFUdrp2m6a2Y3nYAPLgY5PZcbvXO33r17w3rmn+IbRrnSpjPbRzNCz7SuWUAnGe3zD86AOoMYNjg9QN3Xv1rAIi0e7e+tNOa6edwJViOCCeN2MHIPGfQgGuh+0f6I0uxTlsEfnWZJqUVldJB9jnk3xBzIhG1RkjBGQe3b1oA6Oynkmtg9xA1uccqx6cfpWdf+JdJs2cS3SvInVI/nI/AV5x4wuw16StwzWZwUWOUjaw7MD0xyf8Oa4i/wBWnvH8tXmhGBkCPgnGeoHTr+dAHsN3f6BrmJrotGI2zvfg+3H14qpBp2iXDsyuILMcqqNyx69vT29efSvLr24UTWiq6ywMRul2jPTP49K7fQ9bvI4s2qwfZR8xaXb+WPp/X8QDo7PQFOoQz2FlLHDG+5nnYKzEdMD0rd1y71OC2MWmWm6TZzIzZCjuc9yK5G8+I0NtEyJayG6Xhi0m4Kce3A9q43XfG9/dkzyvMIh8oiR9oLdsY49M0AdBrWu6lbWssdwptw4O+T++eB0/u9a5C+8QqImt7ZlnXdzH5W3r6/mfrVCXW/PCzXrtEzA8SuGbcR1J/wA9K8+8XeJtM06EmBzc3f8AezgH16fjQB1fjTxSlnZDMcaBceXGDkDLDn/PvXCx309xbvMkruSVyPuohOOM/nWXc6m13PG7Mnltg7WJxgkZ+uf5ik8R+I4bbT/K07y3Hyk9cdTQBQ8QwQpG0kmpSPkkFANq4yTxzz07VyNzch5EjgGM4GR1PHc0+/1Ce9YLcuzE5JJ/wqNo4UiIgMj3GR9AO34mgBL4SqB5r5ZueTz/AJ4NVA/ynauCScfSpElCEmVQ7e/NNkKTXDkABWbjHQUAMBLYJJ/H1qZYCsfmuyk54Unk1IlrK7RxQZkdiAAoPJzinSWU0D7LoMJz0TqT1oAsxajKdq7EbAwqt90cYqzZXNtFKxui1xKcc5I4rGkgkt2HmjbnBGT2xmhCpYlmOCD2oAva1qBupgI444YwcgJ+VZ43YJBAXP8A+qpJYEKeZu2jIxnqaYUQRZkD5P3QeAfegBixMyl8ZUDJ5HrUlxcu0caELtTIUAe9Ql5B0J20KS5bGD9RWlKn7SSihN2PVj4e1P7akiqCwlU7o3zhuByP7vOa7Cz8y6s1h1Gw8tCx2yDG1hyM556U+FYbu0N3Dm1Mkg3iQEnqD19+PzqHRYL+NW+2XqyhnfZs5XbnHp3IP5j1rMZyMujJpmpTFImvYtu941OGXn9a7Xw/rEM2nf8AEsuGQZJEM6YCjkHPPoagmvdPtJnDt5ExQZ+XIb2/PvWLL4hsrWSVUt0lG0BvKOMkng+tAC63rEn2hXvLZ4m4PmRORkcetOsb8XNyJDHI0ZJJXYAR06+vT9arPGPEEbJaSNblFGVPOc+uen610Gk6I8CvLcjyiSd/lYLevCfT8/woAt6dCtzdCTajFSRkjb3zj6c/rXcWMlxb3kc0dvCY1UMwYHBweh/XmuNtr25sZGa3keRDk7hHlfT5s9OmM10t/rNxJY+YYUMgAO9fk3E56Ad8fjQB3aX2k32pwnatvGADLDGS27nrjHHQdfSoPEuneG725SCOG7Du2CcfJ04/CuL8Oa5NpN6L2EJcBjhw/KsvAxz3H+eter2evaDrSRNqVnDE7HG5uAD/ALw/T/JoA8W1jwvBo+oG6t7mISOMbg2QBt49OeM1z3iTS49TRZbGa3F7CpChwADx/LrXu/ib4eQ6jN5unXMboRzEW5PHY/T2rLl8INptkJb61iUJn5XAZT/s7h7E9aAPA28OSQWwmui0TKuXCDKnv0H1rTttVaWKPNyr25jymwFSD/Trmu9utNhttSklaOKZG4aJScYx7euP88VlXo06NZEi082pc9SRgZPb8AaAOKtLi4m1OSGaYpDGQYi56gA/n0rpDGskYjUIzg8TAbcY4/8Arn8aqzabCJ/OVlOZBhww46cdPrVf7Ve2NxtvruAW75C5O3J5/lxz/WgDYtbGN7VvLeOSVuAzgf3eR7f55qNNOu7QEsyxoFZcZwRjHT0/wPvWP/b1m9zJCrKhRSGcfd4Xpn8+lRal4ggt422RS3BAIzGQUHHB560AdCZ3sJjJDHsc4J8qQA59fTPOfxNWpvFusyJHFayv8zHd5k3X5R7/AKV5tpni/wA55otUtfKZTlTjOBjAq/M6yTrdWt6mNxKqGC4GAOn0/lQB2Nz4l1GKBlnRXcnJ2uT+Y78H/PfDn8T3X2hIbdo4EXPmyOSMjk8ADj8Olch/wk1+6yksJSmQxD7cY6n+tSTa/Z39sf3ZlugScFCcnGc/lQBY1jxKtqZYYr+Z85Zyg6fQ/lTLLxHHar50y7kf5gz5DPgDn9P85rNmmhutN23NsLd8kGKPAJHbk89qptoGqX8QiWJhBuBGSMgbfX3zQBe8Wa5/aNnCsl4PsqZCQxZ4OB745PHFexfs8eKdCsPCGo217qVnaTR37uFuJgjMrRp8wB5xlSPwr5w1TR7vT5PKuVeNQ33twbJxx/I1b0G1lkc+TcQWykcyTdT244oA+208e+GntzEmr2RGf+WbFzn8BXNeLvEFvNc20mnXEsmxG3sA6BSG+U5wD3b25x3r55/tG800RtFKLq3UHcYgMgdB9T0rRPjX7WGdbsbgp/chMsOMk+1AHpjXxeR3eSDaSVDMOnTH41S1Jw+ZJb1sqB8kZC547fgPXvmvLp9WvJbV2VblQTuIyq8H9QQeePWo9P1G+SySJZzBdA5IcGTAAPBOOD1oA75dViicx3MHmSjhIwCCcKOvr2zVu3upJ7hbYssTMhfyg20dPQ9x6kCuBF5rUcinfGxLEmaVQAny9Bjkk/pipbu5hmsyZNQuZ7llxmGME9u4H6e1AHfmW0ErwRuwYNl2R9+c8Z56j6+lZfiTXLTSrblROE6qy7iOBg+v6VxVhFqUJaPTbW6h8zG+4dcHGORn8wa3rfTorO3Y3dyksjkq+5d3y8D+hHcUANuJ4tX0tmEO1COAM7se+T1+p9a5Gyh0+xldlgtHmU7Ck/zkDOQce49+1al7a3N5ezRLcInmE/u4vl4J6CsHU9Bk03y5YIW+crhi+45z0/L/AOtQBBrOq2izMph3PJyy7SiqM9h+tcverbhhJCXdARkdvXFdP9l0Xzn+0yXNxd8ZDYAPPOPxq9puip8xitQxcqSkxBC4Hf370AcU9ypgT5wNqk7NvvUSCWYlFQrnGMDvj/8AXXU6v4dkQnMkER2M7t2Ge2Pz965+7iexPlLKJcNnK8c4FAC2OjzT3jwSrhlGPl554AOR9au3ul2OmMEuC0s5I+VJB8meTnFWNDg1m4s55LG1b5VGHAx6Dr+Oayb7S5bXzXuZ4xKpGER9x5OO1ADrDVZtOkeSyGw5Kq5GSOaittWnhmaYBZLhh/rJOSvPaqYd2dhHnnir2nae0+XkMaxgZYsT/wDroAp3dxJdS5dmeR26+pNb+veDNX8NXcVr4itZLCSRPMjVypLrnHGCe+RWJM6NNkkPjoRwOnFTvdtISGlKpk55z6EYz9BQBfnm0+xjEdvbiSQIQZJTknPQgVlu5uZd8hAXd1/z2qVntCqEhpHB+Yk9eP8A9dUsB3wGO3g4FAEp8naQTkAf41HEgJbDBQKhcIF+XduxzTEkdCdrbc10YWpCnVUql7eW4pK6PoD+0Izci2MaBi4cBh8r9M8+nf8ACtNLuK2MUX2Z2kXd+7J+9nGPfvjHsa5/wlFM9pHaTOjmOQeVLt+ZcHB5/Hj/ACK9G07ZLZQm4hicjcwIH15P5e1c4zhPEEwWzEstpNLEq42FcsoP5DHH5Vzyy3GpOhsbS3lRTxk7cgE/nXtYtbHUbZoo4DGSgAzjGDxz+Y/KuJ8SeFYtOikltZDECGbavf5iPTigDgrhrjT9TjMa3Ni5ALhuV7YPHXr0rrNF1KGW6kkS4SV3IzvJwcHPQjI49qzLuUi2l8zLSwKJAScjcATkVR0TxJDqVxLaXVkocswWRAMjGB1NAHomn6hLplw08fkSoxJ2EcHgjpge/wCFXP7Wsb22mSW1e0lCFflfAxg8c84z1rl9E1xJYZo3gDJGrDLKM8jBx7Y7VNq8sUaSOsbxqQFAV/unB7UAVpWvLPUFDWjyWjSKS7HjOB83au30GFitsIVLw79xywJHT+me3FcXqeomwdWllnaEyBCq4z0z39q7Tw1qwtLeO/SFXjkb5h91sDGAMcdutAHsGlaXG2mwf2XMVmAIlBbDDp1B/wA81z/jHX7zS5/s92izBuQnKcEd/wD9Xr+Eug3N7clr6ymUBWOYphx2x078jmua8W6pFqrkT24U42l1PJHHbp3H60AZmrahayS+ZHCYt7fMGUHGOOT6Vz2r69CtvKYYftTbOhTIIycdh2NP1NTCqG3kOwnI3KO46fh9azHeWC5ZLmQNLjbvRMevvQBh3XjfymZf7NKBXwVXI3Adv1/nVZPE1vdRol5paoWYsA3IJyenHb+VaGr6a+onbAYlIAOWBHGPbNZh0iW3s3ku3jmkjyAPqM9cZ9aAM3xFoiXaG4jhuLUEEkZ6dO30qkbCBLYkSXFywVgVC4APf61taf5WpK63xnPlgMVjkwpAUH6k1rDUEtY3W3gTAXKlhk9OM/iaAODs9VmM0zNY2wG1V/eKQSMdP8KzdQnaS+leKzdMvn9yCAOB29Otd1Ndt5TXiMVB42BRzjtXI6p4nuZ/ktVEJDMNx6kcf40ALpNpK1pMBJHCj4ZpGjyynGa3re8sYbfEuqo7YYkBNm7Hp3+tedi4uHJUTPljuPJ5NbEtvDZRR3VwGuXJUEN7gmgDetLnSrq3OoNBLLcrwEkYkduRz7H8qxNR1u41K5fbI1vECAQshAxjtVe712WWJ4xBDFbEYCIvIJ75781lEnyxMP4pOCTkjgf40ATXgFtKVLNKvbLbqlsrayk3S3c+3Ib5d2Npwe3tWRJI+Sc/NwM9+lRYON+c9Cc0AbL36wp5KruiIJAU8Zznn8a3LbU7jyxb6fpdrkgHe429QAa5Swz56thWwCfm5q5Nc3K3LK0ziPAyFY5IxQB0wvr1bgxXqWyAsckfTpWha6uLSBlQPIy8n5QcDpx+Fcbb37yzK8aIrAnJI64FaNvO+He6kcrwT5eAfmB4oA6291OwvIVS7mkV9xIQNjHygYBA461HpptdPlAtdWZpX48mJCR9ck+xrkZ4reIrcNJOQWLhMA/hn8BVqwhaYGS3KxAIASCcjgDjn3oA9IGtHzI4bkPxuYeYyqOg5Pr+FZ2q6tYrC4WYSSNyRHJt9MjPU9D+dcF4plEcyqi/vCAC5OD0xVDTJVVxF5EbzMcbnJIwMcYoA72zubWPbIsA81zwxfP5D6+1Mur67aJZba3Nw+0bGYlu46Acfw1c8PeHzfuDeNEELksI15OPrXZXHh+xsAp8oO3l5HJ6Y/8ArCgDze38HXM8n27WbuO2uXIIRSCV564rotIstOtQ9vEGuLhSoLluDzg/5/nVhdr6nLL5UauufmGeBuPQfjS3tvDaFrpWlDfeJXGflPT0oAw/EmiSXWnyPDGkICsxYHn73PHpXI6eljpdsZ7yNryQuu2PHGQOATj9K665utR8TqLDTJY7OEAli+SXye5A56V06eDodM0iO61CUXTqRwF4+4ef1oA8nn8TX8xAZnRMbVijULjgen4flVbW/t8tqZJLCaGMkAuwJ689/pXdhrSwuJNQuLUMVJCIh+nc9+tReJtYu5olby4o2eQ7ArEhB83bH1/OgDzmz06TbvkPlFlyAT8x56gVXD7flVjzweff/wDVW5cfZsyzvHI0oOT8/BJPXpWCTmUgfKpO3AoAZMmOF49se1V9pJwTx6Vcu3H3I12gAE89eKgtIGubyK3QgPI4jBPQEnHNAEboyEZ7+lNPAGOpxXu3x8+GmmfDnwX4Uitf9I1O4mma9vDkGRgqfKo7KMnA69zya8JcfKPbgUAIDx354qSB1TdvOPqKYibmA74P6U5FznFdODnKFaMob/8AAFJXR//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transabdominal scans showing the head with the large posterior cephalocele. Note the cranial defects (between the arrows) and the brain, which is present within the cephalocele sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31059=[""].join("\n");
var outline_f30_21_31059=null;
var title_f30_21_31060="Gemfibrozil: Patient drug information";
var content_f30_21_31060=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gemfibrozil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     see \"Gemfibrozil: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lopid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F175722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Gemfibrozil&reg;;",
"     </li>",
"     <li>",
"      Gen-Gemfibrozil;",
"     </li>",
"     <li>",
"      GMD-Gemfibrozil;",
"     </li>",
"     <li>",
"      Lopid&reg;;",
"     </li>",
"     <li>",
"      Mylan-Gemfibrozil;",
"     </li>",
"     <li>",
"      Novo-Gemfibrozil;",
"     </li>",
"     <li>",
"      Nu-Gemfibrozil;",
"     </li>",
"     <li>",
"      PMS-Gemfibrozil",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body. Good cholesterol (HDL) levels rise.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower triglycerides.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop irritation of the pancre",
"1ff8",
"as.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702194",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gemfibrozil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Gallbladder disease, kidney disease, or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span 1ff8 cla ss=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before breakfast and dinner.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12507 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-218.28.111.102-8C7B610DBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31060=[""].join("\n");
var outline_f30_21_31060=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outline d69 Link\" href=\"#F175721\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175722\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019283\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019285\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019284\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019289\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019290\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019292\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019287\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019288\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019293\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019294\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=related_link\">",
"      Gemfibrozil: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_21_31061="Sinonasal polyp Light";
var content_f30_21_31061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sinonasal polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These nonneoplastic polypoid lesions consist of an inflamed and edematous stroma covered by respiratory or metaplastic squamous epithelium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31061=[""].join("\n");
var outline_f30_21_31061=null;
var title_f30_21_31062="Epidemiology of yersiniosis";
var content_f30_21_31062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of yersiniosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31062/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31062/contributors\">",
"     Robert V Tauxe, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31062/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31062/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31062/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31062/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/21/31062/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H99574042\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Yersinia includes 11 species, three of which are important human pathogens: Yersinia pestis, Yersinia enterocolitica, and Yersinia pseudotuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/1\">",
"     1",
"    </a>",
"    ]. The yersinioses are zoonotic infections of domestic and wild animals; humans are considered incidental hosts that do not contribute to the natural disease cycle.",
"   </p>",
"   <p>",
"    Y. enterocolitica and Y. pseudotuberculosis cause yersiniosis, a diarrheal illness. Illness due to Y. enterocolitica is more common than illness due to Y. pseudotuberculosis. Overall, Y. enterocolitica infection occurs more frequently in Europe than in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology of yersiniosis (infection with Y. enterocolitica or Y. pseudotuberculosis) will be reviewed here. The microbiology, pathogenesis, clinical manifestations, diagnosis, and treatment of yersiniosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22373?source=see_link\">",
"     \"Microbiology and pathogenesis of Yersinia infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Yersinia infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32885?source=see_link\">",
"     \"Treatment and prevention of Yersinia enterocolitica and Yersinia pseudotuberculosis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Y. pestis causes plague and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24774?source=see_link\">",
"     \"Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99574049\">",
"    <span class=\"h1\">",
"     RESERVOIRS OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Y. enterocolitica strains have been isolated from a variety of vertebrate hosts, including domesticated animals as well as wildlife [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/3\">",
"     3",
"    </a>",
"    ]. Healthy pigs are frequently colonized with strains that cause human illness, such as serotype O:3 and serotype O:9. In pigs, the organism colonizes the tonsils and other oropharyngeal lymphoid tissues; from these sites it can be shed into the gastrointestinal tract. The organisms can contaminate retail pork products, including neck trimmings, tonsillar tissue, tongue, and tripe, and can be transferred to other cuts of meat during slaughter [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Yersinia pseudotuberculosis has been isolated from a variety of mammals and birds. It causes epizootic disease in European brown hares in Northern Europe, sheep in Australia, and farmed deer in New Zealand [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29219577\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of yersiniosis is largely food or waterborne (",
"    <a class=\"graphic graphic_table graphicRef73024 \" href=\"UTD.htm?10/35/10811\">",
"     table 1",
"    </a>",
"    ). There are also reports of infection related to exposure to household pets [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/9\">",
"     9",
"    </a>",
"    ] and transfusion of blood products [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pork consumption is a major mode of transmission. Case-control studies in Belgium and Norway have noted a strong association between consumption of undercooked or raw pork products and yersiniosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In a Swedish study, strains of Y. enterocolitica isolated from retail pork had the same PFGE profiles as patient isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/14\">",
"     14",
"    </a>",
"    ]. In Norway and New Zealand, yersiniosis has been associated with drinking untreated surface water [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Yersiniosis has been associated with preparation of chitterlings, an ethnic winter holiday dish comprised of pig intestines [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. This was first described during an investigation of bacteremia among bottle-fed African American infants in Atlanta, Georgia in 1989 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/17\">",
"     17",
"    </a>",
"    ]. Illness was thought to occur as a result of cross contamination of infant bottles or formula during chitterling preparation.",
"   </p>",
"   <p>",
"    Other outbreaks related to food contamination have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/20-24\">",
"     20-24",
"    </a>",
"    ], including tofu packaged in untreated spring water [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/20\">",
"     20",
"    </a>",
"    ] and post-pasteurization contamination of milk [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In one outbreak, an infected food handler was a suspected source of contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/25\">",
"     25",
"    </a>",
"    ], although in general, direct fecal-oral person-to-person transmission has not been frequently described.",
"   </p>",
"   <p>",
"    In rare cases, Y. enterocolitica septicemia has been observed following transfusion with packed red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/10\">",
"     10",
"    </a>",
"    ]. Yersinia organisms are ferrophilic and capable of multiplying at cold temperatures prior to transfusion. In one prospective study conducted in 1998 to 2000, the incidence of transfusion associated Yersinia sepsis was 1 in 23.7 million red cell transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/26\">",
"     26",
"    </a>",
"    ]. The number of such infections could potentially be reduced by testing blood products for bacterial contamination and by reducing storage time [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link&amp;anchor=H1968901#H1968901\">",
"     \"Transfusion transmitted bacterial infection\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the transmission of Y. pseudotuberculosis are limited. Outbreaks have been associated with consumption of contaminated lettuce and milk [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29219917\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with yersiniosis include consumption of undercooked or raw pork products, exposure to untreated water, blood transfusion, derangements of iron metabolism (such as cirrhosis, hemochromatosis, aplastic anemia, thalassemia, and iron overload), and other comorbid conditions (such as malignancy, diabetes, malnutrition, and gastrointestinal illness).",
"   </p>",
"   <p>",
"    Individuals with thalassemia are at increased risk for yersiniosis, as patients with thalassemia can develop iron overload in the setting of red cell transfusion and the organism is ferrophilic. However, in one series of patients with thalassemia, severe yersiniosis was observed even when the iron burden was not greatly elevated; the reasons for this observation are not fully understood [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99574057\">",
"    <span class=\"h1\">",
"     INCIDENCE OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic yersiniosis has been observed worldwide. The incidence of disease around the world increased substantially in the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/32\">",
"     32",
"    </a>",
"    ]. It has been reported frequently in northern Europe, particularly in Belgium, Norway, and the Netherlands; it is rarely observed in tropical countries [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/33\">",
"     33",
"    </a>",
"    ]. The reasons for these geographic patterns are not clear but likely reflect the underlying frequency of infection in food animal reservoirs. In addition, Yersinia has a winter peak of infection, which is in contrast to most bacterial foodborne pathogens, which have a summer peak of infection (",
"    <a class=\"graphic graphic_figure graphicRef61688 \" href=\"UTD.htm?40/57/41886\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The peak in incidence in Belgium reached 14.7 per 100,000 in 1986, and subsequently declined in 2003 to 3.3 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/34\">",
"     34",
"    </a>",
"    ]. The majority of Belgian isolates are serogroup O:3; 5 percent are serogroup O:9 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/34\">",
"     34",
"    </a>",
"    ]. In the Netherlands in the 1990s, Y. enterocolitica was the third most common bacterial cause of diarrhea, after Campylobacter and Salmonella [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/35\">",
"     35",
"    </a>",
"    ]. In Norway, the incidence has declined; the reasons are uncertain but may include a combination of public education efforts to reduce consumption of raw or undercooked pork products, changing dietary habits, and efforts by the meat industry to reduce contamination of carcasses during processing [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of yersiniosis in the United States is much lower than in Northern Europe and has decreased over time. In the United States in 2010, the incidence of diagnosed yersiniosis was 0.35 per 100,000 or approximately 1000 cases per year, a decline from an incidence of 1 per 100,000 in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Almost all yersiniosis in the United States is due to Y enterocolitica; between 1996 and 2007, only 1 percent of reported yersiniosis was due to Y pseudotuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/39\">",
"     39",
"    </a>",
"    ]. There is substantial geographic variation within the United States; in 2010, the highest incidence was in California (7.8 cases per million); the lowest was in New Mexico (0.5 cases per million) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/40\">",
"     40",
"    </a>",
"    ]. Between 1996 and 2004, the incidence declined by 52 percent; this may be related to general improvements in meat safety [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/40\">",
"     40",
"    </a>",
"    ]. Before 1990, the most common serotypes were O:5,27 and O:8; since 1990, O:3 and O:9 have predominated, as in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High rates of infection have been described in New Zealand; in one region in 1994, the incidence was reported to be",
"    <span class=\"nowrap\">",
"     87/100,000,",
"    </span>",
"    making it more common than salmonellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/41\">",
"     41",
"    </a>",
"    ]. The majority of isolates were serotype O:3 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of Yersinia infections is highest in young children. In Norway, 34 percent of cases occurred in children &lt;5 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/43\">",
"     43",
"    </a>",
"    ]; in Belgium, 66 percent of cases occurred in the same age group [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/34\">",
"     34",
"    </a>",
"    ]. In the United States, children &lt;5 years comprised 47 percent of Yersinia infections reported to the Foodborne Disease Active Surveillance program of the Centers for Disease Control and Prevention between 1996 and 2009, and the estimated annual incidence was 12.3 per 100,000 among children &lt;1 year of age and 1.4 per 100,000 among 1 to 4-year-olds [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/38\">",
"     38",
"    </a>",
"    ]. Over this time, however, the overall incidence among these two age groups dropped from 9.2 to 1.9 per 100,000. In contrast, the annual incidence among individuals &gt;5 years has remained stable at 0.2 to 0.4 per 100,000.",
"   </p>",
"   <p>",
"    Although the incidence of yersiniosis decreased over this time among children of all racial groups, the most substantial decrease was among African-American children &lt;5 years old, in whom the incidence dropped from 41.5 per 100,000 in 1996 to 3.5 per 100,000 cases in 2009. As of 2007, the highest incidence in children &lt;5 years was noted among Asians. The incidence among Caucasian children remained low, &lt;1 per 100,000. There are no significant racial differences among individuals &gt;5 years old. Yersiniosis is rare among observant Muslim individuals, who do not consume pork [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3696769\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basic tenets of safe food production and preparation are important for prevention of yersiniosis (",
"    <a class=\"external\" href=\"file://www.foodsafety.gov/\">",
"     www.foodsafety.gov",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/36\">",
"     36",
"    </a>",
"    ]. Education about hazards associated with consuming raw pork and changes in the slaughter process may have helped to diminish the incidence in Belgium [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/34\">",
"     34",
"    </a>",
"    ]. Education about the importance of separating chitterling preparation and childcare tasks has been promoted in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reducing the carriage of Y. enterocolitica in pigs has been proposed through the use of attenuated live Yersinia strains that induce cross-protective immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/45\">",
"     45",
"    </a>",
"    ]; this area requires further investigation. In New Zealand, Y. pseudotuberculosis in deer has been controlled by vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31062/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3696776\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Y. enterocolitica and Y. pseudotuberculosis cause yersiniosis, a diarrheal illness. Illness due to Y. enterocolitica is more common than illness due to Y. pseudotuberculosis. Overall, Y. enterocolitica infection occurs more frequently in Europe than in North America; it is rarely observed in tropical countries. (See",
"      <a class=\"local\" href=\"#H99574042\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H99574057\">",
"       'Incidence of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Y. enterocolitica strains have been isolated from a variety of vertebrate hosts, including domesticated animals as well as wildlife. Healthy pigs are frequently colonized with strains that cause human illness. In pigs, the organism colonizes the tonsils and other oropharyngeal lymphoid tissues; from these sites, it can be shed into the gastrointestinal tract. The organisms can contaminate retail pork products including neck trimmings, tonsillar tissue, tongue, and tripe, and can be transferred to other cuts of meat during slaughter. (See",
"      <a class=\"local\" href=\"#H99574049\">",
"       'Reservoirs of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transmission of yersiniosis is largely food or waterborne. Pork consumption is a major mode of transmission; other outbreaks related to food contamination have also been reported. In rare cases, Y. enterocolitica septicemia has been observed following transfusion with packed red cells. Yersinia organisms are ferrophilic and capable of multiplying at cold temperatures prior to transfusion. (See",
"      <a class=\"local\" href=\"#H29219577\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors associated with yersiniosis include consumption of undercooked or raw pork products, exposure to untreated water, blood transfusion, derangements of iron metabolism (such as cirrhosis, hemochromatosis, aplastic anemia, thalassemia, and iron overload), and other comorbid conditions (such as malignancy, diabetes, malnutrition, and gastrointestinal illness). (See",
"      <a class=\"local\" href=\"#H29219917\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Basic tenets of safe food production and preparation are important for prevention of yersiniosis (",
"      <a class=\"external\" href=\"file://www.foodsafety.gov/\">",
"       www.foodsafety.gov",
"      </a>",
"      ). In particular, it is important to separate the task of cleaning raw pork tripe from that of caring for an infant. (See",
"      <a class=\"local\" href=\"#H3696769\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Butler T. Plague and other Yersinia infections, Plenum Medical Books Co., New York 1983.",
"    </li>",
"    <li>",
"     Schmitz AM, Tauxe RV. Yersinia enterocolitica infections. In: Bacterial Infections of Humans, 4th ed, Brachman PS, Abrutyn E.  (Eds), Springer, New York 2009. p.939.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/3\">",
"      Bottone EJ. Yersinia enterocolitica: the charisma continues. Clin Microbiol Rev 1997; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/4\">",
"      de Boer E. Isolation of Yersinia enterocolitica from foods. Contrib Microbiol Immunol 1995; 13:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/5\">",
"      Fredriksson-Ahomaa M, Hielm S, Korkeala H. High prevalence of yadA-positive Yersinia enterocolitica in pig tongues and minced meat at the retail level in Finland. J Food Prot 1999; 62:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/6\">",
"      Wuthe HH, Aleksi S, Kwapil S. Yersinia in the European brown hare of northern Germany. Contrib Microbiol Immunol 1995; 13:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/7\">",
"      Slee KJ, Skilbeck NW. Epidemiology of Yersinia pseudotuberculosis and Y. enterocolitica infections in sheep in Australia. J Clin Microbiol 1992; 30:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/8\">",
"      Wilson PR. Advances in health and welfare of farmed deer in New Zealand. N Z Vet J 2002; 50:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/9\">",
"      Wilson HD, McCormick JB, Feeley JC. Yersinia enterocolitica infection in a 4-month-old infant associated with infection in household dogs. J Pediatr 1976; 89:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Red blood cell transfusions contaminated with Yersinia enterocolitica--United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions. MMWR Morb Mortal Wkly Rep 1997; 46:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/11\">",
"      Guinet F, Carniel E, Leclercq A. Transfusion-transmitted Yersinia enterocolitica sepsis. Clin Infect Dis 2011; 53:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/12\">",
"      Tauxe RV, Vandepitte J, Wauters G, et al. Yersinia enterocolitica infections and pork: the missing link. Lancet 1987; 1:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/13\">",
"      Ostroff SM, Kapperud G, Hutwagner LC, et al. Sources of sporadic Yersinia enterocolitica infections in Norway: a prospective case-control study. Epidemiol Infect 1994; 112:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/14\">",
"      Thisted Lambertz S, Danielsson-Tham ML. Identification and characterization of pathogenic Yersinia enterocolitica isolates by PCR and pulsed-field gel electrophoresis. Appl Environ Microbiol 2005; 71:3674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/15\">",
"      Satterthwaite P, Pritchard K, Floyd D, Law B. A case-control study of Yersinia enterocolitica infections in Auckland. Aust N Z J Public Health 1999; 23:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/16\">",
"      Lee LA, Taylor J, Carter GP, et al. Yersinia enterocolitica O:3: an emerging cause of pediatric gastroenteritis in the United States. The Yersinia enterocolitica Collaborative Study Group. J Infect Dis 1991; 163:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/17\">",
"      Lee LA, Gerber AR, Lonsway DR, et al. Yersinia enterocolitica O:3 infections in infants and children, associated with the household preparation of chitterlings. N Engl J Med 1990; 322:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/18\">",
"      Jones TF. From pig to pacifier: chitterling-associated yersiniosis outbreak among black infants. Emerg Infect Dis 2003; 9:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Yersinia enterocolitica gastroenteritis among infants exposed to chitterlings--Chicago, Illinois, 2002. MMWR Morb Mortal Wkly Rep 2003; 52:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/20\">",
"      Tacket CO, Ballard J, Harris N, et al. An outbreak of Yersinia enterocolitica infections caused by contaminated tofu (soybean curd). Am J Epidemiol 1985; 121:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/21\">",
"      Tacket CO, Narain JP, Sattin R, et al. A multistate outbreak of infections caused by Yersinia enterocolitica transmitted by pasteurized milk. JAMA 1984; 251:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/22\">",
"      Ackers ML, Schoenfeld S, Markman J, et al. An outbreak of Yersinia enterocolitica O:8 infections associated with pasteurized milk. J Infect Dis 2000; 181:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: Yersinia enterocolitica infections associated with pasteurized milk --- southwestern Pennsylvania, March-August, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/24\">",
"      MacDonald E, Heier BT, Nyg&aring;rd K, et al. Yersinia enterocolitica outbreak associated with ready-to-eat salad mix, Norway, 2011. Emerg Infect Dis 2012; 18:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/25\">",
"      Morse DL, Shayegani M, Gallo RJ. Epidemiologic investigation of a Yersinia camp outbreak linked to a food handler. Am J Public Health 1984; 74:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/26\">",
"      Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001; 41:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/27\">",
"      Wagner SJ, Friedman LI, Dodd RY. Transfusion-associated bacterial sepsis. Clin Microbiol Rev 1994; 7:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/28\">",
"      Nuorti JP, Niskanen T, Hallanvuo S, et al. A widespread outbreak of Yersinia pseudotuberculosis O:3 infection from iceberg lettuce. J Infect Dis 2004; 189:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/29\">",
"      Niskanen T, Fredriksson-Ahomaa M, Korkeala H. Occurrence of Yersinia pseudotuberculosis in iceberg lettuce and environment. Adv Exp Med Biol 2003; 529:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/30\">",
"      Nowgesic E, Fyfe M, Hockin J, et al. Outbreak of Yersinia pseudotuberculosis in British Columbia--November 1998. Can Commun Dis Rep 1999; 25:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/31\">",
"      Adamkiewicz TV, Berkovitch M, Krishnan C, et al. Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors. Clin Infect Dis 1998; 27:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/32\">",
"      Worldwide spread of infections with Yersinia enterocolitica. WHO Chron 1976; 30:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/33\">",
"      Ostroff S. Yersinia as an emerging infection: epidemiologic aspects of Yersiniosis. Contrib Microbiol Immunol 1995; 13:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/34\">",
"      Verhaegen J, Charlier J, Lemmens P, et al. Surveillance of human Yersinia enterocolitica infections in Belgium: 1967-1996. Clin Infect Dis 1998; 27:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/35\">",
"      Stolk-Engelaar VM, Hoogkamp-Korstanje JA. Clinical presentation and diagnosis of gastrointestinal infections by Yersinia enterocolitica in 261 Dutch patients. Scand J Infect Dis 1996; 28:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/36\">",
"      Nesbakken T, Eckner K, H&oslash;idal HK, R&oslash;tterud OJ. Occurrence of Y. enterocolitica in slaughter pigs and consequences for meat inspection, slaughtering and dressing procedures. Adv Exp Med Biol 2003; 529:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: incidence and trends of infection with pathogens transmitted commonly through food--foodborne diseases active surveillance network, 10 U.S. sites, 1996-2010. MMWR Morb Mortal Wkly Rep 2011; 60:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/38\">",
"      Ong KL, Gould LH, Chen DL, et al. Changing epidemiology of Yersinia enterocolitica infections: markedly decreased rates in young black children, Foodborne Diseases Active Surveillance Network (FoodNet), 1996-2009. Clin Infect Dis 2012; 54 Suppl 5:S385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/39\">",
"      Long C, Jones TF, Vugia DJ, et al. Yersinia pseudotuberculosis and Y. enterocolitica infections, FoodNet, 1996-2007. Emerg Infect Dis 2010; 16:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/40\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--10 sites, United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:352.",
"     </a>",
"    </li>",
"    <li>",
"     Wright J, Fenwick S, McCarthy M. Yersiniosis: An emerging problem in New Zealand.  N Z Public Health Rep 1995; :65.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/42\">",
"      Fenwick SG, McCarthy MD. Yersinia enterocolitica is a common cause of gastroenteritis in Auckland. N Z Med J 1995; 108:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/43\">",
"      Ostroff SM, Kapperud G, Lassen J, et al. Clinical features of sporadic Yersinia enterocolitica infections in Norway. J Infect Dis 1992; 166:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/44\">",
"      Centers for Disease Control (CDC). Yersinia enterocolitica infections during the holidays in black families--Georgia. MMWR Morb Mortal Wkly Rep 1990; 39:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31062/abstract/45\">",
"      Fukushima H, Ito Y, Saito K, et al. Ecological studies of Yersinia enterocolitica. III. Cross-protection against fecal excretion between Y. enterocolitica serovars 3 and 5.27 in pigs. Vet Microbiol 1984; 9:383.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3144 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31062=[""].join("\n");
var outline_f30_21_31062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3696776\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H99574042\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H99574049\">",
"      RESERVOIRS OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29219577\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29219917\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H99574057\">",
"      INCIDENCE OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3696769\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3696776\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3144\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3144|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/57/41886\" title=\"figure 1\">",
"      Epidemiology of yersiniosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3144|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/35/10811\" title=\"table 1\">",
"      Risk factors for yersiniosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/63/41974?source=related_link\">",
"      Clinical manifestations and diagnosis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/15/11512?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/12/24774?source=related_link\">",
"      Epidemiology, microbiology and pathogenesis of plague (Yersinia pestis infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22373?source=related_link\">",
"      Microbiology and pathogenesis of Yersinia infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/7/32885?source=related_link\">",
"      Treatment and prevention of Yersinia enterocolitica and Yersinia pseudotuberculosis infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_21_31063="Radiologic evaluation of knee tumors in adults";
var content_f30_21_31063=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiologic evaluation of knee tumors in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31063/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31063/contributors\">",
"     Shahla Modarresi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31063/contributors\">",
"     Cecilia M Jude, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31063/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31063/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31063/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31063/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/21/31063/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8715809\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knee is one of the largest and most complex joints in the body. It is lined by synovium and consists of two hinge-type joints between the femoral condyles and the medial and lateral tibial plateaus and of a gliding type joint between the patella and the trochlear groove of the anterior distal femur (",
"    <a class=\"graphic graphic_figure graphicRef69611 \" href=\"UTD.htm?34/27/35251\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The radiographic evaluation of suspected or clinically apparent tumors of, or near, the knee is addressed here, including plain film, magnetic resonance imaging (MRI), and computed tomography (CT) features and the radiographic appearance of selected tumor-like intraarticular disorders.",
"   </p>",
"   <p>",
"    The history and physical examination, which are necessary to develop a differential diagnosis prior to the selection of imaging tests, a general review of imaging tests that are used in the evaluation of bone and joint pain, and the use of imaging in the assessment of children and adolescents with knee pain are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=see_link\">",
"     \"Diagnostic imaging of joint pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=see_link\">",
"     \"Approach to the young athlete with chronic knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715816\">",
"    <span class=\"h1\">",
"     IMAGING MODALITIES FOR MASS LESIONS OF THE KNEE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography, computed tomography (CT), and magnetic resonance imaging (MRI) are the mainstays of diagnostic imaging for patients with intraarticular or juxtaarticular bony or soft tissue mass lesions. The following is a brief discussion of the role of each of these modalities in assessing knee tumors and tumor-like disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715823\">",
"    <span class=\"h2\">",
"     Plain film radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film is the initial modality of choice for detection and assessment of the general features of the tumor. Accuracy of plain film for detection of soft tissue tumors is limited. Plain film is the most valuable method to evaluate the margin between normal bone and a neoplasm that is characteristic of bone tumor (zone of transition). Radiographic features of the zone of transition are important in distinguishing between benign and malignant bone lesions. Plain film radiography also demonstrates the extent of cortical destruction, periosteal reaction, matrix calcifications, and pathological fractures. Certain radiographic patterns, combined with the age of the patient, can be very suggestive of specific tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715830\">",
"    <span class=\"h2\">",
"     CT scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT is the best method for detection of juxtaarticular bone lesions not optimally seen by plain film. CT provides better assessment of cortical invasion, pathological fracture, periosteal reaction, and matrix mineralization and detection of cystic or fatty nature of tumor. CT is used for biopsy guidance, preoperative evaluation, and detection of recurrence. For primary bone tumors, intravenous contrast is not usually indicated. For soft tissue masses, use of CT with intravenous contrast is recommended when MRI is not available or is contraindicated; in these cases, contrast administration helps to delineate the mass, distinguishing it from adjacent soft tissue, and shows cystic and necrotic areas, vascularity, and the relationship to vascular structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715837\">",
"    <span class=\"h2\">",
"     MR imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is nonspecific for differentiation of most tumors. MRI is the modality of choice for local staging, for definition of medullary and extracortical spread, and for delineation of tumor in relation to critical neurovascular structures.",
"   </p>",
"   <p>",
"    The zone of transition, an important feature in plain film imaging, as discussed earlier (see",
"    <a class=\"local\" href=\"#H8715823\">",
"     'Plain film radiography'",
"    </a>",
"    above), is not valid on MRI. Gadolinium contrast administration may be useful to differentiate solid from cystic or necrotic tumor, to evaluate response to nonsurgical therapy, and to detect tumor recurrence.",
"   </p>",
"   <p>",
"    Administration of gadolinium-containing MRI contrast agents should be avoided in patients with severely impaired renal function (eg, estimated glomerular filtration rate &lt;15 to 30",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"    If gadolinium-based imaging must be performed in a patient with moderately to severely impaired renal function, there may be a role for dialysis to reduce the risk of development of nephrogenic systemic fibrosis (NFS). Approaches to prevention of NFS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link&amp;anchor=H24#H24\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'If gadolinium must be given'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715844\">",
"    <span class=\"h2\">",
"     Radionuclide scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of radionuclide bone scan (bone scintigraphy) for tumor is limited to evaluation of metastatic skeletal involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=see_link\">",
"     \"Diagnostic imaging of joint pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715851\">",
"    <span class=\"h1\">",
"     INTRAARTICULAR TUMORS AND TUMOR-LIKE LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign intraarticular lesions of the knee include pigmented villonodular synovitis, synovial chondromatosis (synovial osteochondromatosis), synovial hemangioma, and lipoma arborescens. Primary malignant intraarticular knee lesions include synovial sarcoma and synovial chondrosarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715858\">",
"    <span class=\"h2\">",
"     Pigmented villonodular synovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pigmented villonodular synovitis (PVNS) is an idiopathic, benign disorder occurring primarily in young and middle-aged adults. The pathologic process can involve any joint, bursa, or tendon sheath. The disease is characterized by synovial hypertrophy with diffuse hemosiderin deposits within the joint. The knee is the most commonly involved joint in PVNS. PVNS typically involves one compartment of the knee, and the joint space is maintained until late in the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiography often demonstrates a joint effusion, suprapatellar soft tissue density, and erosions in the femur and tibia, without signs of bone repair or osteophyte formation [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI &mdash; MRI confirms the diagnosis of PVNS. MRI findings of PVNS are joint effusion and nodular intraarticular masses with low signal intensity in all (T1, T2, short tau inversion recovery, etc) sequences from hemosiderin deposition (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54059 \" href=\"UTD.htm?42/37/43602\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/1\">",
"       1",
"      </a>",
"      ]. Bony erosions (when present) and extraarticular extension of the lesion are well-demonstrated on MRI. MRI is useful in the preoperative planning and the postoperative follow-up.",
"     </li>",
"     <li>",
"      CT &mdash; CT demonstrates hyperdense, hemosiderin-laden masses and delineates bone cysts and erosions. CT is also valuable for needle biopsy guidance when MRI is nondiagnostic or is contraindicated and for preoperative planning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715865\">",
"    <span class=\"h2\">",
"     Synovial (osteo)chondromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial chondromatosis is a benign disorder of the synovial lining, characterized by the presence of loose cartilaginous bodies. Ossification of these cartilaginous bodies may occur (osteochondromatosis). This monoarticular disorder is more common in men. The knee is the most commonly involved joint. Secondary osteoarthritis is present due to cartilage damage from the presence of loose bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiography demonstrates joint effusion and is diagnostic when the chondroid loose bodies are ossified enough to be visualized by radiograph (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55713 \" href=\"UTD.htm?2/0/2051\">",
"       image 2",
"      </a>",
"      ). Erosions are not a common feature in the knee because of the expansile nature of this joint as compared with the hip joint [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT and MRI &mdash; CT or MRI is recommended when synovial chondromatosis is clinically suspected and when radiographs are normal or only demonstrate joint effusion. MRI and CT show the loose bodies when they are not visible on plain film. MRI and CT also show the extent of the lesions, required for preoperative assessment [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715872\">",
"    <span class=\"h2\">",
"     Synovial hemangioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial hemangioma is a rare benign vascular lesion that most commonly affects the knee joint. It occurs mostly in children and adolescents and presents with swelling, pain, and non-traumatic hemarthrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5800?source=see_link&amp;anchor=H15#H15\">",
"     \"Hemarthrosis\", section on 'Tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plain film radiography is normal in half of the patients or shows joint effusion, soft tissue swelling, and erosions. The presence of phleboliths is suggestive of hemangioma, but MRI is the modality of choice for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715879\">",
"    <span class=\"h2\">",
"     Lipoma arborescens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoma arborescens is an intraarticular disorder characterized by benign lipomatous proliferation of the synovium, manifested as slowly progressive and painless joint effusion. Etiology is unknown; however, it can be associated with osteoarthritis and rheumatoid arthritis. It occurs more commonly in men, in the fourth and fifth decade, and, most often, in the knee joint. MRI demonstrates characteristic villous synovial masses that have fat signal intensity on all imaging sequences (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64392 \" href=\"UTD.htm?41/9/42131\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715886\">",
"    <span class=\"h2\">",
"     Synovial sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial sarcoma is an uncommon mesenchymal tumor, most commonly involving the knee and the foot. It typically occurs before age 50 and presents with a progressively enlarging soft tissue mass and pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227072#H12227072\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plain film radiography demonstrates a soft tissue mass, occasional bone invasion, and soft tissue calcification. MRI with intravenous gadolinium is the procedure of choice for further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715893\">",
"    <span class=\"h2\">",
"     Synovial chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovial chondrosarcoma is a rare tumor arising from the synovium and most commonly involving the knee joint. It can occur as a primary malignancy or as secondary to malignant transformation of synovial (osteo)chondromatosis. Plain film radiography demonstrates soft tissue mass, chondroid calcifications, and bone destruction. Magnetic resonance imaging (MRI) demonstrates soft tissue mass and bone destruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715900\">",
"    <span class=\"h1\">",
"     JUXTAARTICULAR BONE OR SOFT TISSUE TUMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiography is usually the first imaging modality employed in patients who present with mass lesions in the region of the knee. Further evaluation of bony lesions is facilitated by CT scanning, while MRI is used for soft tissue tumors.",
"   </p>",
"   <p>",
"    The most commonly encountered benign bone lesions that occur around the knee joint are enchondroma, nonossifying fibroma, osteochondroma, giant cell tumor, chondroblastoma, and aneurysmal bone cyst. Malignant bone tumors include osteosarcoma (conventional), osteosarcoma (parosteal), chondrosarcoma, metastases, and myeloma. The most common benign soft tissue tumors around the knee in adults are lipoma and hemangioma. The most common malignant soft tissue tumor around the knee is sarcoma, with malignant fibrous histiocytoma (also known as pleomorphic sarcoma), liposarcoma, leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumor accounting for 75 percent of all soft tissue sarcomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715907\">",
"    <span class=\"h2\">",
"     Enchondroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enchondroma is a common benign bone tumor arising from the hyaline cartilage, seen in young patients, ages 15 to 35 years. It most commonly occurs around the wrist and hand; however, the femur is also affected in approximately 10 percent of cases. Enchondroma is usually asymptomatic, or it may present with painless swelling. The presence of pain is suspicious for malignant transformation to chondrosarcoma or for the presence of pathological fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Enchondroma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiography demonstrates a metaphyseal lesion, which may extend to the diaphyseal or subarticular region of the bone. Enchondroma is a medullary osteolytic lesion, more centrally located within the metaphysis, with a lobulated border. Stippled calcifications are seen in 50 percent of lesions (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77217 \" href=\"UTD.htm?37/18/38191\">",
"       image 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT and MRI &mdash; Enchondroma is a common incidental finding on knee MRI, seen in up to 3 percent of cases. CT and MRI allow differentiation between an enchondroma and a chondrosarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715914\">",
"    <span class=\"h2\">",
"     Nonossifying fibroma (NOF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonossifying fibroma is a benign bone tumor composed of connective tissue, seen in young people of ages 10 to 20 years. NOF is most commonly seen in the tibia and the femur. It is usually clinically silent and is discovered incidentally or following pathological fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Nonossifying fibroma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiography demonstrates a well-circumscribed, eccentric, multiloculated osteolytic lesion, arising from the metaphyseal cortex. Lesions are often bilateral and symmetrical. Most NOFs gradually disappear over time, being replaced by normal bone [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT and MRI &mdash; Cross-sectional imaging is not necessary for the diagnosis of NOF. These lesions may be seen as incidental findings, and their MRI appearance parallels their radiographic findings [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715921\">",
"    <span class=\"h2\">",
"     Osteochondroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteochondroma, also known as exostosis, is a benign tumor of young people, 10 to 30 years of age, frequently around the knee. Osteochondroma presents as a nontender, painless, slow-growing mass. Malignant transformation is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Enchondroma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Osteochondroma is a metaphyseal lesion, occurring often at or near the attachment sites of tendons. It presents as a sessile or pedunculated osseous mass, typically growing away from the adjacent joint. This lesion is in continuity with the medullary cavity and cortex of the parent bone and is covered by a cap of hyaline cartilage (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55150 \" href=\"UTD.htm?22/48/23311\">",
"       image 5",
"      </a>",
"      ). The cartilage cap frequently contains calcifications visible on radiographs [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI &mdash; MRI allows measurement of the thickness of the cartilaginous cap of the enchondroma, which assists in predicting the risk of malignant transformation [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/7-9\">",
"       7-9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715928\">",
"    <span class=\"h2\">",
"     Giant cell tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell tumor is a benign bone tumor affecting predominantly young people, 20 to 40 years of age. Ninety to 95 percent of giant cell tumors are benign, and 5 to 10 percent are locally aggressive or malignant. Giant cell tumors have a predilection for the subarticular region and metaphysis of the long bones, occurring mainly in the distal portion of the femur and in the proximal aspect of the tibia. Giant cell tumor occurs around the knee in 50 to 65 percent of cases. Clinical presentation includes pain, swelling, and limitation of motion. Pathologic fracture occurs in up to 10 percent of cases. Giant cell tumors may be accompanied by a secondary aneurysmal bone cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=see_link\">",
"     \"Giant cell tumor of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiographs demonstrate a subarticular and metaphyseal lytic lesion. The lesion is typically eccentric and elongated, and it may appear multiloculated and expansile. Radiographs are inaccurate for distinguishing benign from aggressive giant cell tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT &mdash; CT allows evaluation of the extraosseous and intraosseous extent of tumor. One or more fluid levels may be appreciated on CT, although this finding is not specific to giant cell tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRI &mdash; The primary role of MRI is to define the intraosseous, intraarticular, and soft tissue extent of the lesion, and its relationship to major vessels and nerves [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715935\">",
"    <span class=\"h2\">",
"     Chondroblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondroblastoma is a benign bone tumor of cartilage origin, occurring in young people, 10 to 25 years of age, more commonly in males. Clinically, chondroblastoma presents with joint pain and swelling. It has predilection for the epiphyses and apophyses, occurring frequently in the femur, tibia, and patella, which is considered an &ldquo;epiphyseal equivalent&rdquo; structure [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Chondroblastoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiographs demonstrate a circular osteolytic lesion, 5 to 6 cm in diameter, arising from the epiphysis or apophysis of the long bones or in the patella. Metaphyseal extension is seen in 25 to 50 percent of cases. Calcification may be seen in the matrix in 30 to 50 percent of cases. Joint effusion is also a common finding [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT and MRI &mdash; CT is used in diagnosis of aggressive or recurrent chondroblastoma. A fluid level may be seen on CT or MRI; however, it is a non-specific finding [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715942\">",
"    <span class=\"h2\">",
"     Aneurysmal bone cyst (ABC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysmal bone cyst is a benign lesion that contains blood-filled cavities and that is seen in young people, 10 to 30 years of age. Although ABC is not a neoplastic lesion, it should be considered in the differential diagnosis of lytic neoplasms around the knee joint. ABC may develop after trauma or may accompany other benign processes, such as giant cell tumor or chondroblastoma. It occurs in the metaphysis of the long bones, including the tibia and the femur. Clinically, ABC presents with pain and swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Aneurysmal bone cyst'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiography of ABC demonstrates an eccentric, thin-walled, expansile osteolytic lesion of the metaphysis of long bones. ABCs usually have a septated, multiloculated appearance with a fluid-fluid level [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT and MRI &mdash; CT and MRI are useful in delineating the size and location of the intraosseous and extraosseous components of an ABC. Presence of a fluid level, although seen in other lesions such as chondroblastoma and giant cell tumor, is most suggestive of an ABC [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715949\">",
"    <span class=\"h2\">",
"     Osteosarcoma (conventional)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional osteosarcoma is a malignant bone tumor seen in young patients, ages 10 to 25. It is a metaphyseal tumor most commonly seen in the distal femur and in the proximal tibia. Fifty to 75 percent of all cases develop around the knee. Clinically, it presents with pain, swelling, restriction of motion, warmth, and fever. Osteosarcoma may result from malignant transformation of benign neoplasms. It frequently metastasizes to other bones and to the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiography of osteosarcoma demonstrates a metaphyseal bone tumor with large soft tissue component. Osteolytic, osteosclerotic, or mixed patterns of medullary and cortical destruction are present. A prominent, aggressive periosteal reaction is commonly seen [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT and MRI &mdash; CT and MRI are useful for delineating the extent of tumor and its relationship to surrounding neurovascular structures and in evaluating the response of tumor to therapy (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63819 \" href=\"UTD.htm?16/27/16817\">",
"       image 6",
"      </a>",
"      ). MRI is superior to CT in defining the intraosseous and extraosseous extent of the tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radionuclide scan &mdash; Bone scan shows increased uptake in the primary tumor and is useful for detecting skeletal metastases, and it may also demonstrate uptake in extraskeletal metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715956\">",
"    <span class=\"h2\">",
"     Osteosarcoma (parosteal)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parosteal osteosarcoma is a malignant bone tumor seen in patients aged 20 to 45 years. It is a metaphyseal bone tumor, particularly common on the posterior surface of the distal femur and the proximal tibia. Parosteal osteosarcomas affect the bones about the knee in approximately 70 percent of cases. Clinically, parosteal osteosarcoma presents with insidious onset of pain, swelling, and palpable mass, often about the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link&amp;anchor=H25#H25\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\", section on 'Surface (juxtacortical) osteosarcomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiography most commonly demonstrates a bone lesion on the posterior surface of the distal femoral metaphysis. Parosteal osteosarcoma presents as a large, oval, sclerotic and sessile lesion of the bone. Ossification begins centrally within the mass, and progresses peripherally [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT and MRI &mdash; CT defines the extent of the tumor and may show medullary involvement. MRI shows the soft tissue and intraosseous components and the relationship of the mass to neurovascular structures [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715963\">",
"    <span class=\"h2\">",
"     Chondrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondrosarcoma is a malignant cartilage tumor seen in patients aged 30 to 60 years. It arises from the femur in 24 percent of cases and, less commonly, from the tibia. Clinically, chondrosarcoma presents with pain, soft tissue mass, pathologic fracture, warmth, and erythema. Chondrosarcoma is classified as central or peripheral, with the peripheral form arising from a preexisting osteochondroma [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link\">",
"     \"Chondrosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography &mdash; Plain film radiography demonstrates an elongated, poorly defined metaphyseal lesion, with cortical destruction, periosteal reaction, and calcification. Calcification is seen in 60 percent of cases. The pattern and density of calcifications correlate with the degree of malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT and MRI &mdash; CT and MRI provide information regarding the intraosseous and soft tissue extent of the tumor. Calcification is more readily detected by CT [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715970\">",
"    <span class=\"h2\">",
"     Skeletal metastasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal metastasis is the most common malignant tumor of the bone, typically seen in patients over 40 years of age. Metastases are most commonly seen in the axial skeleton, with rare occurrence about the knee. Seventy percent of cases exhibit a permeative or moth-eaten appearance of osteolysis. When a joint is involved, both sides of the articulation may show destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715977\">",
"    <span class=\"h2\">",
"     Multiple myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma is a malignant disease of plasma cells and is the most common primary malignancy of bone. The bones about the knee are an uncommon site of involvement for multiple myeloma. Early manifestation of multiple myeloma is diffuse osteopenia. In later stages, widespread, well-defined osteolytic lesions are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715984\">",
"    <span class=\"h2\">",
"     Lipoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoma is the most common soft tissue tumor, occurring commonly after the age of 20 years. Lipoma presents as an asymptomatic, slow-growing, round, well-defined mass with a soft consistency, usually superficial in location. Lipoma may also be intramuscular in location, presenting as a large and less well-defined mass. Plain film radiography reveals a radiolucent, round soft tissue mass, which may demonstrate calcification. CT and MRI show a homogeneously fatty mass. MRI helps in differentiating a lipoma from a liposarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of benign lesions of the skin\", section on 'Lipoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715991\">",
"    <span class=\"h2\">",
"     Hemangioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue hemangioma is one of the most common soft tissue tumors, seen most frequently in infancy and childhood, but it is also encountered in adults, more commonly in women. It is usually intramuscular, although synovial hemangiomas also occur. (See",
"    <a class=\"local\" href=\"#H8715851\">",
"     'Intraarticular tumors and tumor-like lesions'",
"    </a>",
"    above.) Soft tissue hemangioma is a deep intramuscular mass which has cystic, dilated blood-filled spaces. Clinically, it presents as a mass or pain due to muscle hypoxia. Plain film radiographs demonstrate an area of increased density suggestive of a mass, or they may be normal. The presence of phleboliths associated with a soft tissue mass is a specific finding seen in hemangiomas. MRI is useful for characterization of the extent of the hemangioma and demonstrates a specific appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8715998\">",
"    <span class=\"h2\">",
"     Soft tissue sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcoma is the most common malignant soft tissue tumor around the knee, with malignant fibrous histiocytoma (MFH), also known as pleomorphic sarcoma, the most common subtype. MFH is the most common malignant sarcoma of older adults, ages 50 to 70. About 40 percent of soft tissue sarcomas occur in the lower extremities, usually around the knee. Soft tissue sarcomas usually present as a painless mass, often large at the time of diagnosis, and they metastasize hematogenously, mainly to the lung. Plain film radiographs demonstrate a soft tissue mass and may be used to evaluate the bone involvement and calcifications within the tumor. MRI is the imaging modality of choice, showing the extent of the tumor and adjacent neurovascular involvement. MRI is valuable for preoperative planning and for postoperative follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31063/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8716005\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain film radiography, computed tomography (CT), and magnetic resonance imaging (MRI) are the mainstays of diagnostic imaging for patients with intraarticular, juxtaarticular bony, or periarticular soft tissue mass lesions. (See",
"      <a class=\"local\" href=\"#H8715816\">",
"       'Imaging modalities for mass lesions of the knee'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various types of benign and malignant tumors and tumor-like conditions found in or near the knee joint are discussed with an emphasis on the radiologic features of each that are helpful in diagnosis. (See",
"      <a class=\"local\" href=\"#H8715851\">",
"       'Intraarticular tumors and tumor-like lesions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8715900\">",
"       'Juxtaarticular bone or soft tissue tumor'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31063/abstract/1\">",
"      Frick MA, Wenger DE, Adkins M. MR imaging of synovial disorders of the knee: an update. Radiol Clin North Am 2007; 45:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31063/abstract/2\">",
"      Goldman AB, DiCarlo EF. Pigmented villonodular synovitis. Diagnosis and differential diagnosis. Radiol Clin North Am 1988; 26:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31063/abstract/3\">",
"      Beall DP, Ly JQ, Wolff JD, et al. Cystic masses of the knee: magnetic resonance imaging findings. Curr Probl Diagn Radiol 2005; 34:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31063/abstract/4\">",
"      Norman A, Steiner GC. Bone erosion in synovial chondromatosis. Radiology 1986; 161:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31063/abstract/5\">",
"      McKenzie G, Raby N, Ritchie D. A pictorial review of primary synovial osteochondromatosis. Eur Radiol 2008; 18:2662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31063/abstract/6\">",
"      Vilanova JC, Barcel&oacute; J, Villal&oacute;n M, et al. MR imaging of lipoma arborescens and the associated lesions. Skeletal Radiol 2003; 32:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31063/abstract/7\">",
"      Subhas N, Bui KL, Sundaram M, et al. Incidental tumor and tumor-like lesions around the knee. Semin Musculoskelet Radiol 2009; 13:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31063/abstract/8\">",
"      Kransdorf MJ, Peterson JJ, Bancroft LW. MR imaging of the knee: incidental osseous lesions. Radiol Clin North Am 2007; 45:943.",
"     </a>",
"    </li>",
"    <li>",
"     Resnick D. Tumor and yumor-like lesions of bone: Imaging and pathology of specific lesions. In: Diagnosis of Bone and Joint Disorders, 4th, 2002. Vol 4, p.3763.",
"    </li>",
"    <li>",
"     Taylor JA, Hughes TH, Resnick D. Part III: Pelvis and lower extremities, knee. In: Skeletal Imaging: Atlas of the Spine and Extremities, 2009. p.547.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31063/abstract/11\">",
"      Butler MG, Fuchigami KD, Chako A. MRI of posterior knee masses. Skeletal Radiol 1996; 25:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31063/abstract/12\">",
"      van Vliet M, Kliffen M, Krestin GP, van Dijke CF. Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. Eur Radiol 2009; 19:1499.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14916 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-424AE69C25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31063=[""].join("\n");
var outline_f30_21_31063=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8716005\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8715809\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8715816\">",
"      IMAGING MODALITIES FOR MASS LESIONS OF THE KNEE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715823\">",
"      Plain film radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715830\">",
"      CT scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715837\">",
"      MR imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715844\">",
"      Radionuclide scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8715851\">",
"      INTRAARTICULAR TUMORS AND TUMOR-LIKE LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715858\">",
"      Pigmented villonodular synovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715865\">",
"      Synovial (osteo)chondromatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715872\">",
"      Synovial hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715879\">",
"      Lipoma arborescens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715886\">",
"      Synovial sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715893\">",
"      Synovial chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8715900\">",
"      JUXTAARTICULAR BONE OR SOFT TISSUE TUMOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715907\">",
"      Enchondroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715914\">",
"      Nonossifying fibroma (NOF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715921\">",
"      Osteochondroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715928\">",
"      Giant cell tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715935\">",
"      Chondroblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715942\">",
"      Aneurysmal bone cyst (ABC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715949\">",
"      Osteosarcoma (conventional)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715956\">",
"      Osteosarcoma (parosteal)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715963\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715970\">",
"      Skeletal metastasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715977\">",
"      Multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715984\">",
"      Lipoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715991\">",
"      Hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8715998\">",
"      Soft tissue sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8716005\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/14916\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/14916|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/37/43602\" title=\"diagnostic image 1\">",
"      PVNS knee MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/0/2051\" title=\"diagnostic image 2\">",
"      Knee osteochondrom x ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/9/42131\" title=\"diagnostic image 3\">",
"      Lipoma arborescens knee MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/18/38191\" title=\"diagnostic image 4\">",
"      Enchondroma knee Xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/48/23311\" title=\"diagnostic image 5\">",
"      Osteochondroma knee Xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/27/16817\" title=\"diagnostic image 6\">",
"      Osteosarcoma knee CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/14916|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/27/35251\" title=\"figure 1\">",
"      Anterior anatomy of knee",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=related_link\">",
"      Approach to the young athlete with acute knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29223?source=related_link\">",
"      Approach to the young athlete with chronic knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/7/3193?source=related_link\">",
"      Diagnostic imaging of joint pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5658?source=related_link\">",
"      Giant cell tumor of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5800?source=related_link\">",
"      Hemarthrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_21_31064="Hypertriglyceridemia-induced acute pancreatitis";
var content_f30_21_31064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypertriglyceridemia-induced acute pancreatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31064/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31064/contributors\">",
"     Andres Gelrud, MD, MMSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31064/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31064/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31064/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31064/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31064/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/21/31064/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertriglyceridemia (HTG) is the third most common cause of acute pancreatitis (AP) after alcohol and gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is reported to cause 1 to 38 percent of all cases of AP and up to 56 percent of pancreatitis cases during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HTG is defined by fasting serum triglyceride level of &gt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    HTG is classified as mild (150 to 199",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    1.7 to 2.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    moderate (200 to 999",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    2.3 to 11.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    severe HTG (1000 to 1999",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    11.2 to 22.4",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and very severe HTG(&gt;2000",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    &gt;22.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HTG is considered a risk for pancreatitis when levels are &gt;1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/4\">",
"     4",
"    </a>",
"    ]. Early clinical recognition of HTG-associated pancreatitis (HTGP) is extremely important to provide appropriate therapy and to prevent further episodes.",
"   </p>",
"   <p>",
"    This topic review will focus on the etiology, clinical features, and treatment of acute HTGP. Long-term therapy of HTG with diet restrictions and lipid lowering medications are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"       \"Approach to the patient with hypertriglyceridemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"       \"Lipid lowering with diet or dietary supplements\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serum triglyceride (TG) level of approximately 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or greater increases the risk of acute pancreatitis (AP), although some patients have developed AP at lower levels. Hypertriglyceridemia (HTG) is not thought to significantly increase the risk of AP with a triglyceride level &lt;500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/2\">",
"     2",
"    </a>",
"    ]. At high triglyceride levels, the serum becomes lactescent (milky coloration) (",
"    <a class=\"graphic graphic_picture graphicRef58261 \" href=\"UTD.htm?41/13/42192\">",
"     picture 1",
"    </a>",
"    ). Both primary (genetic) and secondary disorders of lipoprotein metabolism are associated with HTG-associated pancreatitis (HTGP). HTG themselves do not appear to be toxic. Rather, it is the breakdown of TG into toxic free fatty acids (FFA) by pancreatic lipases that are the cause of lipotoxicity during acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Thus, the severity of AP in patients with HTG is dependent on both the inflammatory response caused by pancreatitis itself, plus the injury caused by lipotoxicity from TG hydrolysis. There are no clear biomarkers to determine the effects of lipotoxicity independent of AP with normal TG levels, but several studies noted a drop in calcium levels in more severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary hypertriglyceridemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with HTG (&ge;500",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    should be evaluated for a genetic disorder of lipid metabolism. Frederickson classification I (high chylomicrons), IV (high very low density lipoprotein (VLDL)), and V (high chylomicrons and VLDL) dyslipidemias are associated with severe HTG and are predisposed to AP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/9\">",
"     9",
"    </a>",
"    ]. Types I and V can present with AP without an exacerbating factor, whereas type IV usually requires another factor to raise serum triglyceride levels. Type I hyperlipidemia, also known as familial chylomicronemia, often presents in infancy and is caused by an autosomal recessive trait of lipoprotein lipase (LPL) deficiency. Children with inherited disorders of HTG may develop attacks of AP in early childhood. Type IV, known as familial HTG or familial combined hyperlipidemia, is autosomal dominant and presents in adulthood.",
"   </p>",
"   <p>",
"    These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the patient with hypertriglyceridemia\", section on 'Disorders of triglyceride metabolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Secondary hypertriglyceridemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various conditions can raise HTG and lead to HTGP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes mellitus types 1 and 2 and type 1 with diabetic ketoacidosis can trigger HTGP [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. In a retrospective study of 70 cases of HTGP over 12 years of age, the most common underlying cause was poorly controlled diabetes with associated HTG. Lactescent serum on hospital admission was found in 45 percent of patients in this series. The mean serum triglyceride level was 4587",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      3616",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      and 77 percent of patients had a history of HTG [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/1\">",
"       1",
"      </a>",
"      ]. Pancreatitis in diabetic ketoacidosis usually occurs with a low serum pH (&lt;7.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/12\">",
"       12",
"      </a>",
"      ]. Both the hyperglycemia and HTG are likely related to the lack of insulin and the effects of stress hormones. In these cases, the HTG responses to insulin replacement. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Insulin'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Alcohol may cause HTGP, although it is unclear whether alcohol directly causes HTGP or exacerbates an underlying genetic hyperlipidemia [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/2\">",
"       2",
"      </a>",
"      ]. Alcohol increases serum triglyceride concentrations in a \"dose-dependent\" manner. In a study of nearly 8000 men and women, the prevalence of serum triglyceride concentrations above 227",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      increased from 8 to 20 percent as alcohol intake increased from three to nine or more drinks per day [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/13\">",
"       13",
"      </a>",
"      ]. In most alcohol abusers, the triglyceride elevations are transient and likely to be an epiphenomenon rather than a cause of pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link&amp;anchor=H8#H8\">",
"       \"Etiology of acute pancreatitis\", section on 'Alcohol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypothyroidism has been documented to be a cause of HTG and AP [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hormone supplementation with estrogen [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/16\">",
"       16",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/17\">",
"       17",
"      </a>",
"      ] is known to raise the serum triglyceride level. Hormone therapy in women is not recommended when serum triglyceride levels are &gt;500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      due to a heightened risk of HTGP.",
"     </li>",
"     <li>",
"      Other medications associated with elevated serum triglyceride levels include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      , protease inhibitors, antiretroviral agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      , retinoids, thiazide diuretics, and beta-blockers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H8#H8\">",
"       \"Approach to the patient with hypertriglyceridemia\", section on 'Disorders of triglyceride metabolism'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"       \"Etiology of acute pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy-induced HTG has been found to be responsible for up to 56 percent of cases of AP occurring during pregnancy with an estimated overall frequency of 1 in 6790 pregnancies over a 15-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/3\">",
"       3",
"      </a>",
"      ]. Although pregnancy causes an increase in serum triglycerides that peaks in the third trimester, the total serum triglyceride level rarely exceeds 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.3",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      a concentration that is not sufficient to cause pancreatitis. Most causes of HTG are attributable to familial HTG, but nongenetic, nonfamilial pregnancy-induced HTG has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link&amp;anchor=H19#H19\">",
"       \"Etiology of acute pancreatitis\", section on 'Pregnancy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial presentation of hypertriglyceridemic pancreatitis (HTGP) is similar to that of acute pancreatitis (AP) of other causes; abdominal pain, nausea, and vomiting are the major complaints. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Poorly controlled diabetes, alcoholism, obesity, pregnancy, prior pancreatitis, and a personal or family history of hyperlipidemia should suggest the diagnosis of HTGP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/1-3,19\">",
"     1-3,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain features on the physical examination can help identify HTG as the cause of AP. Persistent hyperchylomicronemia may lead to the formation of eruptive xanthomas over the extensor surfaces of the arms, legs, buttocks, and back [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]; lipemia retinalis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]; and hepatosplenomegaly from fatty infiltration of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a progressive risk of AP with serum triglyceride levels over 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    with the risk increasing markedly with levels over 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Triglyceride levels &lt;500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    are associated with a low but measurable risk of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/2,23,25,26\">",
"     2,23,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case series of patients with acute pancreatitis, the mean triglyceride level of patients with HTG as the presumed etiology was 4587",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    3616",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and lactescent serum on hospital admission was found in 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/1\">",
"     1",
"    </a>",
"    ]. A history of HTG preceded AP in 77 percent of these cases.",
"   </p>",
"   <p>",
"    Patients with HTGP may have a worse outcome than patients with other types of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/8\">",
"     8",
"    </a>",
"    ]. However, it is unclear if the severity of pancreatitis is associated with triglyceride levels. In one study of 129 patients with types IV and V HTG, 20 percent of patients developed pancreatitis with risk increasing with TG levels [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/27\">",
"     27",
"    </a>",
"    ]. Of the patients with severe and very severe HTG, 71.5 percent had severe AP. However, in other small case series, the severity of HTGP did not seem to correlate directly with the triglyceride level [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/28\">",
"     28",
"    </a>",
"    ]. These data suggest that other factors such as the pancreatic lipase activity, the efficiency of clearing FFA from the serum and the severity of the underlying pancreatic injury are also important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Confounding laboratory investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated triglyceride levels can alter routine measurements of sodium, amylase, and low density lipoprotein (LDL). The excess triglyceride in a serum sample can displace water containing sodium and cause pseudo-hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/29\">",
"     29",
"    </a>",
"    ]. HTG levels &gt;500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    may cause a falsely normal amylase level, likely from HTG interference of the calorimetric reading. Serial dilutions of the serum amylase sample can reduce the triglyceride interference [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first goal in patients with Hypertriglyceridemia (HTG) should be the prevention of HTG by controlling triglyceride (TG) levels [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/31\">",
"     31",
"    </a>",
"    ]. In children and adults with an inherited disorder of lipoprotein metabolism, pancreatitis can be prevented by lowering the serum triglyceride level to normal (&lt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&lt;2.2",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    The risk of HTGP decreases as TG levels decrease even when TGs are only mildly abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For hyperchylomicronemia, a modest to severe diet restriction of fat and simple sugars is essential, along with exercise. For medical prevention of HTGP in patients with moderate to very severe HTG a fibrate be used as a first-line agent for reduction of triglycerides, with consideration for the use of agents from three drug classes (fibrates, niacin, n-3 fatty acids) alone or in combination with statins for treatment in patients with moderate to severe triglyceride levels [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who develop HTGP, the treatment includes conventional treatment of acute pancreatitis (AP), and management of serum triglyceride levels with an initial goal of &lt;500",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Maintenance of triglyceride levels below 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    has been seen in multiple case series to expedite clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple treatment modalities have been suggested including apheresis, insulin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . No randomized trials have compared the efficacy of apheresis with that of insulin and heparin for the treatment of HTGP, and there are no definitive guidelines for the treatment of severe HTG. Based on the published literature and our own experience with HTGP, we propose an algorithm based primarily on whether the patient has concurrent hyperglycemia (glucose &gt;500",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef54911 \" href=\"UTD.htm?16/53/17233\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/7,32-38\">",
"     7,32-38",
"    </a>",
"    ]. The following is the general approach we use independent of severity. The aim is to prevent pancreatitis from becoming necrotizing and to prevent organ failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Conventional treatment of acute pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional treatment of AP should be started, including but not restricted to aggressive hydration, analgesia, and treatment of other potential causes of AP. Triglyceride intake should be restricted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"     \"Treatment of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Apheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apheresis is a term describing the general process of passing blood through a medical device to separate any components, and returning the remaining components to the body. Plasmapheresis is the removal of up to 15 percent of the plasma, filtration uses a membrane to remove components by size, and therapeutic plasma exchange (TPE) is the removal of plasma and replacement with a colloid solution (eg, albumin or plasma) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/39\">",
"     39",
"    </a>",
"    ]. TPE is the treatment modality of choice for HTGP when apheresis is needed because filters become clogged by plasma triglycerides [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apheresis or TPE should be used to treat patients with severe HTGP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/39\">",
"     39",
"    </a>",
"    ]. In most cases the HTG is transient, and returns to near normal within two to three days, depending on etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/41\">",
"     41",
"    </a>",
"    ]. However, in several severe cases it appears to be beneficial, and potentially lifesaving [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/7,42,43\">",
"     7,42,43",
"    </a>",
"    ]. Urgent TPE should be considered in patients with a combination of severe or very severe HTG plus high lipase levels (&gt;3 times the upper limit of normal) because of the likelihood of very high FFA levels,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in patients with hypocalcemia and lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/8\">",
"     8",
"    </a>",
"    ]. This condition is further complicated by systemic inflammation from both acute pancreatitis and direct activation of TLR2 and TLR4 by FFA.",
"   </p>",
"   <p>",
"    Many case reports and series have described apheresis for HTGP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/38,42,44-54\">",
"     38,42,44-54",
"    </a>",
"    ]. One series of seven patients with an average level of 1406",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    reported a 41 percent decrease in triglyceride levels after one plasma exchange session [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/49\">",
"     49",
"    </a>",
"    ]. In another case report, triglycerides were lowered from 2410 to 138",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    after three days of apheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/54\">",
"     54",
"    </a>",
"    ]. Neither report described the use of adjunctive therapy such as intravenous insulin, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , or oral statins [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common anticoagulant used during apheresis is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , but there are no data to recommend the appropriate apheresis replacement fluid (albumin versus fresh frozen plasma). When plasma exchange is compared with double membrane filtration apheresis, rates of removal of serum lipids have been lower with double membrane filtration apheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main concerns surrounding apheresis include cost and availability. After one cycle, serum triglyceride levels are re-checked and, if less than 500",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    apheresis is stopped. If the triglyceride rises (above 500",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    we generally re-treat with apheresis.",
"   </p>",
"   <p>",
"    Early initiation of apheresis is likely to be beneficial. We generally proceed with apheresis as soon as possible. In a review of 10 patients with HTGP, nine patients received apheresis with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and insulin within 48 hours of the diagnosis of HTGP with successful outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;If apheresis is unavailable, if the patient cannot tolerate apheresis, or if the patient's serum glucose level is &gt;500",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    we use intravenous insulin. Insulin decreases serum triglyceride levels by enhancing lipoprotein lipase activity, an enzyme that accelerates chylomicron and VLDL metabolism to glycerol and fatty free acids [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Insulin also inhibits hormone-sensitive lipase in adipocytes, which is the key enzyme for breaking down adipocyte TG and releasing FFA into the circulation. Because HTGP often presents in patients with uncontrolled diabetes, insulin can decrease both triglyceride and glucose levels.",
"   </p>",
"   <p>",
"    Intravenous insulin may be more effective than subcutaneous insulin in severe cases of HTGP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Many regimens have been reported to lower triglyceride levels to less than 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    over 3.5 to 4 days [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. We typically initiate an intravenous infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    in 5 percent dextrose at a rate of 0.1 to 0.3",
"    <span class=\"nowrap\">",
"     units/kg/hour",
"    </span>",
"    to maintain blood sugar levels between 150 and 200",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"   </p>",
"   <p>",
"    Fingerstick glucose levels every four hours are suggested to ensure glucose control, and triglyceride levels should be monitored every 12 to 24 hours with adjustment of the insulin dosage as needed. Intravenous insulin should be stopped when triglyceride levels are &lt;500",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    which typically occurs within several days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Insulin and heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is controversial. Heparin stimulates the release of endothelial lipoprotein lipase into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/58\">",
"     58",
"    </a>",
"    ] and has been used without insulin to manage HTG [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/55,59,60\">",
"     55,59,60",
"    </a>",
"    ]. Multiple case reports and series have described the use of heparin and insulin to lower HTG [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/7,32-34,61\">",
"     7,32-34,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have used varying doses of insulin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    administered by various routes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/7,32,61\">",
"     7,32,61",
"    </a>",
"    ]. As an example, in two reports subcutaneous heparin at 5000 units twice daily was used with intravenous insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/32,61\">",
"     32,61",
"    </a>",
"    ]. In both healthy volunteers and dialysis patients, low molecular weight heparin has been found to deplete lipoprotein lipase stores as efficiently as heparin and to retard the metabolism of triglyceride [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the reported success of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in combination with insulin in HTG management, the use of heparin to treat HTGP has come under greater scrutiny. Heparin causes an initial rise in circulating lipoprotein lipase levels that is quickly followed by increased hepatic degradation of heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/64\">",
"     64",
"    </a>",
"    ]. This degradation contributes to further depletion of plasma stores of lipoprotein lipase and results in an increase of levels of chylomicrons [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/65\">",
"     65",
"    </a>",
"    ]. The transient nature of the benefit seen with heparin raises question as to its use as monotherapy or in combination with insulin. Another concern with heparin-mediated release of LPL is that the pathophysiology of HTGP is mediated through FFA, not TGs. Rapid reduction of TG levels by converting them to FFA may worsen the condition rather than improve it. Furthermore, heparin increases the risk of bleeding. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antihyperlipidemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihyperlipidemic agents (eg, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    600 mg twice daily) should be initiated as adjuvant therapy in patients with HTGP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"     \"Lipid lowering with diet or dietary supplements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Long-term therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral antihyperlipidemic agents and dietary fat restriction may be needed long-term to prevent recurrences of AP and prevent other complications of HTG. Periodic apheresis has been used with some success as continuing therapy after patients have recovered from their initial episode of AP, and particularly in patients who are noncompliant with diet and oral drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"     \"Lipid lowering with diet or dietary supplements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of HTGP does not differ in pregnancy. Several case reports of gestational HTGP have described the use of apheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], intravenous insulin and glucose with enteral restriction of triglyceride [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/69\">",
"     69",
"    </a>",
"    ], intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/55,59\">",
"     55,59",
"    </a>",
"    ], low fat diet [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31064/abstract/70\">",
"     70",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    . All resulted in the successful control of HTG and delivery of a healthy neonate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertriglyceridemia (HTG) is the third most common cause of acute pancreatitis (AP) after alcohol and gallstones. The risk of hypertriglyceridemic pancreatitis (HTGP) is markedly increased when serum triglyceride levels exceed 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.2",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    The risk begins to increase at triglyceride levels above 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary",
"      (genetic) and secondary disorders of lipoprotein metabolism are associated with HTGP. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe or very severe HTG are at high risk of pancreatitis. Diet, exercise, and potentially medical treatment are recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H300298#H300298\">",
"       \"Approach to the patient with hypertriglyceridemia\", section on 'Severe hypertriglyceridemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The initial clinical presentation of HTGP is similar to that of AP of other causes; abdominal pain, nausea, and vomiting are the major complaints. Poorly controlled diabetes mellitus, alcoholism, obesity, pregnancy, prior pancreatitis, and a personal or family history of hyperlipidemia should suggest the diagnosis of HTGP. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the conventional treatment of AP, management of acute HTGP focuses on decreasing triglyceride levels to &lt;500",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"       \"Treatment of acute pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest treatment with apheresis, and specifically therapeutic plasma exchange (TPE) if the patient has a serum triglyceride level",
"      <span class=\"nowrap\">",
"       &gt;1000mg/dL",
"      </span>",
"      plus lipase &gt;3 times the upper limit of normal",
"      <strong>",
"       and",
"      </strong>",
"      signs of hypocalcemia, lactic acidosis, or signs of worsening inflammation or organ dysfunction, and if there are no contraindications to apheresis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Apheresis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If apheresis is unavailable, if the patient cannot tolerate apheresis, or if the patient's serum glucose level is &gt;500",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      we suggest initiating therapy with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      in 5 percent dextrose at a rate of 0.1 to 0.3",
"      <span class=\"nowrap\">",
"       units/kg/hour",
"      </span>",
"      to maintain blood sugar levels between 150 and 200 mg (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Intravenous insulin should be stopped when serum triglyceride levels are &lt;500",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      which typically occurs within several days. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To prevent recurrences of AP and prevent other complications of HTG, we suggest a fat- and simple sugar-restricted diet and starting oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      600 mg twice daily if the patient can tolerate it (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Antihyperlipidemic therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link\">",
"       \"Lipid lowering with fibric acid derivatives\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"       \"Lipid lowering with diet or dietary supplements\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/1\">",
"      Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol 1995; 90:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/2\">",
"      Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am 1990; 19:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/3\">",
"      Chang CC, Hsieh YY, Tsai HD, et al. Acute pancreatitis in pregnancy. Zhonghua Yi Xue Za Zhi (Taipei) 1998; 61:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/4\">",
"      Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/5\">",
"      Navina S, Acharya C, DeLany JP, et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med 2011; 3:107ra110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/6\">",
"      Yang F, Wang Y, Sternfeld L, et al. The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice. Acta Physiol (Oxf) 2009; 195:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/7\">",
"      Alag&ouml;zl&uuml; H, Cindoruk M, Karakan T, Unal S. Heparin and insulin in the treatment of hypertriglyceridemia-induced severe acute pancreatitis. Dig Dis Sci 2006; 51:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/8\">",
"      Deng LH, Xue P, Xia Q, et al. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol 2008; 14:4558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/9\">",
"      Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med 1971; 75:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/10\">",
"      Havel RJ. Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis. Med Clin North Am 1982; 66:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/11\">",
"      Rivellese AA, De Natale C, Di Marino L, et al. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab 2004; 89:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/12\">",
"      Nair S, Yadav D, Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: observations in 100 consecutive episodes of DKA. Am J Gastroenterol 2000; 95:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/13\">",
"      Whitfield JB, Hensley WJ, Bryden D, Gallagher H. Some laboratory correlates of drinking habits. Ann Clin Biochem 1978; 15:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/14\">",
"      Haber PS, Wilson JS, Apte MV, et al. Lipid intolerance does not account for susceptibility to alcoholic and gallstone pancreatitis. Gastroenterology 1994; 106:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/15\">",
"      O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/16\">",
"      Goldenberg NM, Wang P, Glueck CJ. An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clin Chim Acta 2003; 332:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/17\">",
"      Alagozlu H, Cindoruk M, Unal S. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. Clin Drug Investig 2006; 26:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/18\">",
"      Eskandar O, Eckford S, Roberts TL. Severe, gestational, non-familial, non-genetic hypertriglyceridemia. J Obstet Gynaecol Res 2007; 33:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/19\">",
"      Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 2003; 36:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/20\">",
"      Durrington P. Dyslipidaemia. Lancet 2003; 362:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/21\">",
"      Nayak KR, Daly RG. Images in clinical medicine. Eruptive xanthomas associated with hypertriglyceridemia and new-onset diabetes mellitus. N Engl J Med 2004; 350:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/22\">",
"      Kumar J, Wierzbicki AS. Images in clinical medicine. Lipemia retinalis. N Engl J Med 2005; 353:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/23\">",
"      Lindkvist B, Appelros S, Regn&eacute;r S, Manjer J. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. Pancreatology 2012; 12:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/24\">",
"      Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med 2013; 173:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/25\">",
"      Preiss D, Tikkanen MJ, Welsh P, et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012; 308:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/26\">",
"      Sandhu S, Al-Sarraf A, Taraboanta C, et al. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis 2011; 10:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/27\">",
"      Lloret Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/28\">",
"      Balachandra S, Virlos IT, King NK, et al. Hyperlipidaemia and outcome in acute pancreatitis. Int J Clin Pract 2006; 60:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/29\">",
"      Howard JM, Reed J. Pseudohyponatremia in acute hyperlipemic pancreatitis. A potential pitfall in therapy. Arch Surg 1985; 120:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/30\">",
"      Fallat RW, Vester JW, Glueck CJ. Suppression of amylase activity by hypertriglyceridemia. JAMA 1973; 225:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/31\">",
"      Tsuang W, Navaneethan U, Ruiz L, et al. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol 2009; 104:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/32\">",
"      Jain D, Zimmerschied J. Heparin and insulin for hypertriglyceridemia-induced pancreatitis: case report. ScientificWorldJournal 2009; 9:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/33\">",
"      Henzen C, R&ouml;ck M, Schnieper C, Heer K. [Heparin and insulin in the treatment of acute hypertriglyceridemia-induced pancreatitis]. Schweiz Med Wochenschr 1999; 129:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/34\">",
"      Berger Z, Quera R, Poniachik J, et al. [heparin and insulin treatment of acute pancreatitis caused by hypertriglyceridemia. Experience of 5 cases]. Rev Med Chil 2001; 129:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/35\">",
"      Jabbar MA, Zuhri-Yafi MI, Larrea J. Insulin therapy for a non-diabetic patient with severe hypertriglyceridemia. J Am Coll Nutr 1998; 17:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/36\">",
"      Mikhail N, Trivedi K, Page C, et al. Treatment of severe hypertriglyceridemia in nondiabetic patients with insulin. Am J Emerg Med 2005; 23:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/37\">",
"      Tamez-P&eacute;rez HE, S&aacute;enz-Gallegos R, Hern&aacute;ndez-Rodr&iacute;guez K, et al. [Insulin therapy in patients with severe hypertriglyceridemia]. Rev Med Inst Mex Seguro Soc 2006; 44:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/38\">",
"      Betteridge DJ, Bakowski M, Taylor KG, et al. Treatment of severe diabetic hypertriglyceridaemia by plasma exchange. Lancet 1978; 1:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/39\">",
"      Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/40\">",
"      Yeh JH, Lee MF, Chiu HC. Plasmapheresis for severe lipemia: comparison of serum-lipid clearance rates for the plasma-exchange and double-filtration variants. J Clin Apher 2003; 18:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/41\">",
"      Dominguez-Mu&ntilde;oz JE, Malfertheiner P, Ditschuneit HH, et al. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. Int J Pancreatol 1991; 10:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/42\">",
"      Furuya T, Komatsu M, Takahashi K, et al. Plasma exchange for hypertriglyceridemic acute necrotizing pancreatitis: report of two cases. Ther Apher 2002; 6:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/43\">",
"      Stefanutti C, Di Giacomo S, Labbadia G. Timing clinical events in the treatment of pancreatitis and hypertriglyceridemia with therapeutic plasmapheresis. Transfus Apher Sci 2011; 45:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/44\">",
"      Kyriakidis AV, Raitsiou B, Sakagianni A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion 2006; 73:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/45\">",
"      Bae JH, Baek SH, Choi HS, et al. Acute pancreatitis due to hypertriglyceridemia: report of 2 cases. Korean J Gastroenterol 2005; 46:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/46\">",
"      Bolan C, Oral EA, Gorden P, et al. Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. J Clin Endocrinol Metab 2002; 87:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/47\">",
"      Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol 2004; 10:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/48\">",
"      Iskandar SB, Olive KE. Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis. Am J Med Sci 2004; 328:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/49\">",
"      Kadikoylu G, Yavasoglu I, Bolaman Z. Plasma exchange in severe hypertriglyceridemia a clinical study. Transfus Apher Sci 2006; 34:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/50\">",
"      Kyriakidis AV, Karydakis P, Neofytou N, et al. Plasmapheresis in the management of acute severe hyperlipidemic pancreatitis: report of 5 cases. Pancreatology 2005; 5:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/51\">",
"      Lennertz A, Parhofer KG, Samtleben W, Bosch T. Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher 1999; 3:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/52\">",
"      Mao EQ, Tang YQ, Zhang SD. Formalized therapeutic guideline for hyperlipidemic severe acute pancreatitis. World J Gastroenterol 2003; 9:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/53\">",
"      Yeh JH, Chen JH, Chiu HC. Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apher 2003; 18:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/54\">",
"      Kohli RS, Bleibel W, Shetty A, Dhanjal U. Plasmapheresis in the treatment of hypertriglyceridemic pancreatitis with ARDS. Dig Dis Sci 2006; 51:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/55\">",
"      Sleth JC, Lafforgue E, Servais R, et al. [A case of hypertriglycideremia-induced pancreatitis in pregnancy: value of heparin]. Ann Fr Anesth Reanim 2004; 23:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/56\">",
"      Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/57\">",
"      Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/58\">",
"      KORN ED. Clearing factor, a heparin-activated lipoprotein lipase. I. Isolation and characterization of the enzyme from normal rat heart. J Biol Chem 1955; 215:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/59\">",
"      Loo CC, Tan JY. Decreasing the plasma triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy: a case report. Am J Obstet Gynecol 2002; 187:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/60\">",
"      Sharma P, Lim S, James D, et al. Pancreatitis may occur with a normal amylase concentration in hypertriglyceridaemia. BMJ 1996; 313:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/61\">",
"      Jain P, Rai RR, Udawat H, et al. Insulin and heparin in treatment of hypertriglyceridemia-induced pancreatitis. World J Gastroenterol 2007; 13:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/62\">",
"      Nasstrom B, Stegmayr BG, Olivecrona G, Olivecrona T. Lower plasma levels of lipoprotein lipase after infusion of low molecular weight heparin than after administration of conventional heparin indicate more rapid catabolism of the enzyme. J Lab Clin Med 2003; 142:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/63\">",
"      N&auml;sstr&ouml;m B, Stegmayr B, Gupta J, et al. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrol Dial Transplant 2005; 20:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/64\">",
"      N&auml;sstr&ouml;m B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted. J Lab Clin Med 2001; 138:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/65\">",
"      Weintraub M, Rassin T, Eisenberg S, et al. Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation. J Lipid Res 1994; 35:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/66\">",
"      Piolot A, Nadler F, Cavallero E, et al. Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: value of regular plasmapheresis. Pancreas 1996; 13:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/67\">",
"      Achard JM, Westeel PF, Moriniere P, et al. Pancreatitis related to severe acute hypertriglyceridemia during pregnancy: treatment with lipoprotein apheresis. Intensive Care Med 1991; 17:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/68\">",
"      Yamauchi H, Sunamura M, Takeda K, et al. Hyperlipidemia and pregnancy associated pancreatitis with reference to plasma exchange as a therapeutic intervention. Tohoku J Exp Med 1986; 148:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/69\">",
"      G&uuml;rsoy A, Kulaksizoglu M, Sahin M, et al. Severe hypertriglyceridemia-induced pancreatitis during pregnancy. J Natl Med Assoc 2006; 98:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31064/abstract/70\">",
"      Lykkesfeldt G, Bock JE, Pedersen FD, et al. Excessive hypertriglyceridemia and pancreatitis in pregnancy. Association with deficiency of lipoprotein lipase. Acta Obstet Gynecol Scand 1981; 60:79.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5655 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31064=[""].join("\n");
var outline_f30_21_31064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Secondary hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Confounding laboratory investigations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Conventional treatment of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Apheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Insulin and heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antihyperlipidemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Long-term therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5655\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5655|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?16/53/17233\" title=\"algorithm 1\">",
"      Approach HTG pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5655|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/13/42192\" title=\"picture 1\">",
"      TG lactescent serum sample",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_21_31065="Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis";
var content_f30_21_31065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31065/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31065/contributors\">",
"     Christine H Holschneider, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31065/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31065/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31065/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/21/31065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, mild, moderate, and severe dysplasia were the terms used to describe premalignant squamous cervical cellular changes. This nomenclature, although still in use, has generally been replaced by the term CIN, which is used to describe histologic changes (those detected with biopsy). CIN has three degrees of severity (",
"    <a class=\"graphic graphic_figure graphicRef60116 \" href=\"UTD.htm?4/20/4423\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63660 \" href=\"UTD.htm?39/50/40742\">",
"     picture 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CIN 1 is considered a low grade lesion. It refers to mildly atypical cellular changes in the lower third of the epithelium (formerly called mild dysplasia). HPV viral cytopathic effect (koilocytotic atypia) is often present.",
"     </li>",
"     <li>",
"      CIN 2 is considered a high grade lesion. It refers to moderately atypical cellular changes confined to the basal two-thirds of the epithelium (formerly called moderate dysplasia) with preservation of epithelial maturation.",
"     </li>",
"     <li>",
"      CIN 3 is also considered a high grade lesion. It refers to severely atypical cellular changes encompassing greater than two-thirds of the epithelial thickness, and includes full-thickness lesions (formerly called severe dysplasia or carcinoma in situ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, LSIL and HSIL are also used by some to describe histologic results although this terminology was originally intended for cytology. For histology, LSIL is equivalent to CIN1 and other abnormalities defined above and HSIL comprises either CIN 2 or 3. When HSIL terms are used, however, the grade of CIN (2 versus 3) should be specified, if possible, particularly in women under age 25. CIN 2 lesions will regress following biopsy in nearly 40 percent of this population, and in women under age 20, the colposcopist may elect to follow a patient with a diagnosis of CIN 2 (but no CIN 3) under some circumstances. Of note, the interobserver reproducibility for CIN 2 varies due to the fact that some CIN 1 may be overcalled as CIN 2 on pathology. When the distinction between CIN 1 and CIN 2 is clinically important, particularly in reproductive age women, corroboration of the diagnosis by two or more pathologists is advised [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current terminology for cytologic squamous cell abnormalities is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=see_link&amp;anchor=H2#H2\">",
"     \"Cervical cytology: Interpretation of results\", section on 'Terminology for squamous cell abnormalities'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated annual incidence in the United States of CIN among women who undergo cervical cancer screening is 4 percent for CIN 1 and 5 percent for CIN 2,3 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/3\">",
"     3",
"    </a>",
"    ]. High grade lesions are typically diagnosed in women 25 to 35 years of age, while invasive cancer is more commonly diagnosed after the age of 40, typically 8 to 13 years after a diagnosis of a high grade lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=see_link\">",
"     \"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ROLE OF HUMAN PAPILLOMAVIRUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview of HPV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently implicated sexual activity as the dominant risk factor for occurrence of cervical neoplasia; cervical cancer and its precursors are almost nonexistent in women who have not had any sexual relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/4\">",
"     4",
"    </a>",
"    ]. The major factor causing these disorders is infection with the human papillomavirus (HPV) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The association between HPV and cervical neoplasia is so strong that most other behavioral, sexual, and socioeconomic covariables have been found to be dependent upon HPV infection and do not hold up as independent risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The terms transformation zone and squamocolumnar junction are frequently used interchangeably in the literature. However, these are two distinct entities. The squamocolumnar junction is the area in which the squamous epithelium of the ectocervix meets the columnar epithelium of the endocervix. The cervical transformation zone is a dynamic entity of metaplasia throughout a women&rsquo;s life and is histologically the area where the glandular epithelium has been replaced by squamous epithelium. Thus, the squamocolumnar junction is part of the transformation zone, but the transformation zone comprises a larger area than just the squamocolumnar junction.",
"   </p>",
"   <p>",
"    Recent data suggest that the primary site of carcinogenic HPV-related cervical intraepithelial neoplasia and cervical cancer is not the entire transformation zone, but is a small population of cuboidal cells at the squamocolumnar junction [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/8\">",
"     8",
"    </a>",
"    ]. This group of cells has a unique gene expression profile similar to that found in squamous and glandular high-grade cervical intraepithelial neoplasias and carcinomas.",
"   </p>",
"   <p>",
"    HPV infection is endemic among sexually experienced individuals. The risk correlates with the lifetime number of sex partners, but is relatively high (4 to 20 percent) even in those with one partner. At least 80 percent of sexually active women will have acquired a genital HPV infection by age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most HPV infections occur in young women and are transient. In a study from the United States, the overall prevalence of HPV among 1921 females aged 14 to 59 years was 26.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/10\">",
"     10",
"    </a>",
"    ]. The rate of detection of HPV by age group was: 14 to 19 years (24.5 percent), 20 to 24 years (33.8 percent), 25 to 29 years (27.4 percent), 30 to 39 years (27.5 percent), 40 to 49 years (25.2 percent), and 50 to 59 years (19.6 percent). Point prevalence is much lower, peaking at 30 to 50 percent for women in their 20s and 30s, 15 percent at age 26 to 30, 10 percent at age 31 to 35, 5 to 15 percent at age 40 to 60, but then increasing up to 30 percent after age 50 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=see_link\">",
"     \"Epidemiology of human papillomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As previously noted, most HPV infections are transient: over 50 percent of new infections are cleared in 6 to 18 months, and 80 to 90 percent will have resolved within two to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/13-19\">",
"     13-19",
"    </a>",
"    ]. Transient infections are particularly common in young women in whom the average length of a newly diagnosed HPV infection is 8 to13 months [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/16,18,20\">",
"     16,18,20",
"    </a>",
"    ]. It is unclear whether HPV positive women who become HPV negative actually clear the virus from their bodies or retain the virus in an inactive or low-level state.",
"   </p>",
"   <p>",
"    HPV testing as part of cervical cancer screening is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H11#H11\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'HPV testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sequelae of acute infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical scenarios that may ensue following acute HPV infection include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Latent infection without physical, cytological, or histological manifestations. This is the most common clinical sequelae of HPV infection, occurring in well over 90 percent of infected women.",
"      <br/>",
"      <br/>",
"      Active infection in which HPV undergoes vegetative replication, but not integration into the genome (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Molecular mechanism'",
"      </a>",
"      below).",
"      <br/>",
"      <br/>",
"      Actively replicating HPV produces characteristic cellular changes, such as nuclear enlargement, multinucleation, hyperchromasia, and perinuclear cytoplasmic clearing (halos) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/21\">",
"       21",
"      </a>",
"      ]. On average, these changes occur two to eight months after the woman is first infected [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/22\">",
"       22",
"      </a>",
"      ]. The cytological findings are also the cytological characteristics of LSIL and ASC-US (atypical squamous cells of undetermined significance), thus LSIL and HPV positive ASC-US can be considered cytological manifestations of active HPV infection.",
"      <br/>",
"      <br/>",
"      Resolution of infection is associated with regression of the cytological changes. Resolution appears to be related, at least in part, to formation of HPV antibodies and recruitment of macrophage natural killer cells and activated CD4+ T-lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. In most women the immune response is a dominant process so the infection remains latent or is suppressed quickly; however, these antibodies can take months to develop, or never develop at all [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neoplastic transformation in which HPV integrates into the human genome (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Molecular mechanism'",
"      </a>",
"      below). Possible clinical manifestations of this state include high grade lesions and cancer. This process occurs years after the acute infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"       \"Virology of human papillomavirus infections and the link to cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Factors associated with development of high grade lesions and cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between HPV infection and the development of cervical neoplasia has been consistently supported by epidemiologic and molecular studies. The infection is considered necessary for development of cervical neoplasia, but since the vast majority of women infected with HPV do not develop high grade cervical lesions or cancer, HPV alone is not sufficient to cause these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/26-38\">",
"     26-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two major factors associated with development of high grade lesions and cervical cancer are HPV subtype and persistence. Environmental factors (eg, cigarette smoking) and immunologic influences also appear to play a role (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Cofactors in pathogenesis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are over 100 HPV subtypes; approximately 40 types are specific for the anogenital epithelium and have varying potentials to cause malignant change [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/39\">",
"     39",
"    </a>",
"    ]. The distribution of HPV subtypes in the population varies somewhat by geographic region [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/26\">",
"     26",
"    </a>",
"    ]. Sequential infection with different HPV subtypes and concurrent infection with more than one HPV subtype is common [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Acquisition of one subtype of HPV infection and clearance of another subtype of HPV infection are independent events.",
"   </p>",
"   <p>",
"    The HPV subtype determines the clinical manifestations of the infection and the oncogenic potential (low, intermediate, or high) of the virus (",
"    <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-risk subtypes, such as HPV 6 and 11, do not integrate into the host genome and only cause low grade lesions (eg, LSIL and CIN 1) and benign condylomatous genital warts (",
"      <a class=\"graphic graphic_table graphicRef82294 \" href=\"UTD.htm?27/25/28059\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/42-44\">",
"       42-44",
"      </a>",
"      ]. Overall, HPV 6 and 11 account for 10 percent of low grade lesions and 90 percent of condylomatous genital warts.",
"     </li>",
"     <li>",
"      High risk HPV subtypes, such as 16 and 18, are strongly associated with high grade lesions (HSIL and CIN 2,3), persistence, and progression to invasive cancer, although they may also be associated with low grade lesions. HPV 16 and 18 account for 25 percent of low grade lesions, 50 to 60 percent of high grade lesions, and 70 percent of cervical cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/12\">",
"       12",
"      </a>",
"      ]. High grade lesions are usually flat, but cancers can be nodular, ulcerative, exophytic, or endophytic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are differences in the oncogenic potential of the various oncogenic HPV subtypes and even among the variants within a specific subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The greater association of",
"    <span class=\"nowrap\">",
"     precancer/cancer",
"    </span>",
"    with HPV 16 compared with other oncogenic types was illustrated in a study of women with low grade lesions and HPV 16 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/13\">",
"     13",
"    </a>",
"    ]. The two-year cumulative absolute risk of developing CIN 3 or worse was significantly higher in women with HPV 16 infection than in those with infection involving other high risk subtypes (30 to 40 percent versus 8 to 10 percent).",
"   </p>",
"   <p>",
"    Currently, clinical laboratories report HPV tests as either \"positive,\" meaning one or more high risk oncogenic subtypes was detected or \"negative,\" meaning none of the high risk HPV types that the laboratory tested for was detected. The presence of only low risk HPV types would not be detected and thus reported as a negative test. Data from studies evaluating the clinical course of individual oncogenic subtypes suggest that genotype specific HPV testing, rather than merely reporting HPV tests as positive or negative, might be clinically useful in predicting outcome and making treatment decisions, but these tests are not currently clinically available [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/14,46\">",
"     14,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HPV plays a role primarily in the two most common histologic types of cervical cancer: squamous cell (69 percent of cervical cancers) and adenocarcinoma (25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/47\">",
"     47",
"    </a>",
"    ]. The HPV subtypes associated with squamous cancer are different from those associated with adenocarcinoma. In an international study of over 30,000 cervical cancers, the distribution of HPV subtypes was [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Squamous cell carcinoma &ndash; HPV 16 (59 percent of cases); 18 (13 percent); 58 (5 percent); 33 (5 percent); 45 (4 percent)",
"     </li>",
"     <li>",
"      Adenocarcinoma &ndash; HPV 16 (36 percent); 18 (37 percent); 45 (5 percent); 31 (2 percent); 33 (2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Persistence",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, most HPV infections are transient and asymptomatic (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Overview of HPV infection'",
"    </a>",
"    above). In women with normal or abnormal cervical cytology at baseline, persistent infection with high oncogenic risk HPV subtypes is a key factor in development of high grade cervical lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/15,17,18,49-53\">",
"     15,17,18,49-53",
"    </a>",
"    ] and cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/51-53\">",
"     51-53",
"    </a>",
"    ], while clearance of HPV infection predicts regression of CIN [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/54\">",
"     54",
"    </a>",
"    ]. A persistent HPV infection is variably defined as one that is present at least 6 to 12 months. In one prospective population based cohort study, 21 percent of patients with highly oncogenic HPV infections persisting over 12 months developed CIN 2 or worse over 30 months follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Why HPV persists in some women and not in others is unknown. The likelihood of persistence is related to several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older age &mdash; 50 percent of high risk HPV infections persist in women older than 55 years of age compared with a 20 percent rate of persistence in women under age 25 [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Duration of infection &mdash; The longer an HPV infection has been recognized, the longer it will take to clear. In the ALTS study, 65 percent of infections that had been observed for at least 18 months persisted for another six months, while 37 percent of newly observed HPV infections persisted for six months [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High oncogenic HPV DNA type &mdash; High oncogenic risk HPV subtypes are more likely to persist than low oncogenic types [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of HPV viral load is controversial: some studies show an increased risk of CIN with increasing viral load [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/28,55,56\">",
"     28,55,56",
"    </a>",
"    ], while others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Several hypotheses have been proposed to explain these inconsistencies. One theory is that viral integration, which occurs with high grade disease, is associated with a decrease in measured viral load [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/39\">",
"     39",
"    </a>",
"    ]. Another explanation is that the relationship between cytological changes and viral load varies by HPV type: HPV 16 viral load increases with severity of cytological changes, whereas HPV 18 viral load correlates less well with the degree of cytological abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Molecular mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV is epitheliotropic; once the epithelium is infected, the virus can either persist in the cytoplasm or integrate into the host genome. When HPV remains in an episomal nonintegrated state, the result is a low grade lesion. When the virus becomes integrated into the human genome, high grade lesions and cancer may develop [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important factor in the early stages following infection is the individual's susceptibility to oncogenic HPV types, which is determined by the host's immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/60\">",
"     60",
"    </a>",
"    ]. Viral integration results in the disruption of the E1 and E2 open reading frames and, therefore, in loss of the transcriptional regulation of E6 and E7, with resultant overexpression of these oncoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/27\">",
"     27",
"    </a>",
"    ]. The HPV E6 protein binds to p53 and induces the cellular degradation of p53, while E7 interacts with the retinoblastoma protein (Rb), which leads to dissociation of the transcription factor E2F and promotion of cell cycle progression [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The disabling of these two major tumor suppressor genes, p53 and Rb, is thought to be central to host cell transformation induced by HPV and immortalization of infected cell lines. The presence of extracellular E7 also activates cervical endothelial cells, resulting in overproduction of interleukins 6 and 8, two cytokines that are associated with progression of CIN 2,3 to overt malignancy in more than 80 percent of cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COFACTORS IN PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV infection &mdash; The incidence of CIN is increased in HIV-infected women [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/65-68\">",
"       65-68",
"      </a>",
"      ]. The increased risk of CIN appears related to the greater prevalence of HPV infection in these women (64 percent versus 27 percent in HIV-uninfected women). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=see_link\">",
"       \"Preinvasive and invasive cervical neoplasia in HIV-infected women\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The risk of both HPV infection and CIN increases with increasing degrees of immunosuppression (as measured by CD4 counts and HIV RNA load) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/68-70\">",
"       68-70",
"      </a>",
"      ]. This was illustrated in a longitudinal study that found HIV-infected patients were more likely to be repeatedly HPV positive over a six-year period than women without HIV infection (79 versus 48 percent), and that a subsequent positive HPV test was more common in those with CD4 counts less than",
"      <span class=\"nowrap\">",
"       200/mcL",
"      </span>",
"      than in those with CD4 counts more than",
"      <span class=\"nowrap\">",
"       200/mcL",
"      </span>",
"      (93 versus 48 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/68\">",
"       68",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In addition, cervical cancer is one of the most common AIDS-related malignancies in women [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunosuppressive therapy &mdash; Women with chronic conditions requiring long-term immunosuppressive therapy are at increased risk of developing CIN [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. This association has been described well in transplant recipients and women with systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/74-77\">",
"       74-77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking and HPV infection have synergistic effects on the development of CIN and cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/78-84\">",
"     78-84",
"    </a>",
"    ]. Compared to HPV negative nonsmokers, one study reported the relative risk (RR) of CIN 2,3 with smoking alone, HPV infection alone, and both smoking and HPV infection was approximately 2, 15, and 66, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/82\">",
"     82",
"    </a>",
"    ]. The cumulative exposure to cigarette smoking (as measured by pack-years smoked) is strongly related to the risk of CIN [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/85\">",
"     85",
"    </a>",
"    ]. In another study of HPV positive women, the RR of cervical cancer in smokers was two to four-fold that of nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breakdown products of cigarette smoke, such as nicotine, cotinine, or NNK (ie, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) are concentrated in cervical mucous, where they may induce cellular abnormalities in cervical epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/86,87\">",
"     86,87",
"    </a>",
"    ] and decrease local immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Impaired host immunity may then allow persistence of oncogenic virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Herpes simplex virus and chlamydia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with chlamydia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/90-92\">",
"     90-92",
"    </a>",
"    ], herpes simplex virus (HSV) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/93-95\">",
"     93-95",
"    </a>",
"    ], or other sexually transmitted diseases may be a surrogate marker of exposure to HPV, rather than a causal factor itself (",
"    <a class=\"graphic graphic_table graphicRef59296 \" href=\"UTD.htm?7/37/7771\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/96\">",
"     96",
"    </a>",
"    ]. Alternatively, these infections may modulate host immunity, thereby facilitating persistence of oncogenic HPV virus [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term use of oral contraceptives has been implicated as a cofactor that increases the risk of cervical carcinoma in women who are HPV positive [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/84\">",
"     84",
"    </a>",
"    ]. However, oral contraceptive use may be a surrogate marker of exposure to HPV, rather than a causal factor. The excess risk of cervical cancer declines after discontinuation of oral contraceptives, and by 10 years returns to the baseline risk in nonusers [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H23#H23\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Cervical cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the most part genetic, familial, dietary, and endogenous hormonal factors are not thought to play a role in development of CIN or cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Although familial factors were implicated in some studies of the pathogenesis of squamous cell cervical cancer, familial aggregation due to shared environmental exposures could not be excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. One review found that high parity increased the risk of squamous-cell carcinoma of the cervix among HPV positive women [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/104\">",
"     104",
"    </a>",
"    ]. Several studies have reported that certain HLA types can affect the risk of HPV acquisition and, therefore, may make some patients more susceptible to HPV infection based on a genetic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data regarding the role of marijuana smoking in CIN. The only study was performed in women with human immunodeficiency infection and suggested to increase in the burden of cervical HPV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31065/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of CIN is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"       \"Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=see_link\">",
"       \"Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"       \"Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical intraepithelial neoplasia (CIN) is classified into three degrees of severity: CIN 1 is a low grade lesion confined to the basal third of the epithelium, CIN 2 is a high grade lesion involving the basal two-thirds of the epithelium, CIN 3 is also considered a high grade lesion that encompasses greater than two-thirds of the epithelial thickness. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection with human papillomavirus (HPV) is considered necessary for development of CIN, but since the vast majority of women infected with HPV do not develop CIN or cancer, HPV alone is not sufficient to cause these disorders. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Role of human papillomavirus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two major factors associated with development of high grade CIN and cervical cancer are HPV subtype (",
"      <a class=\"graphic graphic_table graphicRef76394 \" href=\"UTD.htm?0/27/443\">",
"       table 1",
"      </a>",
"      ) and persistence. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Factors associated with development of high grade lesions and cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low oncogenic risk subtypes, such as HPV 6 and 11, do not integrate into the host genome and only cause low grade lesions (eg, LSIL and CIN 1) and benign genital warts. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Subtype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High oncogenic risk HPV subtypes, such as 16 and 18, are strongly associated with high grade lesions, persistence, and progression to invasive cancer, but also cause low grade lesions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Subtype'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Persistence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When HPV remains in an episomal nonintegrated state, the result is a low grade lesion. When the virus is integrated into the human genome, high grade lesions and cancer may develop. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Molecular mechanism'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/1\">",
"      Crum CP. Laboratory management of CIN 2: the consensus is consensus. Am J Clin Pathol 2008; 130:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/2\">",
"      Galgano MT, Castle PE, Stoler MH, et al. Can HPV-16 genotyping provide a benchmark for cervical biopsy specimen interpretation? Am J Clin Pathol 2008; 130:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/3\">",
"      Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004; 191:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/4\">",
"      Shepherd J, Weston R, Peersman G, Napuli IZ. Interventions for encouraging sexual lifestyles and behaviours intended to prevent cervical cancer. Cochrane Database Syst Rev 2000; :CD001035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/5\">",
"      Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/6\">",
"      Kaufman RH, Adam E, Icenogle J, et al. Relevance of human papillomavirus screening in management of cervical intraepithelial neoplasia. Am J Obstet Gynecol 1997; 176:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/7\">",
"      Khan MJ, Partridge EE, Wang SS, Schiffman M. Socioeconomic status and the risk of cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer 2005; 104:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/8\">",
"      Herfs M, Yamamoto Y, Laury A, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012; 109:10516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/9\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet Gynecol 2005; 105:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/10\">",
"      Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/11\">",
"      Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/12\">",
"      Bosch X, Harper D. Prevention strategies of cervical cancer in the HPV vaccine era. Gynecol Oncol 2006; 103:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/13\">",
"      Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/14\">",
"      Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/15\">",
"      Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/16\">",
"      Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423.",
"     </a>",
"    </li>",
"    <li>",
"     Wright TC, Cox JT. Human papillomaviruses &mdash; natural history of infections. In: Clinical uses of human papillomavirus (HPV) DNA testing, American Society for Colposcopy and Cervical Pathology, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/18\">",
"      Rodr&iacute;guez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/19\">",
"      Moore EE, Danielewski JA, Garland SM, et al. Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol 2011; 117:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/20\">",
"      Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/21\">",
"      Nucci MR, Crum CP. Redefining early cervical neoplasia: recent progress. Adv Anat Pathol 2007; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     Association of Reproductive Health Professionals. Clinical Proceedings. Human Papillomavirus (HPV) and cervical cancer, Association of Reproductive Health Specialists, Washington, DC March 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/23\">",
"      Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/24\">",
"      Bontkes HJ, de Gruijl TD, Walboomers JM, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999; 80 ( Pt 2):409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/25\">",
"      Arany I, Tyring SK. Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions. J Interferon Cytokine Res 1996; 16:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/26\">",
"      Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285:2995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/27\">",
"      Beutner KR, Tyring S. Human papillomavirus and human disease. Am J Med 1997; 102:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/28\">",
"      Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/29\">",
"      Ylitalo N, S&oslash;rensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/30\">",
"      Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/31\">",
"      Castellsagu&eacute; X, D&iacute;az M, de Sanjos&eacute; S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/32\">",
"      Alani RM, M&uuml;nger K. Human papillomaviruses and associated malignancies. J Clin Oncol 1998; 16:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/33\">",
"      Ylitalo N, Josefsson A, Melbye M, et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000; 60:6027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/34\">",
"      B&ouml;hmer G, van den Brule AJ, Brummer O, et al. No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol 2003; 189:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/35\">",
"      Wright TC Jr, Denny L, Kuhn L, et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000; 283:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/36\">",
"      Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/37\">",
"      Chichareon S, Herrero R, Mu&ntilde;oz N, et al. Risk factors for cervical cancer in Thailand: a case-control study. J Natl Cancer Inst 1998; 90:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/38\">",
"      Zielinski GD, Snijders PJ, Rozendaal L, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001; 85:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/39\">",
"      de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/40\">",
"      Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/41\">",
"      Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/42\">",
"      Mu&ntilde;oz N, Bosch FX, de Sanjos&eacute; S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/43\">",
"      Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/44\">",
"      Mao C, Hughes JP, Kiviat N, et al. Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol 2003; 188:677.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. STD Prevention. Genital HPV infection, May 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/46\">",
"      Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol Oncol 2006; 103:12.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute; Bethesda, MD 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/48\">",
"      Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/49\">",
"      Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286:3106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/50\">",
"      Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004; 112:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/51\">",
"      Wallin KL, Wiklund F, Angstr&ouml;m T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999; 341:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/52\">",
"      Bory JP, Cucherousset J, Lorenzato M, et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer 2002; 102:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/53\">",
"      Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/54\">",
"      Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 2001; 358:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/55\">",
"      Schlecht NF, Trevisan A, Duarte-Franco E, et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer 2003; 103:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/56\">",
"      Dalstein V, Riethmuller D, Pr&eacute;tet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003; 106:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/57\">",
"      Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002; 360:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/58\">",
"      Castle PE, Schiffman M, Wheeler CM. Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. Am J Obstet Gynecol 2004; 191:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/59\">",
"      Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 2007; 212:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/60\">",
"      Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006; 208:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/61\">",
"      de Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 2003; 103:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/62\">",
"      M&uuml;nger K, Phelps WC, Bubb V, et al. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63:4417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/63\">",
"      D'Anna R, Le Buanec H, Alessandri G, et al. Selective activation of cervical microvascular endothelial cells by human papillomavirus 16-e7 oncoprotein. J Natl Cancer Inst 2001; 93:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/64\">",
"      Klaes R, Woerner SM, Ridder R, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999; 59:6132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/65\">",
"      Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/66\">",
"      Duerr A, Kieke B, Warren D, et al. Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/67\">",
"      Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/68\">",
"      Ahdieh L, Mu&ntilde;oz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000; 151:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/69\">",
"      Vernon SD, Holmes KK, Reeves WC. Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1:S121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/70\">",
"      Jamieson DJ, Duerr A, Burk R, et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol 2002; 186:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/71\">",
"      Maiman M, Fruchter RG, Clark M, et al. Cervical cancer as an AIDS-defining illness. Obstet Gynecol 1997; 89:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/72\">",
"      Williams AB, Darragh TM, Vranizan K, et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol 1994; 83:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/73\">",
"      Sillman F, Stanek A, Sedlis A, et al. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol 1984; 150:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/74\">",
"      Ognenovski VM, Marder W, Somers EC, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004; 31:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/75\">",
"      Malouf MA, Hopkins PM, Singleton L, et al. Sexual health issues after lung transplantation: importance of cervical screening. J Heart Lung Transplant 2004; 23:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/76\">",
"      Ozsaran AA, Ate T, Dikmen Y, et al. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur J Gynaecol Oncol 1999; 20:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/77\">",
"      Tam LS, Chan AY, Chan PK, et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004; 50:3619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/78\">",
"      Castellsagu&eacute; X, Mu&ntilde;oz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; :20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/79\">",
"      Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 2002; 94:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/80\">",
"      Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control 2003; 14:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/81\">",
"      Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000; 83:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/82\">",
"      Olsen AO, Dillner J, Skrondal A, Magnus P. Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Epidemiology 1998; 9:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/83\">",
"      Winkelstein W Jr. Smoking and cervical cancer--current status: a review. Am J Epidemiol 1990; 131:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/84\">",
"      Luhn P, Walker J, Schiffman M, et al. The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol 2013; 128:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/85\">",
"      Trevathan E, Layde P, Webster LA, et al. Cigarette smoking and dysplasia and carcinoma in situ of the uterine cervix. JAMA 1983; 250:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/86\">",
"      Sasson IM, Haley NJ, Hoffmann D, et al. Cigarette smoking and neoplasia of the uterine cervix: smoke constituents in cervical mucus. N Engl J Med 1985; 312:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/87\">",
"      Prokopczyk B, Cox JE, Hoffmann D, Waggoner SE. Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst 1997; 89:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/88\">",
"      Giuliano AR, Sedjo RL, Roe DJ, et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002; 13:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/89\">",
"      Barton SE, Maddox PH, Jenkins D, et al. Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change? Lancet 1988; 2:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/90\">",
"      Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001; 285:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/91\">",
"      Smith JS, Bosetti C, Mu&ntilde;oz N, et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004; 111:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/92\">",
"      Madeleine MM, Anttila T, Schwartz SM, et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer 2007; 120:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/93\">",
"      Herrington CS. Human papillomaviruses and cervical neoplasia. II. Interaction of HPV with other factors. J Clin Pathol 1995; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/94\">",
"      Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/95\">",
"      Hara Y, Kimoto T, Okuno Y, Minekawa Y. Effect of herpes simplex virus on the DNA of human papillomavirus 18. J Med Virol 1997; 53:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/96\">",
"      Jha PK, Beral V, Peto J, et al. Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet 1993; 341:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/97\">",
"      Zhong G, Fan T, Liu L. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J Exp Med 1999; 189:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/98\">",
"      Silins I, Ryd W, Strand A, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005; 116:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/99\">",
"      International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/100\">",
"      Shields TS, Falk RT, Herrero R, et al. A case-control study of endogenous hormones and cervical cancer. Br J Cancer 2004; 90:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/101\">",
"      Garc&iacute;a-Closas R, Castellsagu&eacute; X, Bosch X, Gonz&aacute;lez CA. The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. Int J Cancer 2005; 117:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/102\">",
"      Zelmanowicz Ade M, Schiffman M, Herrero R, et al. Family history as a co-factor for adenocarcinoma and squamous cell carcinoma of the uterine cervix: results from two studies conducted in Costa Rica and the United States. Int J Cancer 2005; 116:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/103\">",
"      Hemminki K, Li X, Mutanen P. Familial risks in invasive and in situ cervical cancer by histological type. Eur J Cancer Prev 2001; 10:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/104\">",
"      Mu&ntilde;oz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002; 359:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/105\">",
"      Mahmud SM, Robinson K, Richardson H, et al. HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis 2007; 196:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31065/abstract/106\">",
"      D'Souza G, Palefsky JM, Zhong Y, et al. Marijuana use is not associated with cervical human papillomavirus natural history or cervical neoplasia in HIV-seropositive or HIV-seronegative women. Cancer Epidemiol Biomarkers Prev 2010; 19:869.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3216 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31065=[""].join("\n");
var outline_f30_21_31065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ROLE OF HUMAN PAPILLOMAVIRUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview of HPV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sequelae of acute infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Factors associated with development of high grade lesions and cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Subtype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Persistence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Viral load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Molecular mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COFACTORS IN PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Herpes simplex virus and chlamydia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3216\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3216|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/20/4423\" title=\"figure 1\">",
"      CIN terminology and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3216|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/50/40742\" title=\"picture 1\">",
"      Comparison of Pap histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3216|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/27/443\" title=\"table 1\">",
"      Risk of cervical CA with HPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/25/28059\" title=\"table 2\">",
"      Clinical manifestations of HPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/37/7771\" title=\"table 3\">",
"      STDs associated with HPV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=related_link\">",
"      Cervical cytology: Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21610?source=related_link\">",
"      Epidemiology of human papillomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28537?source=related_link\">",
"      Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2515?source=related_link\">",
"      Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=related_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=related_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=related_link\">",
"      Preinvasive and invasive cervical neoplasia in HIV-infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_21_31066="Overview of inpatient management in the adult trauma patient";
var content_f30_21_31066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of inpatient management in the adult trauma patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31066/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31066/contributors\">",
"     Babak Sarani, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31066/contributors\">",
"     C Crawford Mechem, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31066/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31066/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/21/31066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/21/31066/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/21/31066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with traumatic injuries presents a variety of challenges. Patients have usually undergone multidisciplinary evaluation, resuscitation and stabilization in the emergency department and possible operative intervention prior to inpatient admission. Patients remain at risk for complications due to unrecognized injuries or related to initial or ongoing management.",
"   </p>",
"   <p>",
"    The general care and management of injured patients who require hospital admission are reviewed here. Initial evaluation and treatment in the emergency department are discussed separately. Specific injuries are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ongoing inpatient assessment and monitoring are critical to managing injured patients. This is particularly true in patients who have undergone damage control surgery or those with injuries that are being managed nonoperatively such as blunt splenic, hepatic, duodenal or pancreatic injury. Recognition of the full extent of traumatic injury requires an accurate history, skillful physical examination, and timely and judicious use of diagnostic studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Obtain complete history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with serious traumatic injuries often are unable to give details of their past medical history upon presentation to the emergency department and collateral sources of information (eg, family or friends) may not be available initially. It is therefore incumbent upon the admitting clinician to obtain additional information about past medical history, outpatient medications, allergies, and any history of drug or alcohol use. In addition to its value in optimizing medical management, accurate information about the medical history can be valuable in estimating prognosis. (See",
"    <a class=\"local\" href=\"#H172458919\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is also important to obtain information about the circumstances that led to the injury since falls from a height or motor vehicle collisions may have been precipitated by medical causes such as cardiac dysrhythmia, hypoglycemia, or stroke, and injuries from assault may be a result of domestic violence. In addition, self-inflicted injuries may be a manifestation of a psychological disorder which needs to be identified and treated.",
"   </p>",
"   <p>",
"    The patient's baseline health status affects the length of stay. One study of over 27,000 trauma admissions found that the probability of a trauma patient remaining hospitalized for more than three weeks nearly doubles in the presence of at least one significant underlying medical condition such as end stage renal disease, chronic obstructive pulmonary disease, or malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, ongoing drug or alcohol dependence was present in over 30 percent of individuals admitted for trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/2\">",
"     2",
"    </a>",
"    ]. These individuals had increased risk of complications during hospitalization, particularly those related to pneumonia and other infections. These patients are at risk for withdrawal syndromes, which may be difficult to recognize in the setting of obtundation, intubation or closed-head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The possibility of an intentional drug overdose prior to injury should also be considered. (See",
"    <a class=\"local\" href=\"#H172460043\">",
"     'Alcohol/drug withdrawal'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15577?source=see_link\">",
"     \"Identification and management of alcohol use disorders in the perioperative period\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172457110\">",
"    <span class=\"h2\">",
"     Repeat physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The injured patient admitted from the emergency department or operating room warrants full re-assessment by the receiving team in accordance with advanced trauma life support (ATLS) guidelines. Missed injuries are more likely to occur in the patient with polytrauma who requires emergent surgical intervention. Performing a repeat trauma survey (tertiary survey) on all patients decreases the frequency of missed injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Consider other potential injuries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Immediate attention should be given to the ABCs, ie, airway, breathing, and circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breath sounds should be evaluated, and, if the patient is intubated, the position of the endotracheal tube should be assessed to ensure that it has not become dislodged during transport. (See",
"      <a class=\"local\" href=\"#H172457118\">",
"       'Review diagnostic studies'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15545?source=see_link\">",
"       \"Endotracheal tube management and complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient's cardiovascular status should be evaluated, the patency of peripheral and central intravascular catheters confirmed, and the total volume of intravenous fluids administered since presentation established. (See",
"      <a class=\"local\" href=\"#H172457494\">",
"       'Fluid therapy and nutritional support'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A complete neurologic examination should be repeated and documented. Sedatives may have to be withheld to obtain an accurate assessment.",
"     </li>",
"     <li>",
"      A complete vascular examination should be repeated and documented. Patients with extremity injury should have ankle pressures taken bilaterally and each compared with their systolic brachial pressure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"       \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient should be examined completely, from head to toe, and front to back, to evaluate for unidentified external injuries and to note and confirm the correct positioning of any catheters, chest tubes, or drains that have been placed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172457118\">",
"    <span class=\"h2\">",
"     Review diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the diagnostic studies the patient has previously undergone, including plain films and computed tomography studies, should be reviewed and the final radiology report obtained. Plans should be made to obtain follow-up studies for injuries that have been identified, when indicated.",
"   </p>",
"   <p>",
"    Repeat chest x-ray should be ordered upon patient arrival to verify accurate endotracheal tube position, if present, and reassess the status of the lungs. The correct positioning of any chest tubes or central lines should also be verified, particularly those that may have been placed emergently (in the emergency department or operating room).",
"   </p>",
"   <p>",
"    Particular attention should be given to any films that may have been performed in the operating room as a result of an incomplete sponge count. Patients who have undergone damage control surgery are at high risk for retained surgical foreign body, and misinterpretation of films obtained in the operating room is not uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26105?source=see_link\">",
"     \"Retained surgical sponge (gossypiboma) and other retained surgical foreign bodies: Prevention and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Consider other potential injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of diagnostic guidelines for the initial evaluation in trauma, the reported incidence of missed injuries ranges from 1.3 to 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The true incidence of missed injuries and delayed diagnoses is difficult to determine, in part, because of the variability in the definition of what constitutes a missed injury. Missed injuries have been shown to increase morbidity, prolong hospital stay and increase mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Missed injuries are more commonly associated with an abbreviated injury scale (AIS) &gt;3, but missed injuries that are life-threatening are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/8\">",
"     8",
"    </a>",
"    ]. Reasons cited for missed diagnoses include assessment errors, misinterpretation of radiographs, and, for musculoskeletal injuries, lack of radiographs of the specific area of injury.",
"   </p>",
"   <p>",
"    A review of 1124 patients admitted to a Level I trauma center identified missed injuries in 8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/9\">",
"     9",
"    </a>",
"    ]. The missed injury involved an extremity in 68 percent of patients. Significant factors associated with missed injury were injury severity score (ISS) &ge;16 and Glasgow coma scale &lt;8. Of the 122 missed injuries, 72 were missed in spite of a tertiary survey.",
"   </p>",
"   <p>",
"    A concerted effort should be made to identify and treat injuries that are potentially life-threatening. These are discussed briefly below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172465552\">",
"    <span class=\"h3\">",
"     Intraabdominal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Missed or delayed diagnosis of intraabdominal injuries constitutes an important cause of preventable death in injured patients, particularly in the setting of blunt trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of 607 abdominal trauma patients revealed that 2 percent of patients had injuries that were missed on initial evaluation or at first surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/15\">",
"     15",
"    </a>",
"    ]. Missed diagnoses were attributed to clinical inexperience, overlooked or atypical radiographic findings, and an unclear history of trauma.",
"   </p>",
"   <p>",
"    A missed intraabdominal injury should be suspected in patients with blunt or penetrating trauma who have evidence of ongoing acidosis, persistent tachycardia, need for fluid resuscitation or transfusion, abdominal sepsis, and systemic inflammatory response syndrome (SIRS). Abdominal sepsis is a late finding, whereas the others usually manifest within 24 to 36 hours of injury.",
"   </p>",
"   <p>",
"    Tests to diagnose intraabdominal injury include diagnostic peritoneal lavage, computed tomography, ultrasound, magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography. However, exploratory laparotomy remains the gold standard and should be performed in any patient for whom a significant operable injury is suspected but cannot be determined by abdominal examination (eg, intubated, spinal cord injury) along with available diagnostic studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172465526\">",
"    <span class=\"h3\">",
"     Diaphragm injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaphragm injuries, particularly related to penetrating trauma, are often difficult to detect. A high index of suspicion should be maintained in patients with injury mechanisms that are associated with diaphragm rupture, such as simultaneous injuries above and below the diaphragm, and liver and spleen injuries among others. The clinical evaluation and diagnosis of diaphragm injury in adults is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28009?source=see_link\">",
"     \"Recognition and management of diaphragmatic injury in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pulmonary contusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary contusion, which is injury to the parenchyma of the lung, is the most common lung injury identified in the setting of blunt chest trauma, occurring in 17 percent of multiple trauma patients. The associated mortality rate ranges from 6 to 25 percent due often to a superimposed pneumonia or acute respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Common mechanisms of pulmonary contusion include rapid deceleration in high speed motor vehicle collisions, falls, assault, penetrating injury, and blast injury (often combined blunt and penetrating trauma) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary contusion is often not initially suspected because the clinical and radiographic findings (homogenous opacification of the lung) are delayed. In addition, pulmonary contusion can occur in the absence of any visible chest wall injury or radiographic evidence of rib fractures, particularly in children [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/18\">",
"     18",
"    </a>",
"    ]. The treatment is supportive. As with any soft-tissue contusion, the extent of injury can be progressive in the initial days following injury, and the patient must be monitored for respiratory failure during this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172462046\">",
"    <span class=\"h3\">",
"     Arterial injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt injury to an artery may not be immediately apparent depending upon the location and grade of the injury. High grade injuries (pseudoaneurysm, transection) are usually symptomatic, causing hard signs of arterial injury (pain, pulsatile mass, hypotension, extremity ischemia); however, intimal tears are often asymptomatic. These lesions may remain static or progress as a subintimal dissection that can cause luminal narrowing or acute vessel occlusion over a variable period of time, reducing distal perfusion. These low grade (minimal) injuries need to be identified so that appropriate therapy, which can be nonsurgical, can be initiated. The diagnosis and management of injuries to the vasculature are discussed in separate topic reviews.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extremity vascular injury &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12186?source=see_link\">",
"       \"Severe extremity injury in the adult patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blunt cerebrovascular injury &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/16/266?source=see_link\">",
"       \"Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=see_link\">",
"       \"Blunt cerebrovascular injury: Treatment and outcomes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aortic injury &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link\">",
"       \"Blunt thoracic aortic injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/45/8921?source=see_link\">",
"       \"Surgical and endovascular repair of blunt thoracic aortic injury\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172463302\">",
"    <span class=\"h3\">",
"     Head injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon, serious intracranial injuries may remain undetected due to a failure to obtain an indicated head CT (penetrating injury, depressed skull fractures, altered mental status), error in interpretation of brain imaging studies, or because the injury was not apparent on the initial scan. Repeat and ongoing neurologic assessment (eg, alteration in mental status, new focal neurologic deficit) determines the need to obtain additional imaging studies.",
"   </p>",
"   <p>",
"    Patients with traumatic brain injury may have indications for intracranial pressure monitoring, and repeat imaging should be utilized liberally for unexplained rises in intracranial pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of acute severe traumatic brain injury\", section on 'Intracranial pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who remain obtunded without a discernible cause on CT scan should undergo further evaluation for possible seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=see_link\">",
"     \"Management of acute severe traumatic brain injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172459815\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for monitoring in patients who require admission for traumatic injury is determined by the nature and severity of their injuries.",
"   </p>",
"   <p>",
"    In general, patients with severe injuries such as intracranial hemorrhage, or multiple intermediate or high-grade organ injuries are admitted to an intensive care unit.",
"   </p>",
"   <p>",
"    Patients with moderate injuries, including isolated conservatively managed solid organ injuries, or very minor intracerebral hemorrhage, may be admitted to a step-down unit for serial examination and close monitoring.",
"   </p>",
"   <p>",
"    Patients with mild injuries such as isolated low-grade or multiple organ injuries, including uncomplicated fractures or concussion, can be admitted to the floor for observation and supportive care. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172465416\">",
"    <span class=\"h2\">",
"     Lab studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon admission from the emergency department or operating room, labs that were abnormal upon admission should be repeated. Other laboratories are obtained based upon diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count is obtained and compared to values obtained upon arrival in the emergency department or in the operating room. Serial hemoglobin measurement may be useful to trend slow, internal bleeding, but is of limited use in guiding transfusion therapy in patients with brisk bleeding. Most importantly, an active search must be initiated to find and arrest the source of hemorrhage. Serial counts are typically obtained every six hours (and as needed based upon clinical condition) in patients with conservatively managed solid organ injuries (liver, spleen, kidney) and in patients with pelvic fracture. In patients without evidence of bleeding, the frequency of repeat blood counts depends upon the clinical situation.",
"     </li>",
"     <li>",
"      Renal function &ndash; Renal function tests (blood urea nitrogen, creatinine) should be obtained daily in patients who received intravenous contrast agents, particularly if the patient is at high risk for contrast-agent-induced nephropathy, such as patients who received contrast agents while hypovolemic and those with chronically impaired renal function. A serum creatinine concentration that begins to increase within 24 to 48 hours of contrast administration, with or without oliguria, may indicate contrast-induced nephropathy. The serum creatinine concentration generally reaches a peak after three to five days and then returns to baseline over a period of one to three weeks. Therapy of contrast-induced nephropathy is primarily supportive; dialysis is rarely required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Coagulation parameters &ndash; Coagulopathy in the injured patient may be the result of physiologic derangements such as acidosis, hypothermia, hemodilution and tissue disruption. An acute coagulopathy can occur in severely injured patients independent of these factors. Coagulopathy can be especially profound following severe traumatic brain injury due to release of brain thromboplastin into the blood stream. Early recognition and management using appropriate transfusion strategies is important to reduce morbidity and mortality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=see_link\">",
"       \"Coagulopathy associated with trauma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Injured patients with normal coagulation parameters on arrival to the emergency department and who do not have signs of bleeding do not require repeat coagulation tests. Those patients who have received massive transfusions (usually defined as 10 units or more of packed red blood cells within the first 24 hours of arrival) or who have ongoing transfusion requirements should have coagulation studies performed every four to six hours or following administration of procoagulant agents until the coagulation parameters correct. In severely injured patients with acute traumatic coagulopathy, thromboelastography may provide a more rapid assessment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=see_link&amp;anchor=H3046566855#H3046566855\">",
"       \"Coagulopathy associated with trauma\", section on 'Thromboelastography'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Creatine kinase and myoglobin &ndash; Rhabdomyolysis and myoglobinuria can develop in patients with significant muscle injury including crush injuries, prolonged immobilization, compartment syndrome, and ischemia-reperfusion following repair of vascular injuries in those who have undergone extensive embolization to arrest hemorrhage (eg, hypogastric artery). Rhabdomyolysis presents with elevated serum muscle enzymes (including creatine kinase), red to brown urine due to myoglobinuria if there is persistent renal function, and electrolyte abnormalities. Peak serum creatine kinase levels depend upon the volume of muscle breakdown and the muscle mass of the patient. Creatine kinase values should be measured if there is a suspicion for rhabdomyolysis and twice daily until decreasing levels are observed. A brisk urine output should be maintained with intravenous fluid therapy until the creatine kinase value starts to decrease. Additionally, the potassium level should be monitored. Potassium levels may decrease due to the brisk urine output or increase if renal function deteriorates or there is ongoing myocyte necrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lactate &ndash; A serum lactate level should be drawn on all severely injured patients. Lactate clearance is a marker of end-organ perfusion and normal metabolism and can serve as a guide for ongoing resuscitation. Failure of lactate to normalize within 24 hours of injury is associated with increased mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Patients who appear euvolemic and are not anemic or bleeding but have a lactate level that does not normalize should be assessed for:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Missed injury, particularly hollow visceral injury (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26522?source=see_link\">",
"       \"Traumatic gastrointestinal injury in the adult patient\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Liver disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"       \"Approach to the patient with abnormal liver biochemical and function tests\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiac dysfunction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=see_link\">",
"       \"Cardiac injury from blunt trauma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172465423\">",
"    <span class=\"h2\">",
"     Monitoring for compartment syndromes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119071180\">",
"    <span class=\"h3\">",
"     Intraabdominal pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal compartment syndrome (ACS) is recognized as a potentially fatal complication of aggressive fluid resuscitation in critically ill trauma patients. Serial monitoring of bladder pressure (which correlates closely with intraabdominal pressure) should be performed in patients at high risk for ACS (",
"    <a class=\"graphic graphic_figure graphicRef56661 \" href=\"UTD.htm?16/37/16981\">",
"     figure 1",
"    </a>",
"    ) (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119071187\">",
"    <span class=\"h3\">",
"     Extremity compartment pressures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with extremity injury can develop increased extremity compartment pressures as a result of crush injury, long bone fracture, or ischemia-reperfusion following revascularization for arterial injury. Although a diagnosis of extremity compartment syndrome may be suggested by an elevation in creatine kinase level, the diagnosis is clinical and the absolute level of creatine kinase is",
"    <strong>",
"     not",
"    </strong>",
"    predictive. Conversely, a low creatine kinase does not rule out the presence of an extremity compartment syndrome. The risk factors for, clinical diagnosis, measurement of compartment pressures and treatment of acute compartment syndrome are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link\">",
"     \"Lower extremity fasciotomy techniques\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H416669268\">",
"    <span class=\"h3\">",
"     Screening for venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for venous thromboembolism (VTE) in injured patients using duplex ultrasound remains controversial. There are no data or guidance to support routine screening. Although the prevalence of occult deep vein thrombosis (DVT) is significantly higher in centers that screen trauma patients, the incidence of pulmonary embolism (PE) is overall unchanged. The Centers for Medicare &amp; Medicaid services included DVT in trauma patients as a never event; however, using this endpoint as a quality measure is being questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/21\">",
"     21",
"    </a>",
"    ]. In spite of adequate pharmacologic anticoagulation in trauma populations, VTE persists. Many clinicians feel that a better assessment of quality of care includes evaluating adherence to an evidence-based regimen for VTE prophylaxis, and rather than using duplex testing to screen for VTE, appropriately evaluating high-risk and symptomatic patients, as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/22\">",
"     22",
"    </a>",
"    ]. A more complete discussion of this issue can be found in a podcast [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/23\">",
"     23",
"    </a>",
"    ], and in topics discussing DVT prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172458230\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS AND PREVENTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Particular attention should be paid toward preventing common complications that are associated with significant traumatic injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172458237\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine antibiotic administration is not warranted in most injured patients. In particular, the presence of a penetrating injury (eg, gunshot wound, stab wound) does not indicate the need for antibiotic coverage in the absence of local signs of infection. For patients who require abdominal exploration, a single dose of prophylactic antibiotics given within one hour of incision is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In the face of hollow viscus injury, antibiotics can be continued, and provided there has been no delay in identification and surgical management, no more than 24 hours should be needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26522?source=see_link\">",
"     \"Traumatic gastrointestinal injury in the adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis is also justified in patients with penetrating thoracic injury who require chest tube placement and for those patients who require surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link&amp;anchor=H733687288#H733687288\">",
"     \"Placement and management of thoracostomy tubes\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172458244\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary embolus (PE) remains a leading cause of preventable mortality in hospitalized trauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/26\">",
"     26",
"    </a>",
"    ]. Risk factors for thromboembolism in injured patients include spinal cord injury, lower extremity and pelvic fractures, need for surgical intervention, increasing age, femoral venous line insertion, surgical repair of venous injuries, prolonged immobilization, prolonged hospital stay, and high injury severity score [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/27-31\">",
"     27-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various strategies for the prevention of thromboembolic complications have been used, including antiembolism stockings, sequential compression devices, antithrombotic therapy, and prophylactic inferior vena cava filter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/27,32-38\">",
"     27,32-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of which of these to use for a particular patient depends greatly on the nature and severity of injuries, and the presence of conditions that contraindicate their use (eg, traumatic brain injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The optimal approach in patients with traumatic injuries remains incompletely defined [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. When possible, all hospitalized patients with traumatic injuries should receive at least one mode of prophylaxis. We generally use a combination of pneumatic compression devices, low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and surveillance duplex ultrasound, depending upon the perceived risk. Patients at risk who do not have a contraindication to antithrombotic therapy should receive pharmacologic prophylaxis irrespective of their mobility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H39#H39\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Special groups'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172459209\">",
"    <span class=\"h2\">",
"     Stress ulcer prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely injured patients (intubated, coagulopathic) and patients with a history of prior ulcer disease are at increased risk for stress ulcerations. Stress ulcerations are mucosal erosions involving the fundus and body of the stomach, but sometimes occurring in the antrum, duodenum, or distal esophagus. They tend to be shallow and cause oozing of blood from superficial capillary beds, but deeper lesions can erode into the submucosa, cause massive hemorrhage, and occasionally perforate. Prophylaxis against stress ulcers is recommended for high-risk patients who require admission to the intensive care unit. Pharmacologic agents used for ulcer prophylaxis that increase the gastric pH may increase the frequency of nosocomial pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link&amp;anchor=H10#H10\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\", section on 'Potential harms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link&amp;anchor=H929814#H929814\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172458611\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients taking glucocorticoids prior to injury may require additional treatment to manage the trauma-induced stress response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=see_link\">",
"     \"The surgical patient taking glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Corticosteroids have been found to decrease the duration to shock reversal in patients with septic shock, but their role in the management of severely injured patients is currently being investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The indications for treatment of relative adrenal insufficiency are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=see_link\">",
"     \"Corticosteroid therapy in septic shock\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study, 23 trauma patients had their",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      dose-response measured before and after the administration of corticosteroids (50 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/45\">",
"       45",
"      </a>",
"      ]. In patients who had required resuscitation for hemorrhagic shock, administration of corticosteroids was associated with a 37 percent decrease in effective dose of phenylephrine.",
"     </li>",
"     <li>",
"      A trial randomly assigned polytrauma patients to a continuous intravenous infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (200 mg daily for five days followed by 100 mg on day six and 50 mg on day seven) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/46\">",
"       46",
"      </a>",
"      ]. The incidence of hospital-acquired pneumonia was significantly lower in the hydrocortisone group (36 versus 51 percent, hazard ratio 0.51, 95% CI 0.30-0.83) compared with placebo, resulting in fewer days of mechanical ventilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172459915\">",
"    <span class=\"h2\">",
"     Pressure ulcer prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injured patients, including those requiring prolonged ventilatory support; those with brain, spine, pelvic or extremity injury; and those being maintained on bed rest for blunt solid organ injury are at risk for developing pressure ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/47\">",
"     47",
"    </a>",
"    ]. Appropriate preventive measures should be undertaken, the choice of which depends upon the nature and severity of injuries. Preventive strategies for reducing the incidence of pressure ulcers in high-risk populations are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1049?source=see_link\">",
"     \"Prevention of pressure ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172467729\">",
"    <span class=\"h2\">",
"     Hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia following injury is due to cold exposure at the time of injury and during initial evaluation, compounded by the administration of unwarmed intravenous fluids. Hypothermia can also represent advanced shock, which in the trauma population is most commonly due to hemorrhage. Patients who require surgery are at a greater risk for hypothermia due to further physical exposure in the operating room, additional fluid administration, and the effects of general anesthesia. Injured patients with hypothermia generally have worse outcomes compared with non-injured patients with hypothermia; however, hypothermia alone is a weak independent predictor of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upon admission, the patient&rsquo;s temperature should be noted and measures instituted to warm the patient if their body temperature is low. Continuous temperature monitoring is essential to ensure that mild hypothermia does not worsen. Specific measures to correct hypothermia include controlling physical exposure, administration of warmed fluids, and passive rewarming with blankets and forced-air devices. In the case of moderate or severe hypothermia and coagulopathy, central rewarming may be needed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172460043\">",
"    <span class=\"h2\">",
"     Alcohol/drug withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injured patients who have been identified as being at risk for alcohol or drug withdrawal should receive appropriate prophylactic treatment. Patients who exhibit delirium or confusion attributable to alcohol or drug withdrawal are treated accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15577?source=see_link&amp;anchor=H18#H18\">",
"     \"Identification and management of alcohol use disorders in the perioperative period\", section on 'Alcohol withdrawal syndrome treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172460051\">",
"    <span class=\"h2\">",
"     Psychological support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have been assaulted, or have suffered severe physical injury, particularly those who required intensive care unit monitoring are susceptible to acute stress disorder and post-traumatic stress disorder (PTSD). These disorders are characterized by intrusive thoughts, nightmares and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, and sleep disturbance. Patients exhibiting persistent symptoms (&gt;2 weeks) should be referred for psychological evaluation and potentially treatment. Anxiolytics may be necessary in the interim. In more severe cases, earlier referral to a psychologist or psychiatrist may be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7080?source=see_link\">",
"     \"Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severely injured patients who require operative intervention have an increased risk for anesthetic underdosing related to the often emergent nature of the procedure and hypotension prior to induction of anesthesia. When possible, patients should be asked if they have any recollection of intraoperative events. Patients who have experienced an awareness event and exhibit signs of psychological disturbance (eg, intrusive thoughts, flashbacks, sleep disturbance) should be referred for psychological evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34504?source=see_link\">",
"     \"Awareness with recall following general anesthesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172457494\">",
"    <span class=\"h1\">",
"     FLUID THERAPY AND NUTRITIONAL SUPPORT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172460163\">",
"    <span class=\"h2\">",
"     Fluid management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon admission, the patient&rsquo;s intake and output record during the course of resuscitation and anesthesia should be obtained and the net fluid balance determined.",
"   </p>",
"   <p>",
"    Hemodynamically stable euvolemic patients should receive maintenance and replacement fluids and electrolytes, as indicated, depending upon dietary status. Drainage from chest tubes, and wound sites such as an open abdomen and fasciotomy wounds should be quantified, if possible. A pre-set fluid replacement regimen is rarely necessary, but these sources of fluid efflux should be considered when adjusting the volume of fluid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=see_link\">",
"     \"Maintenance and replacement fluid therapy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Crystalloid boluses in addition to maintenance fluid are administered to patients who remain hypotensive or oliguric, and may be needed in hemodynamically stable patients who have a negative fluid balance. Therapy should be guided by urine output in patients with normal renal function. Ongoing bleeding requires transfusion therapy (packed red blood cells, fresh frozen plasma, platelets) to maintain an adequate oxygen carrying capacity and to reverse coagulopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A positive fluid balance is likely in severely injured patients, particularly those who have received massive transfusion (eg, acute traumatic coagulopathy). Crystalloid is minimized in this population. Transfusion may be guided by thromboelastography parameters, where available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H3986774#H3986774\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Transfusion for severe ongoing hemorrhage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=see_link&amp;anchor=H184662298#H184662298\">",
"     \"Coagulopathy associated with trauma\", section on 'Thromboelastography-based transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who require repeat radiographic studies with intravenous contrast, prehydration with crystalloid for several hours prior to administering the contrast agent appears to decrease the incidence of nephrotoxicity; the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172460235\">",
"    <span class=\"h2\">",
"     Enteral and parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early institution of high protein nutritional support is essential in the care of the injured patient. Injured patients are susceptible to hypermetabolism, which leads to breakdown of skeletal protein and inhibition of protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, fluid effluent from an open abdomen results in significant protein loss, which can be estimated as 2 g of nitrogen per liter of abdominal fluid lost. This loss needs to be taken into account when calculating daily enteral or parenteral nutrition requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/54\">",
"     54",
"    </a>",
"    ]. The goal of nutritional support is to maintain lean body mass to prevent the negative consequences of protein malnutrition that can lead to multisystem organ dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=see_link\">",
"     \"Perioperative nutritional support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Every effort should be made to provide enteral nutrition to injured patients who cannot eat or who are unable to achieve adequate oral caloric intake. Multiple studies have demonstrated the superiority of enteral nutrition compared with parenteral nutrition. Infectious complications are lower in patients given adequate enteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Enteral nutrition enhanced by supplementation with glutamine and antioxidants may have additional benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing to initiation of enteral nutrition must be tailored to the individual patient based on injuries sustained and interventions performed. Those with significant abdominal injury and operative intervention may not tolerate enteral nutrition and may need supplemental or complete",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN).",
"   </p>",
"   <p>",
"    Absolute contraindications to enteral nutrition mandate parenteral nutrition therapy and are given below. A recent bowel resection and anastomosis is not a contraindication to enteral nutrition and the presence of an open abdomen should not discourage attempts at enteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In a small study, enteral nutrition was successfully implemented in 52 percent of patients with open abdomen within four days of the initial laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients with injury to the proximal gastrointestinal tract (eg, duodenal or pancreatic injury) can be fed through a more distal jejunostomy tube.",
"   </p>",
"   <p>",
"    The indications for complete parenteral nutrition include: patients with persistent progressive ileus, bowel obstruction, massive bowel resection refractory to enteral nutrition, malabsorption, splanchnic hypoperfusion that places the patient at high risk for nonocclusive mesenteric ischemia and bowel necrosis, high output enteral fistula, intolerance of enteral nutrition (documented), and failure of enteral nutrition to meet caloric requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=see_link\">",
"     \"Nutrition support in critically ill patients: Parenteral nutrition\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172458270\">",
"    <span class=\"h2\">",
"     Glucose control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with blood glucose above or below the accepted target range should be treated with insulin or glucose containing intravenous fluids, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are increasing numbers of studies evaluating the adverse impact of the hyperglycemic stress response in injured patents. Prospective studies of injured nondiabetic patients have found that elevated serum glucose on admission, defined as glucose &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    was significantly associated with an increased risk of infection (eg, urinary tract, pneumonia, wound), increased length of stay (hospital, intensive care unit), and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. In a study of 6852 trauma patients, patients with stress-induced hyperglycemia had a more than twofold increased risk for mortality compared with normoglycemic patients (RR 2.41, 95% CI 1.81-3.23), whereas, although there was a trend toward increased mortality among patients with diabetes, the difference was nonsignificant (RR 1.47, 95% CI 0.92-2.36) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172459250\">",
"    <span class=\"h1\">",
"     WOUND CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injured patients present with a myriad of different wounds depending upon the injury mechanism. Upon admission, the location and size of each wound should be documented. Deep and more extensive wounds, particularly those in proximity to major vessels, should be explored in the operating room where lighting is optimal, debridement can be undertaken, and any disrupted vessels can be managed in a controlled fashion.",
"   </p>",
"   <p>",
"    Individual wounds are managed with moist dressings, and closure or coverage, as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link\">",
"     \"Basic principles of wound management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172459868\">",
"    <span class=\"h2\">",
"     Open abdomen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open abdomen is an abdominal wall defect created by intentionally leaving the fascia and skin open at the completion of surgery. Damage control surgery and suspected abdominal compartment syndrome are the most frequent reasons for open abdomen. The open abdomen is managed using temporary abdominal closure techniques that control abdominal fluid losses and assist with the progressive closure of the defect (",
"    <a class=\"graphic graphic_picture graphicRef70808 \" href=\"UTD.htm?2/58/2979\">",
"     picture 1",
"    </a>",
"    ). Management of the abdominal defect is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=see_link\">",
"     \"Management of the open abdomen in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172459899\">",
"    <span class=\"h2\">",
"     Fasciotomy wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute extremity compartment syndrome are treated with fasciotomy. Prophylactic fasciotomy may be indicated in some patients (eg, ischemia-reperfusion following arterial repair, tibial fracture). The fasciotomy wounds are managed with moist dressings initially with subsequent closure of the skin when muscle edema has resolved. The indications for fasciotomy and management of fasciotomy wounds are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H16956064#H16956064\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3400?source=see_link&amp;anchor=H443283577#H443283577\">",
"     \"Patient management following extremity fasciotomy\", section on 'Wound management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172459593\">",
"    <span class=\"h1\">",
"     CATHETERS, TUBES, DRAINS AND LINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the initial assessment in the emergency department, most severely injured patients will have received an indwelling bladder catheter, various intravenous catheters and possibly an endotracheal or chest tube. Postoperative patients, particularly those who underwent damage control surgery, may also have had intraoperative drains placed.",
"   </p>",
"   <p>",
"    Upon admission, the correct positioning of each tube and line should be confirmed, using radiographs if needed. Intravenous lines are often placed under duress during resuscitation and frequent breaks in sterile precautions occur. These lines should be changed, whenever possible. Appropriate care and management of these tubes and drains helps prevent complications. Issues related to surgical tubes and drains are discussed in detail elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bladder catheters &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=see_link\">",
"       \"Placement and management of urinary bladder catheters\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33941?source=see_link\">",
"       \"Complications of urinary bladder catheters and preventive strategies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest tubes &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"       \"Placement and management of thoracostomy tubes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central lines &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"       \"Prevention of intravascular catheter-related infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172459936\">",
"    <span class=\"h1\">",
"     PAIN MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain management in the injured patient follows similar principles for managing postoperative pain. Critically injured patients in the intensive care unit are assessed frequently to ensure that pain control is adequate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest wall injures can cause significant pain which can compromise respiratory function; management may include the use of neuraxial anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=see_link\">",
"     \"Inpatient management of traumatic rib fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172467480\">",
"    <span class=\"h1\">",
"     NONOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonoperative management of hemodynamically stable patients with liver or spleen injury is appropriate for selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/54/1898?source=see_link&amp;anchor=H10#H10\">",
"     \"Management of splenic injury in the adult trauma patient\", section on 'Nonoperative management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9497?source=see_link&amp;anchor=H462306215#H462306215\">",
"     \"Management of hepatic trauma in adults\", section on 'Nonoperative management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, nonoperative management of pancreatic injury may be indicated if the pancreatic duct has not been injured. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22266?source=see_link&amp;anchor=H2054906#H2054906\">",
"     \"Management of duodenal and pancreatic trauma in adults\", section on 'Nonoperative management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A nonoperative management approach may include the use of interventional techniques (eg, arteriography with embolization, endoscopic retrograde cholangiopancreatography). When applied correctly, nonoperative management is associated with shorter hospital stays and improved outcomes. However, it also requires the availability of appropriate institutional resources and a commitment to ongoing patient assessment and monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H172459815\">",
"     'Monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172459320\">",
"    <span class=\"h1\">",
"     DAMAGE CONTROL AND RESUSCITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage control surgery, which has become a common approach to the treatment of the severely injured patient, involves immediate operative control of hemorrhage and contamination (ie, bowel injury) followed by transfer to the intensive care unit for ongoing resuscitation. Damage control surgery has been shown to reduce mortality in severely and multiply injured patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upon arrival to the intensive care unit, acidosis, hypothermia, and coagulopathy are corrected with ongoing fluid resuscitation and component transfusion therapy. Once the patient is stabilized, definitive treatment of the patient&rsquo;s injuries can be undertaken. Damage control and the management of specific injuries are discussed in separate topic reviews.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic injury &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/54/1898?source=see_link\">",
"       \"Management of splenic injury in the adult trauma patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7049?source=see_link\">",
"       \"Surgical management of splenic injury in the adult trauma patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Liver injury &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9497?source=see_link\">",
"       \"Management of hepatic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Duodenal and pancreatic injury &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22266?source=see_link\">",
"       \"Management of duodenal and pancreatic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vascular injury &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=see_link\">",
"       \"Blunt thoracic aortic injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small bowel and colon injury &ndash; (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26522?source=see_link\">",
"       \"Traumatic gastrointestinal injury in the adult patient\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications in injured patients are often related to the nature of the patient&rsquo;s specific injuries (eg, pancreatic fistula, intraabdominal abscess). These complications are discussed in separate reviews that discuss specific injuries. Complications may also arise as a result of resuscitative efforts, prolonged ventilation or immobilization. Complications may also be iatrogenic in nature. Significant complications are briefly reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172468649\">",
"    <span class=\"h2\">",
"     Deep vein thrombosis and pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients sustaining major trauma have a high risk of developing venous thromboembolism, in part due to the number of patients whose injuries contraindicate antithrombotic prophylaxis.",
"   </p>",
"   <p>",
"    The incidence of lower extremity deep vein thrombosis in injured patients who",
"    <strong>",
"     have",
"    </strong>",
"    received thromboprophylaxis ranges from 12 to 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/29,34,72,73\">",
"     29,34,72,73",
"    </a>",
"    ]. The incidence of pulmonary embolism (PE) is estimated between 0.7 and 20 percent, depending upon the population studied [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. In a study of 110 patients with PE following injury, long bone fracture, admission to a ward (not ICU), and female gender were associated with an increased risk for early PE (&lt;4 days), whereas severe head injury, severe chest injury, and major surgery within 48 hours of admission were associated with later PE [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H119069566\">",
"    <span class=\"h2\">",
"     Acute respiratory distress syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are defined by the acute onset of bilateral infiltrates consistent with pulmonary edema, but without evidence of elevated left atrial pressure. The degree of hypoxemia differentiates the two. Severe trauma predisposes to",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    and may be related to the mechanism of injury (eg, lung contusion, long bone fracture leading to fat embolism) or resuscitation (eg, transfusion). The definition, clinical features, diagnosis and management of",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study to identify early clinical predictors of respiratory distress after major traumatic injury, acute respiratory distress syndrome was found in 24 percent of a validation cohort of 1762 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/78\">",
"     78",
"    </a>",
"    ]. Predictors of acute respiratory distress syndrome after trauma included subject age, increasing Acute Physiology and Chronic Health Evaluation II (APACHE II) Score, increasing injury severity score (ISS), and the presence of blunt traumatic injury, pulmonary contusion, massive transfusion, or flail chest injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Transfusion-associated complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute lung injury and noncardiogenic pulmonary edema can develop in response to transfusion of packed red blood cells, or more commonly, plasma transfusion. The diagnosis, distinction of this disorder from transfusion-related circulatory overload, and management are discussed in detail elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172468699\">",
"    <span class=\"h2\">",
"     Ventilator-associated pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injured patients appear to have a higher risk for ventilator associated pneumonia (VAP) compared with non-injured patients. In a study of 2591 patients at a single institution that included 511 trauma patients, the incidence of VAP was significantly greater in the trauma population (18 versus 3.4 percent); however, mortality was significantly less (11 versus 31 percent), compared with nontrauma patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/79\">",
"     79",
"    </a>",
"    ]. VAP occurred earlier in the hospital course in the trauma group. A multivariate regression for VAP in the trauma cohort identified significant independent risk factors to be tracheostomy,",
"    <span class=\"nowrap\">",
"     bronchoscopy/bronchoalveolar",
"    </span>",
"    lavage, and total days of mechanical ventilation (probably a confounded factor). Injury severity score was not a significant factor. No differences in mortality were seen between those with and without. Several other studies have likewise found no significant differences in mortality rates in trauma patients with and without VAP [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. The diagnosis and general management of VAP is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172468706\">",
"    <span class=\"h2\">",
"     Contrast-induced nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation in trauma patients frequently involves the use of contrast media for computed tomography, arteriography, and intravenous pyelography. The true incidence of nephrotoxicity in this population is unknown but is probably less than 1 percent. Intravenous contrast causes nephrotoxicity through a direct toxic effect on tubular epithelial cells and alterations in renal hemodynamics. The risk is increased in patients with baseline renal insufficiency, multiple myeloma, heart failure, volume depletion, dehydration and hypotension. Once established, the treatment is primarily supportive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172468713\">",
"    <span class=\"h2\">",
"     Catheter-associated blood stream infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of catheter-associated infection is higher in trauma populations, which may be due to the placement of lines under less-than-ideal conditions. Issues related to catheter-associated blood stream infection are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172458919\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality among victims of trauma is substantially increased in the presence of one or more underlying chronic conditions. As an example, one study of approximately 7800 patients admitted with traumatic injures found that patients with at least one underlying medical condition had a significantly higher mortality compared with patients without such conditions (9 versus 3 percent), despite similar Glasgow Coma and Injury Severity Scores [",
"    <a class=\"abstract\" href=\"UTD.htm?30/21/31066/abstract/82\">",
"     82",
"    </a>",
"    ]. Underlying renal disease, malignancy, or cardiac disease were particularly ominous indicators. Similar associations have been observed in the APACHE and other models of illness severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=see_link\">",
"     \"Predictive scoring systems in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172468209\">",
"    <span class=\"h2\">",
"     Organ donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impending trauma deaths should be called into the local organ procurement organization (OPO) irrespective of age, injury, or comorbidity. Management of the potential organ donor can be very challenging and is discussed in detail elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=see_link\">",
"     \"Diagnosis of brain death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18566?source=see_link\">",
"     \"Management of the potential deceased donor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A cooperative relationship between trauma centers and the local OPO is essential. Importantly, members of the treating team should",
"    <strong>",
"     not",
"    </strong>",
"    engage in discussions related to organ donation with the patient&rsquo;s family. Procurement rate improves when trained personnel initiate these discussions, and as such, all discussion should be deferred to the OPO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The injured patient admitted from the emergency department or operating room warrants full reassessment of their medical history. Patients with ongoing alcohol or drug dependence are more likely to have complications during their hospital stay, while patients with medical comorbidities have an increased risk of mortality. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Repeat head-to-toe trauma examination (tertiary survey) on all patients decreases the frequency of missed injuries. Missed injuries are more common in multiply injured patients who require emergent surgical intervention shortly after hospital arrival. Extremity injuries are commonly missed. Significant injuries that can be missed during the initial evaluation include intraabdominal injury, diaphragm injury, pulmonary contusion, arterial injury and intracranial injury. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Consider other potential injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive strategies are important to reduce the incidence of common complications and include monitoring to identify and treat extremity and abdominal compartment syndromes, as indicated by the patient&rsquo;s injuries, and prophylactic therapies such as antibiotics prior to surgical intervention, thromboprophylaxis, stress ulcer prophylaxis, steroid prophylaxis for those on chronic therapy, and prophylaxis for",
"      <span class=\"nowrap\">",
"       drug/alcohol",
"      </span>",
"      withdrawal. (See",
"      <a class=\"local\" href=\"#H172465423\">",
"       'Monitoring for compartment syndromes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H172458230\">",
"       'Prophylaxis and preventive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications that may arise in injured patients are often related to specific injuries (eg, biliary fistula), but may also be due to incomplete or absent prophylaxis (eg, deep vein thrombosis), lack of monitoring (eg, abdominal compartment syndrome), or complications arising from diagnostic and resuscitative efforts (eg, contrast-media-associated nephropathy, transfusion-associated acute lung injury), prolonged ventilation (eg, ventilator-associated pneumonia) or immobilization (eg, pressure ulcers). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/1\">",
"      MacKenzie EJ, Morris JA Jr, Edelstein SL. Effect of pre-existing disease on length of hospital stay in trauma patients. J Trauma 1989; 29:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/2\">",
"      Soderstrom CA, Smith GS, Dischinger PC, et al. Psychoactive substance use disorders among seriously injured trauma center patients. JAMA 1997; 277:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/3\">",
"      Jurkovich GJ, Rivara FP, Gurney JG, et al. The effect of acute alcohol intoxication and chronic alcohol abuse on outcome from trauma. JAMA 1993; 270:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/4\">",
"      Milzman DP, Soderstrom CA. Substance use disorders in trauma patients. Diagnosis, treatment, and outcome. Crit Care Clin 1994; 10:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/5\">",
"      Biffl WL, Harrington DT, Cioffi WG. Implementation of a tertiary trauma survey decreases missed injuries. J Trauma 2003; 54:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/6\">",
"      Richards CF, Mayberry JC. Initial management of the trauma patient. Crit Care Clin 2004; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Trauma of the American College of Surgeons. Advanced Trauma Life Support: Course for Physicians, 5th ed, American College of Surgeons, Chicago, 1993, p. 17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/8\">",
"      Pfeifer R, Pape HC. Missed injuries in trauma patients: A literature review. Patient Saf Surg 2008; 2:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/9\">",
"      Giannakopoulos GF, Saltzherr TP, Beenen LF, et al. Missed injuries during the initial assessment in a cohort of 1124 level-1 trauma patients. Injury 2012; 43:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/10\">",
"      Kalemoglu M, Demirbas S, Akin ML, et al. Missed injuries in military patients with major trauma: original study. Mil Med 2006; 171:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/11\">",
"      Brooks A, Holroyd B, Riley B. Missed injury in major trauma patients. Injury 2004; 35:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/12\">",
"      Vles WJ, Veen EJ, Roukema JA, et al. Consequences of delayed diagnoses in trauma patients: a prospective study. J Am Coll Surg 2003; 197:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/13\">",
"      Todd SR. Critical concepts in abdominal injury. Crit Care Clin 2004; 20:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/14\">",
"      Enderson BL, Maull KI. Missed injuries. The trauma surgeon's nemesis. Surg Clin North Am 1991; 71:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/15\">",
"      Sung CK, Kim KH. Missed injuries in abdominal trauma. J Trauma 1996; 41:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/16\">",
"      Allen GS, Coates NE. Pulmonary contusion: a collective review. Am Surg 1996; 62:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/17\">",
"      Cohn SM. Pulmonary contusion: review of the clinical entity. J Trauma 1997; 42:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/18\">",
"      Wanek S, Mayberry JC. Blunt thoracic trauma: flail chest, pulmonary contusion, and blast injury. Crit Care Clin 2004; 20:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/19\">",
"      Ouellet JF, Roberts DJ, Tiruta C, et al. Admission base deficit and lactate levels in Canadian patients with blunt trauma: are they useful markers of mortality? J Trauma Acute Care Surg 2012; 72:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/20\">",
"      R&eacute;gnier MA, Raux M, Le Manach Y, et al. Prognostic significance of blood lactate and lactate clearance in trauma patients. Anesthesiology 2012; 117:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/21\">",
"      Thorson CM, Ryan ML, Van Haren RM, et al. Venous thromboembolism after trauma: a never event?*. Crit Care Med 2012; 40:2967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/22\">",
"      Bandle J, Shackford SR, Kahl JE, et al. The value of lower-extremity duplex surveillance to detect deep vein thrombosis in trauma patients. J Trauma Acute Care Surg 2013; 74:575.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.east.org/resources/traumacast-detail/23 (Accessed on April 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/24\">",
"      Goldberg SR, Anand RJ, Como JJ, et al. Prophylactic antibiotic use in penetrating abdominal trauma: an Eastern Association for the Surgery of Trauma practice management guideline. J Trauma Acute Care Surg 2012; 73:S321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/25\">",
"      Smith BP, Fox N, Fakhro A, et al. \"SCIP\"ping antibiotic prophylaxis guidelines in trauma: The consequences of noncompliance. J Trauma Acute Care Surg 2012; 73:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/26\">",
"      O'Donnell M, Weitz JI. Thromboprophylaxis in surgical patients. Can J Surg 2003; 46:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/27\">",
"      Spain DA, Richardson JD, Polk HC Jr, et al. Venous thromboembolism in the high-risk trauma patient: do risks justify aggressive screening and prophylaxis? J Trauma 1997; 42:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/28\">",
"      Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med 1994; 331:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/29\">",
"      Velmahos GC, Kern J, Chan LS, et al. Prevention of venous thromboembolism after injury: an evidence-based report--part I: analysis of risk factors and evaluation of the role of vena caval filters. J Trauma 2000; 49:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/30\">",
"      Meissner MH, Chandler WL, Elliott JS. Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability? J Trauma 2003; 54:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/31\">",
"      Malinoski D, Ewing T, Patel MS, et al. Risk factors for venous thromboembolism in critically ill trauma patients who cannot receive chemical prophylaxis. Injury 2013; 44:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/32\">",
"      Ginzburg E, Cohn SM, Lopez J, et al. Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma. Br J Surg 2003; 90:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/33\">",
"      Brasel KJ, Borgstrom DC, Weigelt JA. Cost-effective prevention of pulmonary embolus in high-risk trauma patients. J Trauma 1997; 42:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/34\">",
"      Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/35\">",
"      Upchurch GR Jr, Demling RH, Davies J, et al. Efficacy of subcutaneous heparin in prevention of venous thromboembolic events in trauma patients. Am Surg 1995; 61:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/36\">",
"      Fisher CG, Blachut PA, Salvian AJ, et al. Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomized study of compression alone versus no prophylaxis. J Orthop Trauma 1995; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/37\">",
"      Rosenthal D, Wellons ED, Levitt AB, et al. Role of prophylactic temporary inferior vena cava filters placed at the ICU bedside under intravascular ultrasound guidance in patients with multiple trauma. J Vasc Surg 2004; 40:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/38\">",
"      Dossett LA, Adams RC, Cotton BA. Unwarranted national variation in the use of prophylactic inferior vena cava filters after trauma: an analysis of the National Trauma Databank. J Trauma 2011; 70:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/39\">",
"      Kakkos SK, Caprini JA, Geroulakos G, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev 2008; :CD005258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/40\">",
"      Kwiatt ME, Patel MS, Ross SE, et al. Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study. J Trauma Acute Care Surg 2012; 73:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/41\">",
"      Saadeh Y, Gohil K, Bill C, et al. Chemical venous thromboembolic prophylaxis is safe and effective for patients with traumatic brain injury when started 24 hours after the absence of hemorrhage progression on head CT. J Trauma Acute Care Surg 2012; 73:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/42\">",
"      Rogers FB, Cipolle MD, Velmahos G, et al. Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group. J Trauma 2002; 53:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/43\">",
"      Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:188S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/44\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/45\">",
"      Hoen S, Mazoit JX, Asehnoune K, et al. Hydrocortisone increases the sensitivity to alpha1-adrenoceptor stimulation in humans following hemorrhagic shock. Crit Care Med 2005; 33:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/46\">",
"      Roquilly A, Mahe PJ, Seguin P, et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. JAMA 2011; 305:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/47\">",
"      Berg GM, Spence M, Patton S, et al. Pressure ulcers in the trauma population: are reimbursement penalties appropriate? J Trauma Acute Care Surg 2012; 72:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/48\">",
"      Tsuei BJ, Kearney PA. Hypothermia in the trauma patient. Injury 2004; 35:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/49\">",
"      Shafi S, Elliott AC, Gentilello L. Is hypothermia simply a marker of shock and injury severity or an independent risk factor for mortality in trauma patients? Analysis of a large national trauma registry. J Trauma 2005; 59:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/50\">",
"      Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Contrast media-associated nephrotoxicity. Semin Nephrol 1997; 17:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/51\">",
"      Deray G, Jacobs C. Radiocontrast nephrotoxicity. A review. Invest Radiol 1995; 30:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/52\">",
"      Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/53\">",
"      Biffl WL, Moore EE, Haenel JB. Nutrition support of the trauma patient. Nutrition 2002; 18:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/54\">",
"      Cheatham ML, Safcsak K, Brzezinski SJ, Lube MW. Nitrogen balance, protein loss, and the open abdomen. Crit Care Med 2007; 35:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/55\">",
"      Moore EE, Jones TN. Benefits of immediate jejunostomy feeding after major abdominal trauma--a prospective, randomized study. J Trauma 1986; 26:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/56\">",
"      Dissanaike S, Pham T, Shalhub S, et al. Effect of immediate enteral feeding on trauma patients with an open abdomen: protection from nosocomial infections. J Am Coll Surg 2008; 207:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/57\">",
"      Todd SR, Gonzalez EA, Turner K, Kozar RA. Update on postinjury nutrition. Curr Opin Crit Care 2008; 14:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/58\">",
"      Byrnes MC, Reicks P, Irwin E. Early enteral nutrition can be successfully implemented in trauma patients with an \"open abdomen\". Am J Surg 2010; 199:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/59\">",
"      Cothren CC, Moore EE, Ciesla DJ, et al. Postinjury abdominal compartment syndrome does not preclude early enteral feeding after definitive closure. Am J Surg 2004; 188:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/60\">",
"      Kudsk KA, Tolley EA, DeWitt RC, et al. Preoperative albumin and surgical site identify surgical risk for major postoperative complications. JPEN J Parenter Enteral Nutr 2003; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/61\">",
"      Bochicchio GV, Joshi M, Bochicchio KM, et al. Early hyperglycemic control is important in critically injured trauma patients. J Trauma 2007; 63:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/62\">",
"      Bochicchio GV, Salzano L, Joshi M, et al. Admission preoperative glucose is predictive of morbidity and mortality in trauma patients who require immediate operative intervention. Am Surg 2005; 71:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/63\">",
"      Yendamuri S, Fulda GJ, Tinkoff GH. Admission hyperglycemia as a prognostic indicator in trauma. J Trauma 2003; 55:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/64\">",
"      Bochicchio GV, Bochicchio KM, Joshi M, et al. Acute glucose elevation is highly predictive of infection and outcome in critically injured trauma patients. Ann Surg 2010; 252:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/65\">",
"      Kerby JD, Griffin RL, MacLennan P, Rue LW 3rd. Stress-induced hyperglycemia, not diabetic hyperglycemia, is associated with higher mortality in trauma. Ann Surg 2012; 256:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/66\">",
"      van Haarst EP, van Bezooijen BP, Coene PP, Luitse JS. The efficacy of serial physical examination in penetrating abdominal trauma. Injury 1999; 30:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/67\">",
"      Brooks AJ, Rowlands BJ. Blunt abdominal injuries. Br Med Bull 1999; 55:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/68\">",
"      Al-Mulhim AS, Mohammad HA. Non-operative management of blunt hepatic injury in multiply injured adult patients. Surgeon 2003; 1:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/69\">",
"      Rotondo MF, Schwab CW, McGonigal MD, et al. 'Damage control': an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma 1993; 35:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/70\">",
"      Schreiber MA. Damage control surgery. Crit Care Clin 2004; 20:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/71\">",
"      Parr MJ, Alabdi T. Damage control surgery and intensive care. Injury 2004; 35:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/72\">",
"      Chung SB, Lee SH, Kim ES, Eoh W. Incidence of deep vein thrombosis after spinal cord injury: a prospective study in 37 consecutive patients with traumatic or nontraumatic spinal cord injury treated by mechanical prophylaxis. J Trauma 2011; 71:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/73\">",
"      Ho KM, Burrell M, Rao S, Baker R. Incidence and risk factors for fatal pulmonary embolism after major trauma: a nested cohort study. Br J Anaesth 2010; 105:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/74\">",
"      Tuttle-Newhall JE, Rutledge R, Hultman CS, Fakhry SM. Statewide, population-based, time-series analysis of the frequency and outcome of pulmonary embolus in 318,554 trauma patients. J Trauma 1997; 42:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/75\">",
"      O'Malley KF, Ross SE. Pulmonary embolism in major trauma patients. J Trauma 1990; 30:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/76\">",
"      Spencer Netto F, Tien H, Ng J, et al. Pulmonary emboli after blunt trauma: timing, clinical characteristics and natural history. Injury 2012; 43:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/77\">",
"      Brakenridge SC, Toomay SM, Sheng JL, et al. Predictors of early versus late timing of pulmonary embolus after traumatic injury. Am J Surg 2011; 201:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/78\">",
"      Watkins TR, Nathens AB, Cooke CR, et al. Acute respiratory distress syndrome after trauma: development and validation of a predictive model. Crit Care Med 2012; 40:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/79\">",
"      Cook A, Norwood S, Berne J. Ventilator-associated pneumonia is more common and of less consequence in trauma patients compared with other critically ill patients. J Trauma 2010; 69:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/80\">",
"      Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/81\">",
"      Cavalcanti M, Ferrer M, Ferrer R, et al. Risk and prognostic factors of ventilator-associated pneumonia in trauma patients. Crit Care Med 2006; 34:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/21/31066/abstract/82\">",
"      Milzman DP, Boulanger BR, Rodriguez A, et al. Pre-existing disease in trauma patients: a predictor of fate independent of age and injury severity score. J Trauma 1992; 32:236.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7956 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31066=[""].join("\n");
var outline_f30_21_31066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Obtain complete history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172457110\">",
"      Repeat physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172457118\">",
"      Review diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Consider other potential injuries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172465552\">",
"      - Intraabdominal injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172465526\">",
"      - Diaphragm injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pulmonary contusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172462046\">",
"      - Arterial injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172463302\">",
"      - Head injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172459815\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172465416\">",
"      Lab studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172465423\">",
"      Monitoring for compartment syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H119071180\">",
"      - Intraabdominal pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H119071187\">",
"      - Extremity compartment pressures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H416669268\">",
"      - Screening for venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172458230\">",
"      PROPHYLAXIS AND PREVENTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172458237\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172458244\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172459209\">",
"      Stress ulcer prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172458611\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172459915\">",
"      Pressure ulcer prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172467729\">",
"      Hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172460043\">",
"      Alcohol/drug withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172460051\">",
"      Psychological support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172457494\">",
"      FLUID THERAPY AND NUTRITIONAL SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172460163\">",
"      Fluid management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172460235\">",
"      Enteral and parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172458270\">",
"      Glucose control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172459250\">",
"      WOUND CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172459868\">",
"      Open abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172459899\">",
"      Fasciotomy wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172459593\">",
"      CATHETERS, TUBES, DRAINS AND LINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172459936\">",
"      PAIN MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172467480\">",
"      NONOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172459320\">",
"      DAMAGE CONTROL AND RESUSCITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172468649\">",
"      Deep vein thrombosis and pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H119069566\">",
"      Acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Transfusion-associated complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172468699\">",
"      Ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172468706\">",
"      Contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172468713\">",
"      Catheter-associated blood stream infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172458919\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172468209\">",
"      Organ donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/7956\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/7956|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/37/16981\" title=\"figure 1\">",
"      Measurement of intraabdominal pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/7956|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/58/2979\" title=\"picture 1\">",
"      Temporary abdominal closure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7080?source=related_link\">",
"      Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34504?source=related_link\">",
"      Awareness with recall following general anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/266?source=related_link\">",
"      Blunt cerebrovascular injury: Mechanisms, screening, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8953?source=related_link\">",
"      Blunt cerebrovascular injury: Treatment and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/24/9609?source=related_link\">",
"      Blunt thoracic aortic injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=related_link\">",
"      Cardiac injury from blunt trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=related_link\">",
"      Coagulopathy associated with trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33941?source=related_link\">",
"      Complications of urinary bladder catheters and preventive strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=related_link\">",
"      Diagnosis of brain death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15545?source=related_link\">",
"      Endotracheal tube management and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15577?source=related_link\">",
"      Identification and management of alcohol use disorders in the perioperative period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19562?source=related_link\">",
"      Inpatient management of traumatic rib fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=related_link\">",
"      Lower extremity fasciotomy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35882?source=related_link\">",
"      Management of acute severe traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/47/22266?source=related_link\">",
"      Management of duodenal and pancreatic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9497?source=related_link\">",
"      Management of hepatic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/54/1898?source=related_link\">",
"      Management of splenic injury in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1097?source=related_link\">",
"      Management of the open abdomen in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18566?source=related_link\">",
"      Management of the potential deceased donor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/58/8102?source=related_link\">",
"      Nutrition support in critically ill patients: Parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3400?source=related_link\">",
"      Patient management following extremity fasciotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6664?source=related_link\">",
"      Perioperative nutritional support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1049?source=related_link\">",
"      Prevention of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28009?source=related_link\">",
"      Recognition and management of diaphragmatic injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26105?source=related_link\">",
"      Retained surgical sponge (gossypiboma) and other retained surgical foreign bodies: Prevention and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12186?source=related_link\">",
"      Severe extremity injury in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/45/8921?source=related_link\">",
"      Surgical and endovascular repair of blunt thoracic aortic injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7049?source=related_link\">",
"      Surgical management of splenic injury in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17384?source=related_link\">",
"      The surgical patient taking glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26522?source=related_link\">",
"      Traumatic gastrointestinal injury in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_21_31067="Cantu guideline for concussion management";
var content_f30_21_31067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cantu guideline for concussion management",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Presentation",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         1. No loss of consciousness",
"        </p>",
"        <p>",
"         2. Post-traumatic amnesia or other signs lasting less than 30 minutes",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         1. Loss of consciousness for less than 1 minute",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         2. Post-traumatic amnesia or other symptoms for more than 30 minutes, less than 24 hours",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         1. Loss of consciousness for longer than 1 minute",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         2. Post-traumatic amnesia or other symptoms for longer than 24 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Management",
"       </td>",
"       <td>",
"        Athlete may return to play if asymptomatic for one week",
"       </td>",
"       <td>",
"        Athlete may return to play in 2 weeks if asymptomatic at rest and on exertion for 7 days",
"       </td>",
"       <td>",
"        Athlete may return to play in one month if asymptomatic at rest and on exertion for 7 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Cantu, RC, J Athl Train 2001; 36:244.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31067=[""].join("\n");
var outline_f30_21_31067=null;
var title_f30_21_31068="DMSA pediatric lead treatment protocol";
var content_f30_21_31068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric lead treatment protocol with Meso-2,3-dimercaptosuccinic acid (DMSA)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Week/day",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Observation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        0/0",
"       </td>",
"       <td>",
"        DMSA 3 times per day for 5 days*",
"       </td>",
"       <td rowspan=\"2\">",
"        1, 2, 3, 4, 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamins and milk&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        0/5",
"       </td>",
"       <td>",
"        DMSA twice a day for 14 days*",
"       </td>",
"       <td rowspan=\"2\">",
"        2, 3, 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium and iron supplementation if necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1/7",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2, 3, 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3/21",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1, 2, 3, 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5/35",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3 and other tests to check previous abnormalities or as clinically necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7/49",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1, 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9/63",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11/77",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1, 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Lead levels are then obtained at 15 weeks and then every 1-2 months until &lt;45 mcg/dL (2.17 micromol/L)&nbsp;with&nbsp;history and physical examination&nbsp;every other visit. The frequency of visits is individualized by patent's needs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Retreat&nbsp;if level rebounds to &gt;80 percent&nbsp;of original blood level and is &ge;45 mcg/dL (2.17 micromol/L).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        1. History and physical exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        2. Complete blood count, urinalysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        3. Venous lead level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        4. Serum electrolytes, glucose, blood urea nitrogen, creatinine, aspartate aminotransferase, alanine aminotransferase, calcium, magnesium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        5. Iron panel (serum iron, total iron binding capacity [transferrin], and ferritin)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * DMSA:10 mg/kg/dose or 350 mg/M2 /dose rounded to nearest 100 mg, 3 times a day for 5 days; followed by twice a day for 14 days. Capsules only may be opened and sprinkled on small amounts of food.",
"     <br>",
"      &bull; Supplement with: multivitamin with iron and 2-3 8 oz glasses of milk per day for calcium supplementation.",
"      <br/>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31068=[""].join("\n");
var outline_f30_21_31068=null;
var title_f30_21_31069="Generation of ECG";
var content_f30_21_31069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Generation of the normal electrocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 181px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between cardiac depolarization, ventricular repolarization, and the appearance of the normal electrocardiogram, including the P wave, QRS complex, ST segment, and T wave. The PR interval can be prolonged by disease from the atria to the Purkinje fibers (steps 2 to 4). The SA node is not seen on the surface ECG due to its small mass; its activity is inferred from the P wave which reflects atrial activation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Arnsdorf, MA, in: Electrophysiology of the Heart. Electrocardiography II: Applied Theory, Part 1, American Physiological Society, Bethesda, 1978.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31069=[""].join("\n");
var outline_f30_21_31069=null;
var title_f30_21_31070="Inhalation challenge testing II";
var content_f30_21_31070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inhalation challenge testing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 228px; height: 501px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atypical asthmatic reactions after specific inhalation challenge testing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Perrin et al, J Allergy Clin Immunol 1991; 87:630.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31070=[""].join("\n");
var outline_f30_21_31070=null;
var title_f30_21_31071="Cicatricial alopecias";
var content_f30_21_31071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F88347%7EDERM%2F88346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F88347%7EDERM%2F88346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cicatricial (scarring) alopecias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Epidemiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features on scalp",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-scalp involvement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Lymphocytic primary cicatricial alopecias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discoid lupus erythematosus",
"       </td>",
"       <td>",
"        Onset usually in young adulthood; more common in women than men; may occur independently or in patients with SLE",
"       </td>",
"       <td>",
"        Erythematous, atrophic plaques with follicular plugging, hyperpigmentation, and/or hypopigmentation",
"       </td>",
"       <td>",
"        Face, ears, and other sites may be affected; a minority of cases are associated with systemic lupus erythematosus",
"       </td>",
"       <td>",
"        Interface dermatitis, epidermal atrophy, follicular plugging, basement membrane thickening, perifollicular superficial and deep lymphoplasmacytic infiltrate; DIF shows IgG, IgM, and C3 at the BMZ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lichen planopilaris",
"       </td>",
"       <td>",
"        Most common in Caucasian and East Indian women",
"       </td>",
"       <td>",
"        Areas of scarring surrounded by follicles with erythema and scale; itching and pain may be severe",
"       </td>",
"       <td>",
"        May be accompanied by cutaneous, nail, or mucous membrane lichen planus",
"       </td>",
"       <td>",
"        Lichenoid infiltrate around the isthmus and infundibulum, interface dermatitis, concentric lamellar fibroplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frontal fibrosing alopecia",
"       </td>",
"       <td>",
"        Mostly post-menopausal women",
"       </td>",
"       <td>",
"        Perifollicular erythema, follicular hyperkeratosis, band-like frontal alopecia",
"       </td>",
"       <td>",
"        Loss of eyebrows common",
"       </td>",
"       <td>",
"        Lichenoid infiltrate around the isthmus and infundibulum, apoptotic keratinocytes in outer root sheath, concentric lamellar fibroplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Classic pseudopelade of Brocq",
"       </td>",
"       <td>",
"        Most common in middle-aged women",
"       </td>",
"       <td>",
"        Skin-colored scarred plaques resembling \"footprints in the snow\"",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Lymphocytic infiltrate around infundibulum, concentric lamellar fibroplasia around follicles in later lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Central centrifugal cicatricial alopecia",
"       </td>",
"       <td>",
"        Most common in women of African origin",
"       </td>",
"       <td>",
"        Patch of scarring alopecia on crown of scalp that progresses centrifugally",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Premature desquamation of the inner root sheath, loss of sebaceous glands, variable perifollicular chronic inflammation at isthmus and infundibulum, concentric lamellar fibroplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alopecia mucinosa",
"       </td>",
"       <td>",
"        May be associated with mycosis fungoides or CTCL",
"       </td>",
"       <td>",
"        Erythematous or skin-colored indurated plaques with alopecia, follicular papules",
"       </td>",
"       <td>",
"        Eyebrow involvement may be present",
"       </td>",
"       <td>",
"        Mucin deposits in outer root sheath, eventual replacement of follicles by mucin, lymphocytic infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Keratosis folliculars spinulosa decalvans",
"       </td>",
"       <td>",
"        X-linked inheritance of mutation in the MBTPS2 gene; less commonly autosomal dominant transmission",
"       </td>",
"       <td>",
"        Noninflammatory, hyperkeratotic follicular papules and progressive hair loss",
"       </td>",
"       <td>",
"        Eyebrow and eyelash involvement may be present, photophobia",
"       </td>",
"       <td>",
"        Follicular plugging and hypergranulosis, primarily lymphocytic perifollicular infiltrate, fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Neutrophilic primary cicatricial alopecias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dissecting folliculitis",
"       </td>",
"       <td>",
"        Most common in young black men",
"       </td>",
"       <td>",
"        Inflammatory papules, pustules, fluctuant nodules, abscesses; may also have keloidal scarring",
"       </td>",
"       <td>",
"        May be associated with hidradenitis suppurativa and acne conglobata",
"       </td>",
"       <td>",
"        Follicular occlusion, intrafollicular and perifollicular neutrophilic infiltrate; follicular perforation, abscesses and sinus tracts in later stages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Folliculitis decalvans",
"       </td>",
"       <td>",
"        Most common in young and middle aged adults, particularly men",
"       </td>",
"       <td>",
"        Patches of alopecia, erythematous follicular papules, pustules, follicular hyperkeratosis, tufted folliculitis",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Interfollicular and perifollicular neutrophilic infiltrate; mixed infiltrate, granulomas, and fibrosis in later lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Mixed primary cicatricial alopecias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acne keloidalis nuchae",
"       </td>",
"       <td>",
"        Most common in young black men",
"       </td>",
"       <td>",
"        Dome-shaped papules and pustules on the occipital scalp and nape of the neck; keloids may develop",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Neutrophilic or lymphocytic inflammatory infiltrate around the isthmus and infundibulum; granulomatous infiltrate may also be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acne necrotica",
"       </td>",
"       <td>",
"        Usually occurs in adults",
"       </td>",
"       <td>",
"        Umbilicated, pruritic, painful papules that undergo central necrosis and resolve with varioliform scars",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Infundibular folliculitis with necrosis, lymphocytic or mixed inflammatory infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erosive pustular dermatosis of the scalp",
"       </td>",
"       <td>",
"        Most common in the elderly, particularly women",
"       </td>",
"       <td>",
"        Pustules, erosions, and crusted plaques",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Nonspecific early findings; older lesions with a chronic mixed inflammatory infiltrate and fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tinea capitis",
"       </td>",
"       <td>",
"        Usually affects children",
"       </td>",
"       <td>",
"        Scaly patches or plaques; kerion may develop",
"       </td>",
"       <td>",
"        Tinea corporis may be present",
"       </td>",
"       <td>",
"        Perifollicular inflammation and fungal elements within or around the hair shaft",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CTCL: cutaneous T-cell lymphoma; SLE: systemic lupus erythematosus; DIF: direct immunofluorescence; BMZ: basement membrane zone; SLE: systemic lupus erythematosus.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Otberg N, Shapiro J. Hair growth disorders. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds), McGraw Hill 2012.",
"      </li>",
"      <li>",
"       Childs JM, Sperling LC. Histopathology of scarring and nonscarring hair loss. Dermatol Clin 2013; 31:43.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonscarring alopecias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Epidemiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features on scalp",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-scalp involvement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hair pull test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Focal hair loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alopecia areata*",
"       </td>",
"       <td>",
"        Onset most common in childhood or young adulthood",
"       </td>",
"       <td>",
"        Round patches of alopecia with&nbsp;exclamation point hairs; may extend to&nbsp;total hair loss on scalp (alopecia totalis) or loss of all body hair (alopecia universalis); uncommon is a diffuse hair loss presentation",
"       </td>",
"       <td>",
"        Other hair-bearing sites may be affected, nail pitting, trachyonychia",
"       </td>",
"       <td>",
"        Peribulbar lymphocytic infiltrate resembling \"swarm of bees\"; multiple miniaturized hair follicles; in chronic disease, increased catagen/telogen follicles",
"       </td>",
"       <td>",
"        Postive hair pull test, telogen hairs and dystrophic anagen hairs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Traction alopecia",
"       </td>",
"       <td>",
"        Individuals with chronic use of traction-inducing hairstyles",
"       </td>",
"       <td>",
"        Loss of terminal hairs in areas of traction; prolonged traction may lead to cicatricial alopecia",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        <p>",
"         Acute: increased catagen/telogen hairs, occasional pigment casts",
"        </p>",
"        Chronic: reduction in terminal hairs, occasional fibrous tracts, retained sebaceous glands",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alopecia syphilitica",
"       </td>",
"       <td>",
"        Most common in young adults; occurs due to secondary syphilis",
"       </td>",
"       <td>",
"        Patchy hair loss, \"moth-eaten\" appearance",
"       </td>",
"       <td>",
"        Other mucocutaneous manifestations of secondary syphilis",
"       </td>",
"       <td>",
"        Increase in catagen/telogen follicles, perifollicular inflammation with plasma cells",
"       </td>",
"       <td>",
"        Positive for telogen hairs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temporal triangular alopecia",
"       </td>",
"       <td>",
"        Lifelong, usually detected in infancy or childhood",
"       </td>",
"       <td>",
"        Triangular or oval area with absent terminal hair in temporal region that is a few centimeters in diameter; vellus hairs visible on close inspection",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Predominance of vellus hairs",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pressure-induced (postoperative) alopecia",
"       </td>",
"       <td>",
"        Most commonly seen in surgical patients",
"       </td>",
"       <td>",
"        Hair loss localized to area of prolonged pressure, such as the posterior scalp after prolonged general anesthesia",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Nearly all hairs in catagen/telogen phase, trichomalacia",
"        <sup>",
"         &bull;",
"        </sup>",
"        , melanin in the collapsed outer root sheath, thrombosis, necrosis",
"       </td>",
"       <td>",
"        Normal or positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Patterned hair loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male pattern hair loss (androgenetic alopecia in men)",
"       </td>",
"       <td>",
"        Most common in adult men, prevalence increases with age",
"       </td>",
"       <td>",
"        Slow, progressive terminal hair loss on the frontal, temporal, and/or vertex scalp",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Marked variation in follicular size, increased proportion of vellus follicles, slight increase in telogen follicles, fibrous streamers beneath miniaturized hairs",
"       </td>",
"       <td>",
"        Generally normal; may be positive in areas of active hair loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female pattern hair loss*",
"       </td>",
"       <td>",
"        Most common in adult women, prevalence increases with age",
"       </td>",
"       <td>",
"        Slow, progressive terminal hair loss on the crown of the scalp; frontal hairline is often relatively spared",
"       </td>",
"       <td>",
"        If related to hyperandrogenism signs of hirsutism or virilization may be present",
"       </td>",
"       <td>",
"        Same as in male pattern hair loss",
"       </td>",
"       <td>",
"        Generally normal; may be postive in areas of active hair loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trichotillomania",
"       </td>",
"       <td>",
"        May occur in children and adults",
"       </td>",
"       <td>",
"        Broken hairs often distributed in a bizarre pattern",
"       </td>",
"       <td>",
"        May be associated with ingestion of hair and risk for trichobezoar",
"       </td>",
"       <td>",
"        Follicular distortion, pigment casts, trichomalacia",
"        <sup>",
"         &bull;",
"        </sup>",
"        , melanin pigment in collapsed root sheaths, fractured hairs, follicular hemorrhage",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Diffuse hair loss*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Telogen effluvium",
"       </td>",
"       <td>",
"        Women more likely to present for evaluation than men",
"       </td>",
"       <td>",
"        Acute or chronic diffuse hair thinning",
"       </td>",
"       <td>",
"        Findings associated with underlying cause may be present",
"       </td>",
"       <td>",
"        Increase in the proportion of telogen follicles (20 to 50 percent of follicles are in telogen)",
"       </td>",
"       <td>",
"        Positive in active phase; telogen hairs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anagen effluvium",
"       </td>",
"       <td>",
"        Seen in association with chemotherapy, radiation, toxins",
"       </td>",
"       <td>",
"        Acute loss of hair",
"       </td>",
"       <td>",
"        Findings associated with underlying cause may be present; hair loss in other sites",
"       </td>",
"       <td>",
"        Increased proportion of telogen follicles, dystrophic anagen hairs; rare cases of permanent hair loss may demonstrate linear basaloid structures",
"       </td>",
"       <td>",
"        Postive in active phase, dystrophic anagen hairs or broom-shaped anagen hairs with a pigmented bulb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loose anagen syndrome",
"       </td>",
"       <td>",
"        Affects children; most common in girls; often blond hair",
"       </td>",
"       <td>",
"        Hair is easily dislodged from follicles without pain; hair density appears normal or reduced",
"       </td>",
"       <td>",
"        May be solitary or associated with developmental defects",
"       </td>",
"       <td>",
"        Dystrophic anagen hairs",
"       </td>",
"       <td>",
"        Very positive; majority of hairs are anagen hairs with a ruffled cuticle and absent inner root sheath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrichia with papular lesions",
"       </td>",
"       <td>",
"        Autosomal dominant disorder, presents in infancy",
"       </td>",
"       <td>",
"        Hair normal at birth, hair loss in infancy due to&nbsp;abnormality in first hair cycle (defect in catagen phase); papular follicular cysts develop later",
"       </td>",
"       <td>",
"        Hair loss and follicular cysts in other sites",
"       </td>",
"       <td>",
"        Absence of mature hair follicles, cysts present",
"       </td>",
"       <td>",
"        Normal; may be positive in initial stages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypotrichosis simplex",
"       </td>",
"       <td>",
"        Group of hypotrichosis disorders; usually autosomal dominant",
"       </td>",
"       <td>",
"        Usually progressive loss of scalp hair during childhood",
"       </td>",
"       <td>",
"        May or may not have involvement of other hair-bearing sites",
"       </td>",
"       <td>",
"        Reduced number of follicles, follicular miniaturization",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Alopecia areata and female pattern hair loss occasionally present with diffuse hair loss.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Trichomalacia is a histological finding of distortion of the hair shaft and pigment that results from repeated hair&nbsp;plucking or other&nbsp;injury.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Otberg N, Shapiro J. Hair growth disorders. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds), McGraw Hill 2012.",
"      </li>",
"      <li>",
"       Childs JM, Sperling LC. Histopathology of scarring and nonscarring hair loss. Dermatol Clin 2013; 31:43.",
"      </li>",
"      <li>",
"       Michailidis E, Theos A, Zlotogorski A, et al. Atrichia with papular lesions resulting from novel compound heterozygous mutations in the human hairless gene. Pediatr Dermatol 2007; 24:E79.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_21_31071=[""].join("\n");
var outline_f30_21_31071=null;
